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CDC has a long history of monitoring the use of clinical preventive services to provide public health agencies, health care providers 
and their partners information needed to plan and implement programs that increase use of these services and improve the health 
of the U.S. population. Better use of clinical preventive services could prevent tens of thousands of deaths each year. W ith passage 
of the Patient Protection and Affordable Care Act of 2010 as amended by the Heathcare and Education Reconciliation Act of 
2010, which expands health insurance coverage for the United States population and increases access to preventive services, there 
are new opportunities to promote and improve use of these valuable and life-saving services. This report provides baseline data 
prior to implementation of the provisions of the Affordable Care Act.
Public health and clinical medicine complement and enrich each other, but they must engage with each other to maximize their 
impact. Synergies created through cooperation can amplify the impact that either might produce working alone. Public health 
can also serve as an honest broker by providing unbiased and scientifically accurate information to policy makers, the health-care 
community, and the public, and is well equipped to monitor health systems to facilitate increases in effectiveness and efficiency.
This M M W R  Supplement on the Use o f Selected Clinical Preventive Services AmongAdults —  United States, 2007—2010 is the first 
in a periodic series of reports examining use of selected clinical preventive services. There are other important preventive health 
services, such as screening and brief intervention for problem alcohol use and screening and effective treatment of depression, 
but robust national data for these services are not currently available. For other important health problems, there are no proven, 
recommended clinical preventive services at present. The report focuses on the following adult services:
• Use of aspirin or antiplatelet therapy to prevent recurrent cardiovascular disease events among adults with a history of ischemic 
vascular disease and use of aspirin in the general population among those at increased risk for cardiovascular disease,
• control of blood pressure among adults with hypertension,
• screening for lipid disorders,
• control of blood glucose among adults who have had diabetes diagnosed,
• screening for tobacco use in office-based ambulatory-care settings and tobacco cessation counseling and medication use among 
current tobacco users,
• screening using mammography for breast cancer among women,
• screening for colorectal cancer in the adult population,
• assuring awareness of human immunodeficiency virus-status among those who are infected, and
• vaccination against influenza in adults.
The findings of this report indicate that tens of millions of people in the United States have not been benefitting from key 
preventive clinical services, and that there are large disparities by demographics, geography, and health care coverage and access 
in the provision of these services.
• Slightly less than half of patients with diagnosed ischemic cardiovascular disease were prescribed aspirin or other antiplatelet 
agents.
• Despite improvements in hypertension treatment and control over the past10 years, slightly less than half of persons in the 
United States with high blood pressure had it under control, and levels of control were particularly low for people who are 
uninsured or do not have a usual source of heath care.
• Only two thirds of adults (68%) had their cholesterol levels checked during the preceding 5 years, and among persons with 
high LDL cholesterol levels, less than one third (31.6%) had it under control. More than one third (36%) of people in the 
United States had elevated levels of low-density lipoprotein cholesterol.
• More than one third (37.3%) of outpatient visits had no documentation of tobacco use status; just one in five (20.9%) who 
screened positive for tobacco use received tobacco cessation counseling, and less than one in 13 (7.6%) tobacco users were 
prescribed cessation medications. Rates of counseling were particularly low among younger smokers, despite a high level of 
interest in quitting in this population; younger smokers have been shown to be more likely to try to quit but less likely 
to succeed, hence could benefit particularly from improved counseling and treatment
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• Approximately 2.3 million adults (12.9%) with diagnosed diabetes had poor glycemic control (A1c > 9.0).
• Approximately one in five women age 50—74 years had not had a mammogram during the preceding 2 years.
• Although there have been large increases in recent years, still approximately one third of adults aged 50—75 years were not 
up-to-date with screening for colorectal cancer, which is the second leading cause of cancer death in the United States, the 
leading cause of cancer death among nonsmokers, and which can be prevented through screening and follow-up.
• Approximately one in five of the 1.1 million persons in the United States living with HIV had not been diagnosed.
• Only approximately one in four (28%) of adults aged <65 years were vaccinated against influenza; 133 million adults were not 
vaccinated, and vaccination rates were particularly low among the poor and those without health insurance or a medical home.
Improved clinical management of the ABCS —  aspirin, blood pressure control, cholesterol management, and smoking cessation 
—  can significantly reduce the risk for cardiovascular disease, our nation’s leading killer, and could save approximately 100,000 
lives each year. The Million Hearts initiative, which targets improvements in both clinical preventive practice (e.g., ABCS) and 
community prevention (e.g., reducing smoking and exposure to secondhand smoke and decreasing sodium and artificial trans­
fat intake) by engaging public and private sectors, can prevent a million heart attacks and strokes over the next 5 years. This can 
reduce the number of people who need treatment and the costs of health care to our society.
This report documents the potential benefits of selected clinical preventive services, the problem of their underuse, and effective 
collaborative strategies to improve use. I hope the report will help increase use of these services and thereby help people in the 
United States live longer, healthier, and more productive lives.
2 MMWR / June 15, 2012 / Vol. 61
Supplement
Rationale for Periodic Reporting on the Use of Selected Adult Clinical 
Preventive Services —  United States
Ralph J. Coates, PhD1 
Paula W. Yoon, ScD2 
Stephanie Zaza, M D3 
Lydia Ogden, PhD4 
Stephen B. Thacker, M D5
1Public Health Surveillance and Informatics Program Office, Office o f  Surveillance, Epidemiology, and Laboratory Services 
2D ivision fo r  Heart Disease and Stroke Prevention, National Center fo r  Chronic Disease Prevention and Health Promotion 
3Epidemiology and Analysis Program Office, Office o f  Surveillance, Epidemiology, and Laboratory Services 
4(Office o f  the Associate Director fo r  Policy 
5Office o f  the Director, Office o f  Surveillance, Epidemiology, and Laboratory Services
Corresponding author: Ralph J. Coates, PhD, Office of Surveillance, Epidemiology, and Laboratory Services, CD C , 1600 Clifton Rd., N E, MS E-97, 
Atlanta, GA 30333. Telephone: 404-498-0080; Fax: 404-498-0595; E-mail: RCoates@cdc.gov.
S u m m a ry
This supplement introduces a CDC initiative to monitor and report periodically on the use o f a set ofselected clinical preventive 
services in the U.S. adult population in the context o f recent national initiatives to improve access to and use o f such services. 
Increasing the use o f these services has the potential to lead to substantial reductions in the burden o f illness, death, and disability 
and to lower treatment costs. The majority o f clinical preventive services are provided by the health-care sector, and public health 
agencies play important roles in helping to support increases in the use ofthese services (e.g., by identifying and implementing policies 
that are effective in increasing use ofthe services and by collaborating with stakeholders to conduct programs to improve use). Recent 
health reform initiatives, including efforts to increase the accessibility and affordability o f preventive services, fu n d  community 
prevention programs, and improve the use o f health information technologies, offer opportunities to enhance use o f preventive 
services. This supplementprovides baseline information on a set ofselected clinicalpreventive services before implementation ofthese 
recent reforms and discusses opportunities to increase the use o f such services. This information can help public health practitioners 
collaborate with other stakeholders that have key roles to play in improving public health (e.g., employers, health plans, health 
professionals, and voluntary associations), understand the potential benefits o f the recommended services, address the problem 
o f underuse, and identify opportunities to apply effective strategies to improve use and foster accountability among stakeholders.
Clinical Preventive Services
Optimal provision of clinical preventive services has the 
potential to enable U.S. adults to live longer, healthier lives 
by reducing the burden of illness, death, and disability (1—5). 
These services include clinical interventions to reduce the 
risk for an adverse health condition, screening to identify and 
treat a condition early to reduce severity and duration, and 
clinical interventions to reduce complications from a condition 
or recurrence of a condition (6). Expert panels use multiple 
methods and procedures to review and evaluate the evidence on 
the benefits and harms from use of specific clinical preventive 
services and to develop recommendations (5,7,8). The U.S. 
Preventive Services Task Force (9), the Advisory Committee 
on Immunization Practices (ACIP) (10), National Institutes 
of Health consensus panels (11), and other committees (5) 
supported by federal agencies make recommendations for 
clinical preventive services. In addition, associations of health
professionals (e.g., the American College of Physicians) and 
volunteer associations (e.g., the American Diabetes Association) 
also organize and support panels to issue guidelines (5,12,13).
Approximately half of the U.S. adult population does not 
use commonly recommended preventive services (1—4,14,15). 
The Healthy People 2020 initiative, which identifies national 
objectives for improving population health, reports low levels of 
use of multiple clinical preventive services recognized as having 
national importance (16). For example, in 2007, only 8% of 
ambulatory care physician office visits included counseling or 
education related to exercise. In 2008, less than half of primary 
care physicians regularly assessed the body mass index of their 
adult patients. During 2005—2008, of adults aged >18 years 
with hypertension, 30% were not taking prescribed blood 
pressure medications.
The health-related costs of underuse of recommended 
clinical preventive services are substantial. Researchers have 
reported that increasing use of nine clinical preventive services
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to more optimal levels (i.e., levels achieved by high-performing 
health plans) could prevent an estimated 50,000—100,000 
deaths each year among adults aged <80 years (4). Another 
study found that adopting 20 preventive services recommended 
by the U.S. Preventive Services Task Force could prevent an 
estimated annual loss in life expectancy for the U.S. population 
as a whole of approximately 2 million years (3).
Role o f Public H ealth  in Clinical 
Preventive Services
W ith their focus on population health, public health 
agencies have played and will continue to play important 
roles in increasing use of recommended clinical preventive 
services (17—22). Two long-standing roles for public health 
are developing policies and plans to improve individual and 
community health and ensuring provision of health care when 
it is not otherwise available (17—19). For example, CDC- 
supported panels make policy recommendations for a range 
of clinical preventive services including vaccinations of adults 
and children; counseling, screening, and prevention of human 
immunodeficiency virus (HIV) and sexually transmitted 
diseases; and prevention and control of health-care—associated 
infections (23—25). In addition, public health agencies 
improve access to clinical preventive services to the broader 
population by providing services directly, funding the delivery 
of services through nonprofit community public health clinics, 
community organizations, or private practices and by providing 
selected services in nonclinic settings (26—28).
Another important role o f public health is identifying 
community preventive services (i.e., policies, laws, programs 
and initiatives, education programs, and health system 
interventions) that are effective in increasing use of clinical 
preventive services (19,22). To support this function, in 1996, 
the U.S. Department of Health and Human Services initiated 
the Community Preventive Services Task Force to examine 
the effectiveness of a range of community preventive services. 
The Community Preventive Services Task Force conducts 
systematic literature reviews to evaluate evidence and uses 
explicit criteria and procedures to make recommendations
(22). Among the community preventive services reviewed and 
recommended by the Community Preventive Services Task 
Force are policy and health system interventions that facilitate 
the delivery of clinical preventive services. These interventions 
act by reducing patients’ out-of-pocket costs (e.g., policies 
that require no or reduced copayment for clinical preventive 
services), reducing barriers to access (e.g., through changes in 
clinic hours or providing services through mobile vans), and 
using patient tracking systems to identify eligible patients
and provide decision support (e.g., patient and provider 
reminders about the need for and timing of clinical services). 
In addition, the Community Preventive Services Task Force 
recommends ongoing surveillance to monitor, evaluate, and 
report on performance in the use of clinical preventive services, 
which is an effective and important means of increasing 
service delivery by clinicians and health plans (22). The 
Community Preventive Services Task Force also reviews and 
makes recommendations about policy changes, public health 
education programs, employee wellness programs, and changes 
in the physical and social environment to promote use of 
clinical preventive services and healthy behaviors (e.g., tobacco 
avoidance, physical activity, weight control, and seatbelt use). 
Community interventions to promote healthy behaviors have 
the potential to reduce the need for certain clinical preventive 
services (e.g., by reducing the prevalence of tobacco use and 
obesity), thereby decreasing the need for counseling and other 
clinical interventions.
Public health also plays a critical role in collaborating 
with other stakeholders to implement effective community 
interventions to increase use of clinical preventive services. 
Population health is the outcome not only of services provided 
by the health-care system and public health agencies but 
also by the activities of private and voluntary organizations 
and persons, including employers, health plans, and other 
stakeholders (17—20). Each stakeholder can implement 
interventions to increase use of clinical preventive services. 
C D C  has played a leading role in collaborating with 
stakeholders at the national level and in supporting state and 
local public health agencies to develop community coalitions 
to engage in prevention and control programs, including, but 
not limited to, increasing implementation of interventions 
recommended by the Community Preventive Services Task 
Force (24,29,30,31).
Finally, to help other stakeholders plan effective collaborations, 
public health has a role in monitoring, evaluating, and 
reporting on how well communities and stakeholders are doing 
in increasing use of recommended community interventions as 
well as use of clinical preventive services (20,32). An example 
of such surveillance is CDC’s State Tobacco Activities Tracking 
and Evaluation (STATE) System, which tracks state tobacco- 
control policies (33). Monitoring the number and percentage 
of employers whose employee health insurance policies provide 
coverage for clinical preventive services recommended by the 
National Business Group on Health (29) is another example of 
the type of surveillance that could be conducted. To promote 
accountability among stakeholders responsible for population 
health, public health authorities will need to develop additional 
performance-measurement systems that track specific, effective 
actions by stakeholders (e.g., worksite wellness programs
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and use of patient tracking and reminder systems for clinical 
preventive services) as well as health outcomes (e.g., lower 
disease rates) (20,32).
O pp ortun ities  O ffered  by Recent 
Changes to  th e  U.S. H ealth-C are  
System
Recent changes in the U.S. health-care system provide 
opportunities to expand use of preventive services. The Patient 
Protection and Affordable Care Act of 2010 as amended by 
the Healthcare and Education Reconciliation Act of 2010 
(referred to collectively as the Affordable Care Act [ACA]) 
emphasizes both population-based prevention and individual 
clinical preventive services (34—38). Implementation of the 
Affordable Care Act has the potential to lead to substantial 
reductions in morbidity, premature mortality, and associated 
health spending by expanding access to health insurance 
and increasing use of preventive services (34—38). In 2009, 
an estimated 58.5 million persons in the United States 
lacked health insurance for at least some part of the previous 
12 months; among adults aged 18—64 years, 25.6% were 
uninsured for at least part of the year (39). The Congressional 
Budget Office has estimated that implementation of the 
Affordable Care Act will extend insurance coverage to 93% of 
the nonelderly U.S. population by 2016 (38). Medicare now 
covers adult clinical preventive services graded A (strongly 
recommended) or B (recommended) by the U.S. Preventive 
Services Task Force and immunizations recommended by 
ACIP. These services, together with recommended preventive 
services for children, youth, and women, will be covered at 
no cost sharing by newly qualified private health plans in the 
state-based insurance exchanges that are to start operating in 
2014, when a competitive insurance marketplace will be set up 
in the form of state-based insurance exchanges (ACA §1311). 
These exchanges will allow eligible persons and small businesses 
with up to 100 employees to purchase health insurance plans 
that meet criteria outlined in the Affordable Care Act (34,37). 
If a state does not create an exchange, the federal government 
will operate it. Beginning in 2013, state Medicaid programs 
that eliminate cost sharing for these clinical preventive services 
might receive enhanced federal matching funds for them 
(34,35). In addition, Medicare covers an annual wellness visit 
(which includes a health-risk assessment and a personalized 
prevention plan) at no cost to beneficiaries. In December 2011, 
as required by the Affordable Care Act, CDC issued evidence- 
based guidelines for individualized health-risk assessment (40). 
Improved insurance coverage, expanded benefits, reduced 
cost-sharing and improved access to health services can increase
use of clinical preventive services (22,29,35). The uninsured 
are identified frequently as one of the population subgroups 
with the lowest use of clinical preventive services (41). Even 
for those who are insured, cost is often a barrier to service use 
(42). The Affordable Care Act addresses cost impediments 
to care through additional provisions, including eliminating 
lifetime and annual limits on private insurance coverage 
and providing premium rebates if insurers’ administrative 
costs are too high, offering discounted prescription drugs for 
seniors; providing tax credits for insurance coverage for those 
from 100%—400% of the federal poverty limit and for small 
businesses, and extending coverage for young adults up to 
age 26 years through continued coverage under their parents’ 
insurance plans.
The Affordable Care Act reauthorized the U.S. Preventive 
Services Task Force (and for the first time authorized the 
Community Preventive Services Task Force) to continue 
updating and conducting new reviews, identify research gaps, 
and make recommendations for evidence-based prevention 
programs. In addition, the Affordable Care Act created and 
provided funding for the Prevention and Public Health Fund, 
which enables communities to prevent the leading causes 
of death, strengthens state and local disease detection and 
response, and produces information for action (34—36). In 
Fiscal Year 2011, CDC was allocated $611 million from the 
Prevention and Public Health Fund to strengthen prevention, 
improve the health of the U.S. population, and bolster the 
ability to detect and respond to both natural and deliberate 
disease threats. The Affordable Care Act substantially expanded 
funding for federally qualified community health centers 
through the Health Resources and Services Administration 
(HRSA), com m itting $11 billion over 5 years. It also 
authorized demonstrations of new payment and care delivery 
models (e.g., accountable care organizations and community 
health teams) to promote a population health approach to 
clinical care (43). Together, these provisions will work to 
integrate primary care services into community-based mental 
and behavioral health settings and will support the expansion 
of the primary care workforce, which can increase access to 
preventive services (34—36).
Recognizing the importance of broad collaboration for 
prevention, Congress included the National Prevention 
Strategy in the Affordable Care Act. Created by the National 
Prevention, Health Promotion, and Public Health Council in 
consultation with the public and an advisory group of outside 
experts, the comprehensive plan, which was released on June 
16, 2011, includes specific actions public and private partners 
can take to help Americans stay healthy (44). The National 
Prevention Strategy encourages partnerships among federal, 
state, tribal, local, and territorial governments; business,
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industry, and other private sector partners; philanthropic 
organizations; community and faith-based organizations; 
and individuals to improve health through prevention. It 
is a cross-sector, integrated national strategy that identifies 
priorities for improving the health of the U.S. population. 
Through these partnerships, the National Prevention Strategy 
aims to improve public health by helping to create healthy 
and safe communities, expand clinical and community-based 
preventive services, empower people to make healthy choices, 
and eliminate health disparities (44).
Other national initiatives that have been implemented in 
recent years are also likely to increase use of preventive services. 
The American Recovery and Reinvestment Act (ARRA) of 
2009 invested in the expansion of community health centers 
(45). The portion of ARRA known as the Health Information 
Technology for Economic and Clinical Health (HITECH) 
Act, as well as amendments to the Public Health Service 
Act, support increased use of health information technology 
as a means of improving the quality, efficiency, and safety 
of health care (46,47). A draft national strategic plan for 
health information technology published in 2011 for public 
comment outlines multiple strategies that have the potential 
to increase use of preventive services in health care through the 
use of electronic information technologies (47). The Centers 
for Medicare and Medicaid Services is offering incentives to 
providers to increase their use of electronic health information 
systems and has included selected clinical preventive services 
as potential quality of care measures (48). Electronic health 
information systems increase the ability of clinicians and health 
plans to identify all patients in need of preventive services 
more easily and systematically, deliver reminders to patients 
and providers, and assist them in making informed decisions. 
They also could contribute to evaluating and reporting on 
the timeliness and quality of care. In addition, by facilitating 
information exchange, such systems could support patient 
self-management and improve coordination of care among 
primary care professionals and specialists. Finally, the new 
health information technologies together with the other health 
reform initiatives create opportunities for greater sharing of 
information and closer collaboration between public health 
and clinical care professionals to improve the health of the 
U.S. population.
A b o ut This Surveillance S upp lem ent
This surveillance supplement is the first of a series of 
periodic reports from CDC to monitor and report on progress 
made at the population level in increasing the use of a set of 
clinical preventive services identified by CDC as public health
priorities. The audience for the report is the broad range of 
stakeholders who shape the health of the U.S. population, 
including public health practitioners, employers, health 
plans, health professionals, and voluntary associations. Before 
selecting a limited set of clinical preventive services to include 
in this report, CDC considered a wide range of services and 
surrogate measures of service use (e.g., proximal biologic 
outcome measures) to indicate whether a disease is under 
control. For example, CDC considered a set of adult clinical 
preventive services that were identified by the Affordable Care 
Act and that have been evaluated and recommended by the 
U.S. Preventive Services Task Force or by ACIP (34). Also 
reviewed were clinical preventive services for areas of public 
health identified by CDC as priorities, including aspirin 
therapy, blood pressure and cholesterol control, and smoking 
cessation (the ABCS for heart disease and stroke prevention) 
(49) as well as those related to food safety, immunizations, 
health-care—associated infections, HIV, motor-vehicle injuries, 
obesity, teen pregnancy, and tobacco use (50).
To select indicators important to the public, stakeholders, 
and policy makers, CDC identified a set of clinical preventive 
services that 1) address leading causes of illness, injury, 
disability, or death; 2) are underutilized but have the potential 
for substantial increases in use over the next few years with 
focused effort; 3) have substantial effects on population health, 
as measured by deaths prevented or healthy life years gained 
(2—4); 4) are priorities of CDC public health programs and 
the coalitions of stakeholders; and 5) have routinely collected 
nationally representative surveillance data available for 
measurement. Consideration also was given as to whether the 
same or similar indicators were used by other national efforts 
to monitor and promote progress in use of clinical preventive 
services, including Healthy People 2020, the National Quality 
Forum, and the National Committee for Quality Assurance 
(16,51,52).
Using these criteria, CDC leadership initiated an iterative 
process to develop the final list of indicators. A work group that 
included leaders from multiple CDC programs was formed to 
develop a proposal; the proposal was then reviewed in more 
detail by personnel from a broader set of CDC programs and 
by an external expert work group convened by a member of 
the Advisory Committee of the Director of CDC.* The work 
group included leaders in academia, public health, other 
government agencies, and the private sector. A revised proposal 
was developed and approved by CDC leadership.
*A list of the members of the two work groups appears on page 78.
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Clinical Preventive Services Indicators
The indicators used in this surveillance supplem ent 
address leading causes of death and disability in the United 
States among adults: heart disease, stroke, cancer, diabetes, 
influenza, and HIV (13,23,53—65) (Table). Also addressed is 
tobacco use, which is a major contributor to many of those 
diseases (53—55,62). Most of the indicators are for services 
recommended by the U.S. Preventive Services Task Force or 
ACIP, but include others as well. The indicators measure use 
or biologic effects of preventive services that are underutilized 
and that, if increased over the next few years, could improve 
the health of the U.S. population substantially. Improvement 
in the use of those services is also a focus of public health and 
community programs as well as national health-care quality 
improvement efforts.
Given the large number of clinical preventive services 
recommended for adults, children, or adolescents combined, 
and recognizing that the set of stakeholders and surveillance 
systems for adult services differ somewhat from those for 
adolescent and children’s services, CDC decided to limit 
the scope of this supplement to adult services. A separate 
supplement covering indicators for clinical preventive services 
in children is being planned.
For multiple reasons, certain potentially important adult 
services were not included. For example, the U.S. Preventive 
Services Task Force does not address food safety specifically 
and has determined that evidence is insufficient to recommend 
counseling and other clinical interventions to prevent motor- 
vehicle injuries, increase physical activity, or counsel most 
patients to promote a healthy diet, although intensive dietary 
counseling is recommended for obese adults and those with 
high cholesterol or cardiovascular disease (9). Obesity screening
and alcohol screening are recommended (9), but surveillance 
data were not available for adequate indicators. Screening for 
depression also is excluded because current surveillance systems 
do not have information on the ability of clinician practices 
to provide effective supportive care for depression. The 
U.S. Preventive Services Task Force recommends depression 
screening only when staff-assisted depression care supports 
are available to assure accurate diagnosis, effective treatment, 
and follow-up (9). The U.S. Preventive Services Task Force 
recommends against screening when such supportive care is 
not available because the benefit of screening depends on the 
availability of beneficial interventions (9).
Use of This Report
In its 2011 report on the role of measurement in action 
and accountability in public health (20), the IOM outlined 
several uses for the kind of information provided in this 
supplement. The reports in this supplement provide the public 
and stakeholders responsible for population health (including 
public health agencies, employers, health plans, health 
professionals, community groups, and voluntary associations) 
with easily understood and transparent information about the 
use of clinical preventive services that can improve population 
health. Stakeholders can use this information to increase use of 
these services and to stimulate action, promote responsibility, 
and hold each other accountable for implementing effective 
strategies to increase use. In addition, publication of this 
information on a diverse set of selected adult services in a 
single supplement offers the opportunity for stakeholders to 
reduce the burden of both chronic and infectious diseases 
simultaneously by coordinating efforts when appropriate to 
increase use of all of these preventive services for all U.S. adults.
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TABLE. Selected adult clinical preventive services and the clinical practice recommendation or guideline for the preventive service, by topic, 




Aspirin and other antiplatelet therapy
Percentage o f adults aged >18 years w ith  a history o f history o f ischemic vascular disease w ho are prescribed aspirin or o ther antip la telet 
m edications to  prevent recurrent CVD 
Percentage o f men aged 45 -79  years and wom en aged 55-79 years w ith o u t ischemic vascular disease w ho are prescribed aspirin when the 
potentia l benefit o f a reduction in myocardial infarction or stroke, respectively, outw eighs the potentia l harm a ttribu tab le  to  an increase in 
gastrointestinal hem orrhage 
Hypertension management 
Percentage o f adults aged >18 years w ith  hypertension whose blood pressure is under control 
Lipid management 
Percentage o f men aged >35 years w ho have been screened for lip id disorders
Percentage o f men aged 20-34 years at increased risk for coronary heart disease w ho have been screened for lip id disorders 
Percentage o f wom en aged >45 years at increased risk for coronary heart disease w ho have been screened for lip id disorders 
Percentage o f wom en aged 20-44 years at increased risk for coronary heart disease w ho have been screened for lip id disorders 
Percentage o f adults aged >20 years w ith  abnorm al lipids at increased risk for coronary heart disease w ho had high LDL cholesterol, were 
taking lip id -low ering m edication, and whose high LDL cholesterol was under control 
Diabetes management
Percentage o f adults aged >18 years w ith  diagnosed diabetes whose glycohem oglobin (A1c) is <9%
Tobacco cessation
Percentage o f office-based am bulatory care setting visits w ith  screening for tobacco use am ong adults aged >18 years 
Percentage o f office-based am bulatory care setting visits w ith  tobacco cessation counseling am ong current tobacco users in adults aged 
>18 years
Percentage o f office-based am bulatory care setting visits w ith  tobacco cessation m edications am ong current tobacco users in adults aged 
>18 years
Percentage o f recent smoking cessation success by adult smokers aged >18 years, w ho ever smoked 100 cigarettes, w ho do not smoke now, 
and last smoked 6 m onths to  1 year ago 
Breast cancer screening 
Percentage o f wom en aged >40 years w ho had a m am m ogram  w ith in  the previous 2 years 
Percentage o f wom en aged 50-74 years w ho had a m am m ogram  w ith in  the  previous 2 years 
Colorectal cancer screening
Percentage o f adults aged 50-75 years w ho have had a fecal occu lt blood test (FOBT) w ith in  the past year, or sigm oidoscopy w ith in  the  past 
5 years and FOBT w ith in  the past 3 years, or colonoscopy w ith in  the past 10 years 
HIV screening
Percentage o f persons aged >13 years liv ing w ith  HIV w ho know  they are infected 
Influenza vaccination 
Percentage o f adults aged 18-64 years vaccinated annually against seasonal influenza
JNC7§
u s p s t f ’
u s p s t f ’
u s p s t f ’
u s p s t f ’
NCEP**
NDQIA
u s p s t f1
uspstf
u s p s t f3
u s p s t f3
u s p s t f ’
u s p s t f ’
USPSTFt
ACIP*
u sp stf ’ ’ ’ / c d c ’ ’ ’
Abbreviations: ACC = American College o f Cardiology; ACCP = American College o f Chest Physicians; ACIP = Advisory Com m ittee on Im m unization Practices; ADA = 
American Diabetes Association; AHA = American Heart Association; CHD = coronary heart disease; CVD = cardiovascular disease; HDL-C = h igh-density lipoprote in 
cholesterol; HIV = Human Im m unodeficiency Virus; JNC7 = Seventh Report o f the Joint National Com m ittee on Prevention, Detection, Evaluation, and Treatm ent o f 
High Blood Pressure; LDL-C = low -density lipopro te in  cholesterol; NCEP = National Cholesterol Education Program; NDQIA = National Diabetes Q uality Im provem ent 
Alliance; TC = to ta l cholesterol; USPSTF = U.S. Preventive Services Task Force.
* Sources: Becker RC, Meade TW, Berger PB, et al. The prim ary and secondary prevention o f coronary artery disease: American College o f Chest Physicians evidence- 
based clinical practice guidelines. 8th ed. Chest 2008;133:776S; Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients w ith
coronary and other atherosclerotic vascular disease, 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72.
+ Source: U.S. Preventive Services Task Force. Aspirin for prevention o f cardiovascular disease. Available at http://www.uspreventiveservicestaskforce.org/uspstf/ 
uspsasmi.htm.
§ Source: National Heart, Lung, and Blood Institute. The seventh report o f the Joint National Com m ittee on the  Prevention, Detection, Evaluation, and Treatment 
o f High Blood Pressure. NIH Publication No. 03-5233. December, 2003.
’  Source: US Preventive Services Task Force. Screening for lipid disorders in adults, 2008. Available at http://www.uspreventiveservicestaskforce.org/uspstf/uspschol.htm.
**  Source: National Heart, Lung, and Blood Institu te. Third report o f the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and
Treatm ent o f High Blood Cholesterol in adults (Adult Treatm ent Panel III). NIH Publication No. 01-3670. May, 2001.
++ Source: National Diabetes Quality Im provem ent Alliance. Performance measurement set for adult diabetes. Available at h ttp ://w w w -nehc.m ed.navy.m il/bum ed/ 
diabetes/docum ent% 20folders/diabetes/cpg/dqia.m srs.pdf.
§§ Source: US Preventive Services Task. Counseling and interventions to  prevent tobacco use and tobacco-caused disease in adults and pregnant wom en, 2009. 
Available at http://www.uspreventiveservicestaskforce.org/uspstf/uspstbac2.htm .
’ ’  Source: US Preventive Services Task Force. Screening for breast cancer, 2002. Available at http://www.uspreventiveservicestaskforce.org/uspstf/uspsbrca2002.htm.
***  Source: US Preventive Services Task Force screening for breast cancer, 2009. Available at http://uspreventiveservicetaskforce.org/uspstf/uspsbrca.htm
+++ Source: US Preventive Services Task Force. Screening for colorectal cancer, 2009. Available at http://www.uspreventiveservicestaskforce.org/uspstf/uspscolo.htm .
§§§ Source: US Preventive Services Task Force. Screening for HIV, 2007. Available at http://www.uspreventiveservicestaskforce.org/uspstf/uspshivi.htm .
’ ’ ’  Source: CDC. HIV guidelines and recommendations. Available at h ttp://w w w .cdc.gov/hiv/resources/gu idelines.
* ***  Source: CDC. Prevention and control o f influenza w ith  vaccines: recom m endations o f the  Advisory Com m ittee on Im m unization Practices (ACIP), 2010. MMWR 
2010;59(No. RR-8).
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In troduction
Cardiovascular disease (CVD) is the most highly prevalent 
disease in the United States and remains the leading cause of 
death among adults aged >18 years despite advancements in 
treatment and prevention in recent decades (1). Each year, 
approximately 800,000 persons die from CVD, which includes 
coronary heart disease (CHD) (1,2); the majority of those 
persons who die from CVD had underlying atherosclerosis. 
Approximately 7.9 million U.S. adults have a history of heart 
attack, approximately 7 million U.S. adults have a history of 
stroke (1), and, approximately 16 million U.S. adults have 
received a diagnosis of CHD (2). CVD and CH D  cause a 
substantial economic burden in the United States. In 2010, 
the estimated annual cost (direct and indirect) of CVD in the 
United States was approximately $450 billion, including $109 
billion for CHD and $54 billion for stroke alone (3).
Preventive care and lifestyle interventions have proven to be 
effective in reducing atherosclerotic CVD (4,5). Taking aspirin 
or other antiplatelet medications is one of several preventive 
interventions that can provide substantial benefit for patients 
with ischemic vascular disease and is strongly recommended in 
practice guidelines (6,7). This report summarizes the estimated 
prevalence of physician prescription of aspirin and other 
antiplatelet medications for patients with or without ischemic 
vascular disease as recommended by the U.S. Preventive 
Services Task Force (USPSTF) and other major guidelines 
(8—15). Previous research has indicated that the use of aspirin 
among eligible patients is suboptimal, even for those patients 
at highest risk (16). In persons who do not have a history of 
ischemic vascular disease, the net benefit is dependent upon 
the patient’s risk for suffering a stroke or myocardial infarction 
compared with their chances of harm from treatment.
The information in this report is intended for clinicians who 
treat patients with ischemic vascular disease and patients who 
are at high risk for suffering cardiovascular disease and stroke. 
In addition, this information can serve as a baseline to monitor 
progress and measure the impact of use of recommended 
clinical preventive services.
M ethods
To estimate the prevalence of physician-prescribed aspirin 
and other antiplatelet medications (e.g., clopidogrel, ticlid, and 
dipyridamole) among adults aged >18 years with or without 
ischemic vascular disease as recommended by USPSTF and 
other major guidelines, CDC analyzed 2005—2008 data from 
the National Ambulatory Medical Care Survey (NAMCS) 
and the National Hospital Ambulatory Medical Care Survey 
(NHAMCS) (17). These two national surveys collect data 
annually on the provision of ambulatory care services to 
patients of all ages from office-based physicians and in-hospital 
outpatient departments. The methods and sampling frame 
of NAMCS and NHAMCS have been described in detail 
elsewhere (18). Pregnant women (ICD-9-CM codes: V22, 
V23, and V28), visits for pre- or postsurgery follow-up, patients 
with documented contraindications to chronic aspirin use 
(coagulation defects, purpura and other hemorrhagic conditions, 
subarachnoid hemorrhage, intracerebral hemorrhage, acute 
hepatic failure, and gastrointestinal hemorrhage), and persons 
prescribed anticoagulant medication (warfarin, heparin, or low 
molecular weight heparins) were excluded from this analysis of 
patients with or without ischemic vascular disease. In addition, 
patients without ischemic vascular disease who were prescribed 
nonsteroidal anti-inflammatory drugs (NSAIDs) were excluded 
from analyses because of the increased risk for bleeding 
complications when NSAIDs are used together with aspirin.
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For both study groups (patients with and those without 
ischemic vascular disease), the unit of analysis used was a 
patient visit. W ith the exception of physician and clinic 
specialty (obtained from the provider interview and sampling 
frames), all data in this analysis were obtained through 
abstraction of patient visit records using a standardized patient 
record form. Key items included on the patient record form 
include major reason for visit (new problem [<3 months], 
chronic problem [routine or flare-up], and preventive care); 
a maximum of three ICD-9-CM diagnosis codes related to 
the visit); systolic blood pressure; regardless of visit diagnoses, 
separate checkboxes identifying patients with diagnoses of 
cerebrovascular disease, congestive heart failure, diabetes, 
hypertension, hyperlipidemia, and ischemic heart disease; 
check boxes to identify patient’s tobacco use (“current,” “not 
current,” or “unknown”); and up to eight over-the-counter or 
prescription drugs that were “ordered, supplied, administered, 
or continued at this visit.” Aspirin and other antiplatelet 
medications identified as either “new” or “continued at this 
visit” were considered as prescribed in this analysis.
O f a total of 198,042 patient visits among adults aged 
>18 years, 6,574 (4.0%) visits met the criteria for visits by 
patients having ischemic vascular disease. For patients with 
ischemic vascular disease, analysis was limited to visits to 
physicians in the following specialties: general medicine, 
family practice, general practice, general medicine, geriatric 
medicine, internal medicine, cardiovascular diseases, and 
neurology as well as to hospital outpatient department clinics 
specializing in general medicine or obstetrics and gynecology. 
Ischemic vascular disease was determined by the presence of 
an International Classification of Disease, Ninth Revision, 
Clinical Modification (ICD-9-CM) code for ischemic heart 
disease, ischemic stroke or carotid stenosis, peripheral vascular 
disease, or atheroembolic disease (ICD-9-CM codes: 410, 
411, 412, 413, 414.0, 414.2, 414.8, 414.9, 429.2, 433, 434, 
435, V12.54, 437.0, 437.1, 440.1, 440.2, 444, 445, V45.81, 
and V45.82) or by the presence of a current diagnosis of 
cerebrovascular disease or ischemic heart disease.
O f 198,042 patient visits among adults aged >18 years, 9,369 
(6.1%) visits met the criteria for visits by patients without 
ischemic vascular disease. For patients without ischemic 
vascular disease, the analysis was limited to practitioners in 
general medicine, family practice, general practice, geriatric 
medicine, cardiovascular diseases, and internal medicine. The 
inclusion criteria for patients without ischemic vascular disease 
were defined so as to include men aged 45—79 years at risk for 
myocardial infarction and women aged 55—79 years at risk for 
stroke. The inclusion criteria were based on clinical guidelines 
(10,12—15) and USPSTF recommendations identifying the
risk levels at which benefit of treatment outweighs the harm 
of treatment (e.g., gastrointestinal or cerebral hemorrhage) (8).
Sex-specific risk levels for myocardial infarction and stroke 
were based on Framingham risk for coronary heart disease risk 
for men and Framingham stroke risk for women (19). Visits 
by men aged 45—59 years with at least an intermediate risk (> 
6% for a 10-year risk) for coronary heart disease were defined 
as one or more risk factors (hypertension, current tobacco user, 
hypercholesterolemia, or diabetes). Visits by men aged 60—79 
years with a high risk (>10% for a 10-year risk) for coronary 
heart disease were defined as having two or more risk factors 
(hypertension, current tobacco user, hypercholesterolemia, or 
diabetes). Visits by women aged 55—64 years with a moderate 
risk for stroke (i.e., >6% for a 10-year risk) were defined as 
having 1) atrial fibrillation, 2) left ventricular hypertrophy 
plus either hypertension or diabetes or current tobacco use, or 
3) hypertension, diabetes, and current tobacco use. Visits by 
women aged 65—79 years with a high risk for stroke (i.e., >10% 
for a 10-year risk) were defined as having atrial fibrillation or 
any two risk factors (left ventricular hypertrophy, hypertension, 
diabetes, or current tobacco use).
Data from NAMCS and NHAMCS were combined, and 
two time intervals were selected for analysis: 2005—2006 and 
2007—2008. Patient visit weights were used to extrapolate 
these findings to national estimates. Chi-square or the Fisher 
exact test was used to test for the statistical significance of the 
associations, and a two-tailed p-value at the p = 0.05 level 
was deemed statistically significant. If chi-square tests were 
statistically significant, a post hoc t-test procedure was used to 
make pairwise comparisons. All data analyses were performed 
with SAS (Release 9.2, Cary, North Carolina). To account for 
survey design features, including clustering and weighting, all 
statistical analyses were performed with the statistical software 
package SUDAAN (Release 9.2, Research Triangle Institute, 
Research Park, North Carolina).
Results
During 2007—2008, physicians prescribed aspirin and other 
antiplatelet medications at 46.9% of patient visits for patients 
with ischemic vascular disease, with no change compared 
with 2005—2006 (Table 1). Aspirin and other antiplatelet 
medications were prescribed less often at visits by female 
patients compared with visits by male patients (p = 0.002). O f 
the disease subgroups examined, physicians prescribed aspirin 
and other antiplatelet medications significantly more often 
when a patient had hyperlipidemia or ischemic heart disease 
and significantly less often for a patient with cerebrovascular 
disease. Cardiologists prescribed aspirin and other antiplatelet 
medications at 68% of visits compared with primary care
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TABLE 1. Aspirin and other antiplatelet medication prescribed at outpatient visits among patients with ischemic vascular disease — National 
Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, United States, 2005-2008
Characteristic
Aggregate 2005-2008 2005
Antiplatelet m edication prescribed %  (SE) 














1 8 -4 4 343 (5.2) 4 3.9 (7.5) 56.1 (7.5) 36.3 (6.7) 63.7 (6.7)
4 5 - 5 4 834 (12.7) 48.2 (4.6) 51.8 (4 6) 41.5 (3.9) 58.5 (3.9)
5 5 -6 4 1,475 (22.4) 47.3 (3.5) 52.7 (3.5) 48.5 (2.8) 51.5 (2.8)
6 5 -7 9 2,600 (39.6) 4 5.9 (2.6) 54.1 (2.6) 4 7 .4 (3.2) 52.6 (3.2)
>79 1,322 (20.1) 44.1 (3.8) 55.9 (3.8) 4 8 .6 (3.4) 51.4 (3.4)
Sex
Fem ale 3,019 (45.9) 4 0.8 (2.6) 59.2 (2.6) 42.3 (2.3) 57.7 (2.3)
M a le 3,555 (54.1) 50.0 (2.6) 50.0 (2.6) 50.4 (2.5) 4 9 .6 (2.5)
Race/Ethnicity
W h ite , n o n -H is p a n ic 4,940 (75.1) 46.4 (2.2) 53.6 (2.2) 4 7 .8 (2.3) 52.2 (2.3)
B lack, n o n -H is p a n ic 759 (11.6) 45.6 (6.1) 54.4 (6.1) 4 4 .8 (4.0) 55.2 (4.0)
H isp a n ic 560 (8.5) 43.4 (4.7) 56.6 (4.7) 41.3 (4.5) 58.7 (4.5)
O th e r 315 (4.8) 42.2 (7.1) 57.8 (7.1) 47.1 (6.9) 52.9 (6.9)
Region1
N o rth e a s t 1,691 (25.7) 46.8 (3.0) 53.2 (3.0) 45.9 (2.9) 54.1 (2.9)
M id w e s t 1,435 (21.8) 45.9 (2.6) 54.1 (2.6) 4 8 .0 (2.8) 52.0 (2.8)
S o u th 2,469 (37.6) 42.1 (5.3) 57.9 (5.3) 37.1 (4.8) 62.9 (4.8)
W e st 979 (14.9) 48.7 (8.6) 51.3 (8.6) 51.6 (5.6) 4 8 .4 (5.6)
Source of paym ent (n = 6,455)
P riva te 1,764 (27.3) 50.9 (4.0) 49.1 (4.0) 4 5 .8 (4.2) 54.2 (4.2)
M e d ic a re 3,663 (56.8) 4 9.0 (3.9) 51.0 (3.9) 49.5 (2.6) 50.5 (2.6)
M e d ic a id 536 (8.3) 4 2.9 (3.4) 57.1 (3.4) 4 6 .7 (4.0) 53.3 (4.0)
O th e r 492 (7.6) 4 1.5 (5.8) 58.5 (5.8) 45.5 (5.0) 54.5 (5.0)
Systolic blood pressure (n = 5,978)
S ys to lic  < 1 4 0 4,094 (68.5) 4 5.9 (2.4) 54.1 (2.4) 4 9 .4 (2.4) 50.6 (2.4)
S ys to lic  1 4 0 -1 5 9 1,323 (22.1) 4 6.6 (3.2) 53.4 (3.2) 44.3 (3.3) 55.7 (3.3)
S ys to lic  > 1 6 0 561 (9.4) 51.7 (4.7) 48.3 (4.7) 50.3 (6.3) 4 9 .7 (6.3)
M ajor reason for visit (n = 6,468)
P re v e n tiv e  ca re 685 (10.6) 4 3.0 (5.0) 57.0 (5.0) 4 9 .0 (4.7) 51.0 (4.7)
N e w  p ro b le m 1,418 (21.9) 39.6 (3.2) 60.4 (3.2) 38.2 (3.1) 61.8 (3.1)
C h ro n ic 4,365 (67.5) 49.3 (2.4) 50.7 (2.4) 49.3 (2.4) 50.7 (2.4)
Enrolled in disease m anagem ent program
E n ro lle d /o rd e re d /a d v is e d  t o  e n ro ll 1,164 (17.7) 53.8 (3.8) 46.2 (3.8) 43.2 (4.9) 56.8 (4.9)
N o t e n ro lle d 1,902 (28.9) 48.1 (3.0) 51.9 (3.0) 51.6 (4.4) 4 8 .4 (4.4)
U n k n o w n /N o t a p p lic a b le 3,508 (53.4) 4 0.6 (2.8) 59.4 (2.8) 4 6 .0 (2.5) 54.0 (2.5)
Specialty
C a rd io lo g y 2,162 32.9) 66.5 (2.9) 33.5 (2.9) 68.0 (2.9) 32.0 (2.9)
N e u ro lo g y 629 (9.6) 4 6.8 (4.0) 53.2 (4.0) 4 2 .4 (5.0) 57.6 (5.0)
G e n e ra l m e d ic in e /P r im a ry  care 3,783 (57.5) 37.9 (2.7) 62.1 (2.7) 34.8 (2.3) 65.2 (2.3)
Ischem ic heart disease
Yes 4,933 (75.0) 4 7.6 (2.2) 52.4 (2.2) 50.9 (2.1) 49.1 (2.1)
N o 1,641 (25.0) 4 0.5 (3.7) 59.5 (3.7) 34.5 (3.7) 65.5 (3.7)
Cerebrovascular disease
Yes 1,890 (28.8) 4 4.4 (3.7) 55.6 (3.7) 37.3 (3.3) 62.7 (3.3)
N o 4,684 (71.2) 4 6.4 (2.2) 53.6 (2.2) 50.8 (2.3) 49.2 (2.3)
Diabetes
Yes 1,898 (28.9) 42.1 (2.9) 57.9 (2.9) 4 4 .4 (2.8) 55.6 (2.8)
N o 4,676 (71.1) 4 7.4 (2.3) 52.6 (2.3) 4 7 .8 (2.4) 52.2 (2.4)
Hypertension
Yes 4,201 (63.9) 4 9.5 (2.4) 50.5 (2.4) 49.2 (2.3) 50.8 (2.3)
N o 2,373 (36.1) 39.3 (2.9) 60.7 (2.9) 4 2 .6 (3.1) 57.4 (3.1)
Hyperlip idem ia
Yes 3,280 49.9) 50.7 (2.5) 49.3 (2.5) 56.1 (2.5) 43.9 (2.5)
N o 3,294 (50.1) 4 0.5 (2.6) 59.5 (2.6) 36.8 (2.8) 63.2 (2.8)
Congestive heart failure
Yes 752 (11.4) 35.1 (5.1) 64.9 (5.1) 47.5 (4.8) 52.5 (4.8)
N o 5,822 (88.6) 4 7.3 (2.2) 52.7 (2.2) 4 6 .8 (2.1) 53.2 (2.1)
Total 6,574 45.9 (2.1) 54.1 (2.1) 46.9 (2.1) 53.1 (2.1)
Abbreviation: SE =  s ta n d a rd  error.
* Denominator used equals 6,574 unless otherwise specified by category.
+ Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont. Midwest: Illinois, Indiana, Iowa, 
Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin. South: Alabama, Arkansas, Delaware, District o f Columbia, 
Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia. West Alaska, 
Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.
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specialists, who prescribed aspirin and other antiplatelet 
medications at only 35% of visits (p<0.001).
Although systolic blood pressure was measured as >160 mm 
Hg at only 9.4% of visits among those with ischemic vascular 
disease, physicians prescribed aspirin and other antiplatelet 
medications at 50% of these visits (Table 1). Aspirin use in 
the presence of uncontrolled hypertension increases the risk 
for hemorrhagic stroke (20). Among visits for preventive care 
or chronic disease care, physicians prescribed aspirin and other 
antiplatelet medications (both at 49%) compared with 38% 
for visits for a new problem (p<0.05 and p<0.01, respectively). 
During 2007—2008, the distribution of aspirin and other 
antiplatelet medications prescribed at visits among those with 
ischemic vascular disease (total: 1,732 sample visits when 
aspirin and other antiplatelet medications were prescribed), 
indicated that aspirin alone was prescribed at 59.3% of visits, 
aspirin and another antiplatelet medication was prescribed 
at 24.2% of visits, and an antiplatelet medication other than 
aspirin was prescribed at 16.6% of visits.
Physicians prescribed aspirin and other antiplatelet 
medications at 17.1% of visits during 2007—2008 for patients 
at risk for ischemic vascular disease (Table 2). If the analysis 
were limited to aspirin, with other antiplatelet medications 
excluded, the corresponding prescribing rate would be 14.9%. 
During 2007—2008, physicians prescribed aspirin and other 
antiplatelet medications at relatively few of the visits by patients 
in the USPSTF population recommended for consideration 
of aspirin for prevention of CVD and stroke (16.2% of visits 
by males and 21.7% of visits by females; p<0.05). Physicians 
prescribed antiplatelet medications at 14.1% of patient visits 
with a measured systolic blood pressure of >160 mm Hg 
for patients without ischemic vascular disease. Physicians 
were more likely to prescribe aspirin or other antiplatelet 
medications for patients seen for a chronic condition than they 
were for those seen for a new problem (19.5% versus 12.8%, 
respectively; p<0.01). Physicians were least likely to prescribe 
antiplatelet medication at visits paid by Medicaid (13.1%) 
whereas physicians prescribed these medications most often 
at visits paid by Medicare (21.9%; p<0.01).
During 2007—2008, the distribution of aspirin and other 
antiplatelet medications prescribed for patients without 
ischemic vascular disease (total: 1,030 sample visits at which 
aspirin and other antiplatelet medications were prescribed) 
indicated that aspirin alone was prescribed at 82.3% of visits, 
aspirin and another antiplatelet medication was prescribed at 
6.7% of visits, and an antiplatelet medication other than aspirin 
was prescribed at 6.8% of visits (data not reported). At the 
visit level, among patients without ischemic vascular disease, 
physicians were most likely to prescribe aspirin and other 
antiplatelet medications for those patients with congestive 
heart failure (26.4%; p<0.05).
Discussion
The findings provided in this report indicate that prevalence 
of prescribing aspirin or other antiplatelet medications at 
outpatient health-care visits is low for patients who have 
been recommended to receive these medications based on the 
presence of ischemic vascular disease or certain risk factors. 
Despite the low prevalence of aspirin prescribing identified in 
this analysis, other studies using the same data sources have 
demonstrated that aspirin and other antiplatelet medication 
prescribing among patients with ischemic vascular disease was 
only 32.8% in 2003 (16). Previous reports have estimated that 
for every 10% increase in the use of antiplatelet medication 
among eligible adults aged 18—79 years, an estimated 8,000 
deaths per year would be prevented (21). A 2006 study that 
ranked clinical preventive services based on cost effectiveness 
and the clinically preventable burden of disease demonstrated 
that aspirin prevention counseling was one of three prevention 
services that received the highest score among 25 studied 
preventive services (22).
Use of aspirin or other antiplatelet medications among 
patients with ischemic vascular disease is recommended by 
multiple guidelines addressing prevention of atherosclerotic 
heart disease, ischemic stroke and transient ischemic attacks, and 
peripheral vascular disease (8—15). The results of this analysis 
demonstrate that even among patient visits with evidence 
of ischemic or atherosclerotic heart, brain, and peripheral 
vascular disease, prescribing of aspirin and other antiplatelet 
medications is <50% despite many guidelines recommending 
treatment and multiple National Quality Forum (N Q F)- 
endorsed measures of care supporting their use. Among patient 
visits by those with ischemic vascular disease, primary care 
providers prescribed antiplatelet medication at only 35% of 
visits. Cardiologists prescribed antiplatelet medications more 
frequently (at 68% of visits) than physicians in other specialties 
examined. Cardiologist prescribing practices were similar to 
that seen in the Reduction of Atherothrombosis for Continued 
Health (REACH) Registry (23) of 71% antithrombotic use 
among patients with established atherothrombosis or three 
or more risk factors for cardiovascular disease and stroke. 
Consistent with this finding, treatment by a cardiologist was 
associated with a higher frequency of prescribing antiplatelet 
therapy compared with prescribing by neurologists and primary 
care providers.
Differences in categorization of patients to those with or 
without ischemic vascular disease might explain lower rates 
of antiplatelet medication prescribed in the group at risk for 
ischemic vascular disease compared with other reports (24). 
Patients who had evidence of ischemic or atherosclerotic 
disease of the brain, heart, or peripheral vasculature but 
had not experienced a stroke or myocardial infarction were
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TABLE 2. Aspirin and other antiplatelet m edication prescribed at outpatient v isits am ong patients at risk for developing ischemic vascular 
disease* — National Am bulatory Medical Care Survey and National Hospital Am bulatory Medical Care Survey, United States, 2005-2008
Antiplatelet medication prescribed % (SE)
Sample (%) Yes No Yes No
Characteristic no. (n = 9,369)+ (n = 771) (n = 3,613) (n = 1,030) (n = 3,955)
Aggregate 2005-2008  2005-2006______________   2007-2008______________
Age groups (yrs)
45 -54  (men only) 3,556 (38.0) 11.8 (1.5) 88.2 (1.5) 12.2 (1.3) 87.8 (1.3)
55-64 2,626 (28.0) 17.0 (2.3) 83.0 (2.3) 15.7 (1.7) 84.3 (1.7)
65-79 3,187 (34.0) 22.9 (2.1) 77.1 (2.1) 22.3 (1.8) 77.7 (1.8)
Sex
Female 1,632 (17.4) 16.9 (2.5) 83.1 (2.5) 21.7 (2.4) 78.3 (2.4)
Male 7,737 (82.6) 16.9 (1.4) 83.1 (1.4) 16.2 (1.2) 83.8 (1.2)
Race/Ethnicity
White, non-Hispanic 5,911 (63.1) 18.2 (1.5) 81.8 (1.5) 16.8 (1.3) 83.2 (1.3)
Black, non-Hispanic 1,805 (19.3) 9.1 (2.0) 90.9 (2.0) 16.9 (2.2) 83.1 (2.2)
Hispanic 1,080 (11.5) 13.0 (3.5) 87.0 (3.5) 19.6 (2.7) 80.4 (2.7)
Other 573 (6.1) 18.6 (6.5) 81.4 (6.5) 17.2 (4.0) 82.8 (4.0)
Region§
Northeast 2,461 (26.3) 16.8 (2.8) 83.2 (2.8) 17.6 (3.0) 82.4 (3.0)
M idwest 2,227 (23.8) 18.9 (2.7) 81.1 (2.7) 21.8 (2.4) 78.2 (2.4)
South 3,079 (32.9) 15.4 (1.8) 84.6 (1.8) 16.1 (1.8) 83.9 (1.8)
West 1,602 (17.1) 17.5 (3.9) 82.5 (3.9) 14.1 (2.1) 85.9 (2.1)
Source of payment (n = 9,169)
Private 3,495 (38.1) 16.0 (1.8) 84.0 (1.8) 14.4 (1.5) 85.6 (1.5)
Medicare 3,181 (34.7) 22.1 (2.1) 77.9 (2.1) 21.9 (1.7) 78.1 (1.7)
Medicaid 1,216 (13.3) 9.7 (3.7) 90.3 (3.7) 13.1 (2.3) 86.9 (2.3)
Other 1,277 (13.9) 7.3 (1.7) 92.7 (1.7) 16.0 (2.6) 84.0 (2.6)
Systolic blood pressure (n = 8,549)
Systolic <140 5,413 (63.3) 18.3 (1.6) 81.7 (1.6) 17.9 (1.5) 82.1 (1.5)
Systolic 140-159 2,224 (26.0) 17.3 (2.1) 82.7 (2.1) 18.7 (1.8) 81.3 (1.8)
Systolic >160 912 (10.7) 11.2 (2.4) 88.8 (2.4) 14.1 (2.7) 85.9 (2.7)
Major reason for visit (n = 9,230)
Preventive care 1,227 (13.3) 19.9 (3.6) 80.1 (3.6) 15.0 (2.3) 85.0 (2.3)
New problem 2,457 (26.6) 12.6 (1.6) 87.4 (1.6) 12.8 (1.5) 87.2 (1.5)
Chronic 5,546 (60.1) 18.3 (1.6) 81.7 (1.6) 19.5 (1.6) 80.5 (1.6)
Enrolled in disease management program
Enrolled/ordered/advised to  enroll 1,797 (19.2) 18.9 (3.1) 81.1 (3.1) 21.1 (2.4) 78.9 (2.4)
Not enrolled 2,649 (28.3) 17.0 (1.8) 83.0 (1.8) 17.4 (2.3) 82.6 (2.3)
U nknow n/N ot applicable 4,923 (52.6) 16.2 (1.8) 83.8 (1.8) 16.0 (1.3) 84.0 (1.3)
Diabetes
Yes 4,548 (48.5) 20.0 (2.0) 80.0 (2.0) 18.3 (1.5) 81.7 (1.5)
No 4,821 (51.5) 14.9 (1.3) 85.1 (1.3) 16.1 (1.3) 83.9 (1.3)
Hypertension
Yes 7,091 (75.7) 19.2 (1.5) 80.8 (1.5) 18.6 (1.3) 81.4 (1.2)
No 2,278 (24.3) 10.3 (1.7) 89.7 (1.7) 11.7 (1.8) 88.3 (1.8)
Hyperlipidemia
Yes 4,380 (46.8) 21.7 (1.9) 78.3 (1.9) 20.7 (1.7) 79.3 (1.7)
No 4,989 (53.3) 11.0 (1.4) 89.0 (1.4) 12.5 (1.2) 87.5 (1.2)
Congestive heart failure
Yes 365 (3.9) 35.0 (8.4) 65.0 (8.4) 26.4 (4.4) 73.6 (4.4)
No 9,004 (96.1) 16.5 (1.3) 83.5 (1.3) 16.8 (1.1) 83.2 (1.1)
Total 9,369 16.9 (1.3) 83.1 (1.3) 17.1 (1.1) 82.9 (1.1)
Abbreviation: SE = standard error.
* The pa tient popula tion at risk for developing ischemic vascular disease was defined according to the  guidelines issued by the U.S. Prevention Services Task Force, 
which recommends the  use o f aspirin to  reduce the  risk for myocardial infarctions am ong men aged 45 -79  years and to  reduce the  risk for stroke am ong women 
aged 55-79 years.
+ D enom inator used equals 9.369 unless otherw ise specified by category.
5 Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Verm ont. Midwest: Illinois, Indiana, Iowa, 
Kansas, Michigan, M innesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin. South: Alabama, Arkansas, Delaware, D istrict o f Columbia, 
Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia. West: Alaska, 
Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, W ashington, and W yoming.
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included in the ischemic vascular disease category (consistent 
with NQF quality measures #0068 [25], “Use of aspirin 
or other antithrombotic for ischemic vascular disease” and 
#0076 [26], “Percentage of adult patients aged 18—75 years 
who have ischemic vascular disease with optimally managed 
modifiable risk factors [low-density-lipoprotein (LDL), blood 
pressure, tobacco-free status, daily aspirin use.”) Reasons for 
nonadherence to prescribing, whether at the patient or provider 
level, cannot be assessed; however, a recent study indicated that 
elderly patients frequently perceive the use of cardiovascular 
preventive medications as having greater risk for harm and side 
effects than benefit (27).
USPSTF recommends shared decision making between 
patient and physician for patients who are at risk for developing 
ischemic vascular disease. Patient-centered care regarding 
the use o f aspirin for prevention o f vascular disease events 
involves consideration of the individual patient’s potential of 
experiencing a vascular event, their potential of sustaining harm 
from aspirin, and the patient’s preference after discussing these 
considerations in consultation with their health-care provider 
(8,28—31). On the basis of this analysis, the opportunity 
exists for physicians to improve compliance with existing 
clinical guidelines for aspirin use to prevent the recurrence 
and progression o f ischemic vascular disease.
Multiple reasons might account for low prevalence of 
prescribing aspirin or other antiplatelet medications. First, 
providers might lack knowledge of clinical guidelines. Second, 
different reasons for the visit might compete with counseling 
for physicians’ time, and this might differ by provider type 
or payment source. Finally, physicians might be less likely 
to prescribe aspirin or other antiplatelet medications when 
they expect their patients not to adhere to their advice. These 
possibilities warrant future research.
Physician prescribing of aspirin requires a careful estimate 
o f the benefit provided by aspirin and the potential harm 
attributable to aspirin, including shared decision making 
between patient and health-care provider. The American 
College of Cardiology and the American Heart Association 
recommend that patients have a comprehensive cardiovascular 
health assessment at least every 5 years starting at age 18 years 
and that those with cardiovascular risk factors (e.g., diabetes, 
hypertension, or tobacco use) should have their cardiovascular 
health risk assessed more frequently (14,29). The Patient 
Protection and Affordable Care Act of 2010 (as amended by 
the Healthcare and Education Reconciliation Act of 2010 
and referred to collectively as the Affordable Care Act [ACA]) 
(32) provides several opportunities to assist in cardiovascular 
prevention with medications, promoting health risk assessment 
and patient-centered health care. The Affordable Care Act 
provides for a health-risk assessment in the annual wellness visit
for Medicare patients, as well as counseling services aimed at 
reducing risk factors for chronic disease, including heart disease 
and stroke are provided in the Affordable Care Act (ACA 
§4103). In December 2011, CDC issued a framework for 
patient-centered health risk assessments (33). This framework 
is designed to provide health-care providers, payors, and 
policymakers with information on ways to increase adherence 
to evidence-based guidelines for prevention o f chronic disease 
and to improve health outcomes through early identification 
of modifiable health risk factors and early implementation of 
behavior change interventions to prevent chronic disease such 
as heart disease and stroke.
The National Strategy to Improve Health Care Quality (ACA 
§3011) calls for promoting the most effective prevention and 
treatment practices for the leading causes of mortality, starting 
with cardiovascular disease, and includes efforts to decrease 
preventable hospitalizations such as those due to adverse drug 
events (e.g., hemorrhagic complications from antiplatelet 
use); promote treatment according to guidelines through 
quality improvement initiatives such as the Physician Quality 
Reporting System (ACA §3002), development of quality 
measures (ACA §3012), and meaningful use; accountable care 
organizations to better coordinate patient care and improve 
quality; create community health teams that coordinate 
prevention and disease management and support primary care 
providers (ACA §3502); and develop medication management 
services by pharmacists that can increase patient adherence 
(ACA §3503).
In September 2011, the U.S. Department of Health and 
Human Services launched Million Hearts (34), a national 
initiative to prevent 1 million heart attacks and strokes over 
the next 5 years. Led by CDC and the Centers for Medicare 
and Medicaid Services, the Million Hearts initiative aims to 
improve heart disease and stroke prevention by improving 
access to effective care, improving the quality o f care, focusing 
more clinical attention on heart attack and stroke prevention, 
increasing public awareness of how to lead a heart-healthy 
lifestyle, and increasing the consistent use o f high blood 
pressure and cholesterol medications. Improving appropriate 
use o f aspirin through adherence to clinical guidelines, quality 
improvement initiatives, use of electronic medical records with 
programmed physician reminders, and academic detailing 
(academic educational outreach to physicians on current 
guidelines and best practices) has the potential to prevent 
cardiovascular events and improve the quality o f life in 
patients with ischemic vascular disease. Coordinating disease 
management for patients with complex chronic disease can 
assist in optimizing vascular care and decreasing risk factors 
for vascular disease.
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The findings in this report are subject to at least six 
limitations. Many o f these limitations relate to the distinction 
between actual aspirin use in compliance with the USPSTF 
recommendations versus receipt o f a prescription during 
the visit assessed by the survey. First, prescribing aspirin and 
other antiplatelet medications is contraindicated in patients 
with diseases that put them at high risk for bleeding or in 
combination with other medications that augment the risk 
for bleeding. An underestimation of aspirin use might have 
occurred because the ability to identify those conditions 
definitively is limited because only three ICD-9-CM codes 
per visit were permitted. Second, this analysis cannot assess 
instances in which providers considered aspirin use for 
patients who met the USPSTF guidelines but elected not to 
prescribe the medication based on a risk assessment and the 
patient’s informed decision. Nonprescribing based on patient 
preference with respect to perceived benefit and harm is not 
captured in this analysis. Therefore, a higher percentage of 
physicians might be discussing aspirin with their patients than 
is reflected by what is documented as having been prescribed. 
Third, aspirin is an over-the-counter drug, so physicians might 
not be as likely to document aspirin use as they would be to 
document use of other prescription drugs. This might lead to 
an underestimation of providers’ compliance with guidelines 
and recommendations. Fourth, data on required risk factors 
frequently were absent. For example, information on tobacco 
use was missing at 28.1% of visits during 2005—2006 and 
27.5% of visits during 2007—2008 among those without 
ischemic vascular disease. For systolic blood pressure, the 
missing percentage was 3.8% during 2005—2006 and 7.1% 
during 2007—2008 for visits among those with ischemic 
vascular disease. In addition, certain risk factors (e.g., left 
ventricular hypertrophy and atrial fibrillation) would only 
be identified from one o f the three visit ICD-9-CM  visit 
diagnosis codes and might also be underestimated. This missing 
information might lead to underestimation of persons with a 
high enough risk for stroke or myocardial infarction to warrant 
consideration of aspirin or antiplatelet medications; it might 
also be differential with respect to patient characteristics. 
Fifth, the analysis was limited to primary care physicians 
and specialties most likely to care for patients with ischemic 
vascular disease or at high risk for ischemic vascular disease. 
Although this analysis indicated that cardiologists prescribed 
aspirin more frequently than primary care providers, this 
difference might reflect which provider assumes the prime role 
in addressing the patient’s CVD rather than reflect awareness 
of USPSTF guidelines. Finally, NAMCS and NHAMCS are 
representative of patient visits rather than individual patients. 
Therefore, patients who visit their doctors most frequently such 
as those who are sicker could potentially be represented more
often in the survey. This bias might lead to an overestimation 
o f aspirin use although this bias is presumed to be small given 
that NAMCS and NHAMCS surveys each physician practice 
for only a 1-week period. NCHS has taken steps to address 
some of the limitations inherent in this current analysis by 
gathering more detailed information regarding care delivered 
to patients with cardiovascular disease risk factors over time. 
In particular, in 2012, NAMCS and NHAMCS will include 
modules to gather data regarding care delivered during the 12 
months before the sampled visit for patients with cardiovascular 
disease risk factors such as hypertension, hypercholesterolemia, 
and prior stroke. For each prior visit, this new module includes 
data on medications prescribed, changes in medications, family 
history, and contraindications to certain medications. These 
changes in data collection methods should make it possible to 
better identify patients at risk for CVD per USPSTF guidelines 
who are without contraindication to aspirin therapy and 
better understand how prescribing aspirin and antiplatelet 
medications fits into patients’ broader treatment patterns over 
time (35).
Conclusion
The findings provided in this report indicate that aspirin 
and other antiplatelet medication prescribing among patients 
with ischemic vascular disease increased from 32.8% in 2003
(16) to 46.9% during 2007—2008. Caution should be used in 
interpreting the magnitude of this change because o f changes 
in the survey methods over time, which could bias comparisons 
with previous studies. However, these rates can serve as a 
baseline to track progress and measure the impact of use of 
preventive services as provided for in the Affordable Care Act. 
Increased use o f aspirin and other antiplatelet medications 
according to established guidelines for patients with ischemic 
vascular disease is likely to reduce incident and recurrent 
myocardial infarctions and stroke substantially. Because CVD 
and stroke are leading causes of disability and death, efforts to 
improve access to prevention through health risk assessments 
and early identification of modifiable health risk behaviors, 
the implementation of accountable care organizations to better 
coordinate care and improve quality of care for patients with 
chronic disease, and medication therapy management services 
by pharmacists are important steps in providing appropriate 
aspirin and other antiplatelet medications to patients with 
or at risk for cardiovascular disease. The Affordable Care Act 
provides opportunities with respect to all these aspects of 
care. Continued public and private partnerships can provide 
opportunities to maximize use of clinical preventive services 
such as prescribing aspirin and other antiplatelet medications 
to reduce the incidence of CVD and stroke.
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In troduction
Cardiovascular disease (CVD) is the leading cause of 
preventable death in the United States, and approximately 
1 million heart attacks and 700,000 strokes occur annually
(1). Hypertension is a major risk factor for cardiovascular 
disease and stroke; the unadjusted prevalence of hypertension 
among U.S. adults aged >18 years is approximately 31% 
(representing 68 million adults), and hypertension increases 
with age to approximately 70% among persons aged >65 years
(2). Hypertension contributes to one out of every seven deaths 
in the United States, and approximately 70% of persons who 
have a first heart attack or stroke or who have heart failure have 
hypertension (1). In clinical trials, treatment of hypertension 
was associated with substantial reductions in stroke incidence 
(35% -40% ), myocardial infarction (20% —25% ), and 
heart failure (>50%) (3). The estimated annual direct costs 
of hypertension are approximately $69.9 billion, and the 
estimated annual indirect costs are $23.6 billion (4).
Hypertension is defined as having a systolic blood pressure 
of >140 mm Hg or a diastolic blood pressure of >90 mm Hg 
(5). The U.S. Preventive Services Task Force guidelines for the 
prevention of hypertension call for hypertension screening in 
adults aged >18 years (a grade A recommendation: strongly 
recommended) (6). The seventh report of the Joint National 
Com m ittee on Prevention, D etection, Evaluation, and 
Treatment of High Blood Pressure (JNC7) recommended 
screening every 2 years in persons with blood pressure of 
<120/80 mm Hg and every year for those with a systolic 
blood pressure of 120—139 mm Hg or diastolic blood pressure 
of 80—89 mm Hg (5). Once treatment has been initiated in 
patients identified with hypertension, monthly follow-up and 
adjustment of medications is recommended until the blood 
pressure goal is reached. Because the relationship between 
systolic blood pressure and diastolic blood pressure and 
cardiovascular risk is continuous and graded, the actual level 
of blood pressure elevation should not be the sole factor when
making treatment decisions. Clinicians also should consider the 
patient’s overall cardiovascular risk profile, including smoking, 
diabetes, abnormal blood lipid values, age, sex, sedentary 
lifestyle, and obesity (5). In addition to pharmacologic 
therapy for hypertension control, nonpharm acologic 
therapies (e.g., reduction of dietary sodium intake, potassium 
supplementation, increased physical activity, weight loss, and 
reduction of alcohol intake) are associated with a reduction 
in blood pressure (7). This report analyzes 2005—2008 data 
from the National Health and Nutrition Examination Survey 
(NHANES) to determine the prevalence o f hypertension 
treatment and control among U.S. adults. Public health 
authorities and clinicians can use these data to identify 
population subgroups that might require additional strategies 
to access preventive services needed to control hypertension.
M ethods
To estimate the percentage of adults aged >18 years with 
hypertension whose blood pressure is under control, CDC 
analyzed data from NHANES from two survey cycles: 
2005—2006 and 2007—2008. NHANES is a complex, 
multistage probability sample o f the noninstitutionalized 
U.S. population.* Mobile examination center response rates 
for NHANES during the study period were 76%.  ̂ A total 
of 11,154 participants aged >18 years were interviewed 
and examined. An average o f up to three blood pressure 
measurements was obtained under standard conditions as 
part o f a single physical examination at a mobile examination 
center. Women who were pregnant or whose pregnancy status 
could not be determined (n = 505) were excluded, as were 
participants who did not have complete data to determine 
hypertension status (n = 601) or who were missing covariates
* Additional information is available at http://www.cdc.gov/nchs/nhanes.htm.
 ̂The response rate is the percentage of persons who were examined among all 
screened persons.
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of interest (n = 66). Some participants were excluded on the 
basis of more than one criteria, yielding an eligible sample 
of 10,043 persons; of these, 3,567 (35.5% unweighted) had 
hypertension and were included in this analysis.
Approximately 95% of the participants had two or three 
complete blood pressure measurements. Hypertension was 
defined as having an average systolic blood pressure of >140 
mmHg, an average diastolic blood pressure of >90 mmHg, 
or self-reported current use of blood pressure-lowering 
medication. Treatment of blood pressure was defined as the self­
reported current use of blood pressure-lowering medication, 
and its prevalence was calculated among all those defined as 
having hypertension. Blood pressure control was defined as 
having an average systolic blood pressure of <140 mmHg 
and diastolic pressure of <90 mmHg, and its prevalence was 
calculated among all those defined as having hypertension. 
Blood pressure control among persons who were treated was 
defined as an average systolic blood pressure of <140 mmHg 
and diastolic pressure of <90 mmHg, and its prevalence was 
calculated among persons who self-reported current use of 
blood pressure-lowering medication. Hypertension treatment, 
control, and control among treated estimates were analyzed by 
diagnosed diabetes and chronic kidney disease (CKD)status 
and by certain demographic characteristics (i.e., sex, age group, 
race/ethnicity, poverty-income ratio,§ education level, health 
insurance status,? having a usual source of medical care,** the 
number of times medical care was received in the previous 
year,tt and the type of place most often visited for health 
care§§). Diagnosed diabetes is based on a participant’s positive 
response to the question, “Other than during pregnancy, have 
you ever been told by a doctor or health professional that you 
have diabetes or sugar diabetes?” CKD was defined as estimated 
glomerular filtration rate of <60 mL/min/1.73 m2 calculated 
or albumin-creatinine ratio of >30 mg/g (8). Participants 
with missing data for CKD were assumed to be negative.
§ Poverty-income ratio defined as the family income relative to the family size 
and age of the members adjusted for inflation using the poverty thresholds 
developed by the U.S. Census Bureau. 
i  Private insurance, Medicare, and public insurance include all public non­
Medicare coverage, with the exception of the Indian Health Service (IHS). 
Uninsured includes participants with IHS or single-service plan only.
** Participants were asked, “Is there a place that you usually go when you are
sick or need advice about your health?” “Yes” responses include those who 
answered “yes” or “there is more than one place.”
^  Participants were asked, “During the last 12 months, how many times have 
you seen a doctor or other health professional about your health at a doctor’s 
office, a clinic, hospital emergency room, at home or some other place? Do 
not include times you were hospitalized overnight.”
§§ Participants were asked “What kind of place do you go to most often: is it a 
clinic, doctor’s office, emergency room, or some other place?” Answers were 
categorized as 1) a clinic, health center, or hospital outpatient department; 2) 
a doctor’s office or HMO; or 3) a hospital emergency room, other place, or 
none.
All analyses were conducted by using statistical software to 
account for sampling weights and to adjust variances for the 
multistage, clustered sample designs. Estimates for prevalence 
of hypertension were standardized to the age distribution of 
the 2000 U.S. standard population, based on the following 
age groups: 18-29, 30-39, 40-49, 50-59, 60-69, 70-79, 
and >80 years. Estimates o f treatment and control among 
those with hypertension and control among those treated were 
standardized to the age distribution of the 2000 U.S. standard 
population, based on the following age groups: 18-49, 50-59, 
60-69, 70-79, and >80 years.
To assess trends over time for the prevalence of hypertension, 
treatment, control, and control among treated, CDC analyzed 
data from the most recent five available NHANES cycles 
(1999-2000, 2001-2002, 2003-2004, 2005-2006, and 
2007-2008). Estimates from single cycles were standardized 
to the age distribution of the 2000 U.S. standard population 
based on the following age groups: 18-39, 40-59, 60-74, 
and >75 years. Logistic regression models, adjusted for sex, 
age group, and race/ethnicity, were used to test for statistically 
significant trends over time. Tests were considered statistically 
significant at the p<0.01 level.
Results
The findings indicate that prevalence of hypertension in U.S. 
adults did not change significantly from 1999-2000 (28.7%) 
to 2007-2008 (29.5%) (p = 0.41). However, the prevalence 
o f treatment, control among all persons with hypertension 
and control among persons taking blood pressure-lowering 
medication increased during the 10-year period 1999-2008 
(Figure).
During 2005-2008, the age-standardized prevalence of 
hypertension among U.S. adults was approximately 29.3%. 
The prevalence of hypertension among persons with diabetes 
or CKD was 42.9%. Persons with diabetes or CKD accounted 
for 24.6% of U.S. adults with hypertension. Among all persons 
with hypertension, the age-standardized estimated prevalence 
of pharmacologic treatment during 2005-2008 was 61.7% 
(Table). Control o f hypertension among all persons with 
hypertension was 43.6%, and control was 71.7% among 
persons who reported that they were currently taking blood 
pressure-lowering medication. The prevalence of treatment 
was lower among persons without diabetes or CKD (58.9%) 
compared with those with diabetes or CKD (70.8%). The 
prevalence o f treatment was lowest among males (54.9%), 
persons aged 18-39 years (37.4%), Mexican-Americans 
(45.3%), those without a usual source of medical care (19.3%), 
those who reported receiving medical care less than twice
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FIGURE. Estim ated prevalence of hypertension,* hypertension 
treatment,^ and blood pressure control5 among adults aged >18 












-  • Hypertension prevalence 
 Hypertension treatment**
- - - Blood pressure control among all persons with hypertension*
 Blood pressure control among persons being treated
for hypertension**
1999-2000 2001-2002 2003-2004 2005-2006 2007-2008
Year
* Hypertension defined as an answer of"yes” to the question,"Are you currently 
taking m edication to  lower your blood pressure?” or an average systolic blood 
pressure o f >140 mm Hg, or an average diastolic blood pressure o f >90 mm 
Hg (unweighted denom inator = 23,489).
f  Treatm ent defined as an answer o f "yes” to  the question, "Are you currently 
taking m edication to  lower your blood pressure?” Calculated am ong those 
w ith  hypertension (unweighted denom inator = 8,321).
§ Blood pressure contro l defined as an average systolic blood pressure o f <140 
mm Hg and an average diastolic blood pressure o f <90 mm Hg. Calculated 
am ong those w ith  hypertension (unw eighted denom ina tor = 8,321) and 
am ong those being treated (unweighted denom inator = 5,435).
11 Standardized to  the age d is tribu tion  o f the  2000 U.S. standard population.
W eighted estimates.
**  M ultivariable logistic regression analysis indicated a significant linear increase 
over tim e  after adjusting for sex, age group, and race/ethnicity (p<0.0001).
during the previous year (27.2%), those who reported being 
uninsured (41.9%), and those who reported usually receiving 
care at a hospital emergency room or other location (26.3%). 
The prevalence of control was lowest among males (38.8%), 
persons aged 18—39 years (31.4%), Mexican-Americans 
(32.0%), those without a usual source of medical care (10.8%), 
those who received medical care fewer than two times in the 
previous year (17.1%), those who reported being uninsured 
(26.5%), and those who reported usually receiving care at a 
hospital emergency room, other location or none (16.7%). 
The prevalence of control among persons who were treated 
was lowest among persons with diabetes or CKD (60.3%) 
compared with persons without these conditions and among 
persons aged >65 years (58.8%) (Table).
Discussion
The results of this analysis demonstrate that while the 
prevalence of hypertension remained flat at approximately 
30% during 1999—2008, the prevalence of hypertension 
treatment and control increased steadily during the 10-year 
period. Despite this progress, prevalence of treatment, control 
among all persons with hypertension, and control among 
persons who were treated are lower among certain subgroups 
of the population. Persons aged 18—39 years had the lowest 
prevalence of treatment and control compared with persons 
aged >40 years, but younger persons who reported that they 
were currently taking hypertension medications had the highest 
control levels (84.1%) among the three age groups surveyed. 
Persons with diabetes or CKD had a higher prevalence of 
treatment compared with those without these conditions 
(70.8% versus 58.9%), but control among persons who were 
treated was lower for persons with diabetes or CKD (60.3% 
versus 76.0%). Control rates for persons with diabetes or CKD 
would have been even lower if control were defined as <130/80 
mm Hg for these groups at high risk for CVD as recommended 
by the American Diabetes Association and the National Kidney 
Foundation (9,10). Persons with diabetes or CKD might visit a 
clinician more frequently and are likely to be under treatment 
for hypertension as part o f their chronic care management, but 
the complexity of the multiple comorbidities might make the 
hypertension more difficult to control.
The most disadvantaged persons in terms of treatment and 
control are those with no usual source of health care, those 
who received medical care fewer than two times in the previous 
year, those who were uninsured, and those who reported 
usually receiving care at a hospital emergency room, receiving 
care at some other location, or not receiving care. However, 
despite low levels of treatment and control for persons without 
regular access to primary health care, those who reported that 
they were taking hypertension medications currently achieved 
levels of control similar to persons who had regular access to 
primary care. On the basis of this analysis, approximately 18 
million adults with hypertension have no usual source of care, 
receive care fewer than two times per year, are uninsured, or 
usually receive care at an emergency room or other location, 
representing 37% of the adult population with hypertension.
Impending changes in the U.S. health-care system offer 
opportunities to increase prevalence of preventive services to 
control hypertension. The Patient Protection and Affordable 
Care Act of 2010 (as amended by the Healthcare and Education 
Reconciliation Act of 2010 and referred to collectively as the
0
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TABLE. Estimated prevalence* of blood pressure treatment and control among all adults (aged>18 years) with hypertension, and control 












l l V * U C I  JVJI I j VVIL I I
hypertension1 % (95% CI) % (95% CI) treated1 % (95% CI)
Morbidity
Diabetes or CKD§ 1,292 70.8 (64.8-76.2) 42.4 (35.9-49.1) 1,018 60.3 (53.0-67.2)
No diabetes or CKD 2,275 58.9 (55.3-62.4) 44.2 (41.5-46.9) 1,509 76.0 (72.3-79.4)
Total 3,567 61.7 (58.6-64.8) 43.6 (40.9-46.4) 2,527 71.7 (68.5-74.7)
Sex
Male 1,770 54.9 (50.3-59.3) 38.8 (35.0-42.9) 1,166 71.6 (65.9-76.7)
Female 1,797 71.4 (68.1-74.5) 51.3 (48.1-54.5) 1,361 72.3 (68.7-75.7)
Age group (yrs)
18-39 261 37.4 (30.2-45.2) 31.4 (24.6-39.1) 101 84.1 (74.9-90.3)
40 -64 1,600 65.6 (61.9-69.2) 47.2 (44.1-50.3) 1,110 72.1 (67.8-76.1)
>65 1,706 79.6 (77.2-81.8) 47.0 (44.2-49.8) 1,316 58.8 (55.9-61.7)
Race/Ethnicity11
White, non-Hispanic 1,842 62.6 (58.3-66.7) 46.1 (42.8-49.5) 1,335 74.8 (71.3-78.1)
Black, non-Hispanic 954 67.4 (63.5-71.1) 41.4 (37.6-45.2) 706 61.9 (57.0-66.6)
Mexican-American 442 45.3 (39.2-51.6) 32.0 (27.2-37.2) 272 73.9 (65.4-80.8)
Poverty-income ratio***
<100% 551 67.3 (60.1-73.8) 43.5 (35.0-52.5) 390 65.3 (55.4-74.0)
100%-199% 1,571 60.7 (54.4-66.6) 40.2 (33.8-46.8) 1,093 67.0 (60.4-73.0)
200%-499% 618 63.1 (57.1-68.7) 46.4 (41.6-51.4) 448 74.5 (67.1-80.6)
>500% 563 60.3 (53.1-67.0) 46.9 (40.9-53.0) 413 79.3 (72.4-84.9)
Education (age >25 yrs)
Less than high school 1,184 57.8 (49.6-65.6) 35.8 (27.5-45.1) 815 62.8 (52.9-71.7)
High school graduate 925 65.0 (60.3-69.4) 46.9 (41.1-52.7) 671 73.1 (66.3-79.0)
Some college 829 65.2 (59.2-70.9) 44.6 (39.3-50.1) 601 68.8 (62.7-74.2)
College graduate 578 63.3 (55.1-70.8) 49.7 (42.8-56.6) 433 79.7 (72.4-85.4)
Usual source of care+tt
Yes 3,329 66.6 (63.0-70.0) 47.5 (44.5-50.5) 2,476 72.1 (69.0-75.0)
No 238 19.3 (13.9-26.2) 10.8 (6.7-17.1) 51 59.4 (33.6-80.9)
No. times received health care 
in past 12 months§§§
0-1 680 27.2 (22.9-31.9) 17.1 (13.1-22.0) 221 65.8 (52.3-77.1)
2-3 2,173 74.5 (70.8-77.9) 53.2 (49.4-57.0) 1,715 71.7 (67.4-75.7)
>4 714 74.3 (67.0-80.4) 54.5 (47.8-61.1) 591 74.2 (67.5-79.9)
Health insurance status111
Medicare 1,788 79.6 (64.5-89.3) 62.3 (48.6-74.3) 1,399 78.5 (70.2-84.9)
Private 1,032 61.6 (55.9-67.0) 42.5 (38.9-46.2) 694 69.5 (64.4-74.1)
Public 308 70.1 (59.7-78.8) 49.4 (39.6-59.2) 233 72.2 (64.9-78.5)
Uninsured 439 41.9 (34.6-49.6) 26.5 (20.4-33.7) 201 62.7 (52.5-72.0)
Type of place usually receive care****
Clinic/Health center/Hospital ou tpa tien t 675 59.6 (50.8-67.9) 41.4 (32.6-50.9) 490 70.6 (61.8-78.1)
Doctor's office/HM O 2,543 69.1 (65.6-72.4) 49.6 (46.5-52.7) 1,928 72.4 (68.8-75.7)
Hospital ER/Other/None 349 26.3 (20.6-33.1) 16.7 (12.1-22.5) 109 64.9 (48.9-78.2)
Abbreviations: CI = confidence interval; CKD = chronic kidney disease; HMO = health maintenance organization; ER = emergency room.
* Weighted estimates standardized to the age distribution of the 2000 U.S. standard population.
+ Hypertension defined as either 1) an answer of "yes” to the question, "Are you currently taking medication to lower your blood pressure?” 2) an average systolic blood pressure
of >140 mm Hg, or 3) an average diastolic blood pressure of >90 mm Hg.
§ Diabetes defined by self-reported diabetes. CKD defined as estimated glomerular filtration rate of <60 mL/min/1.73 m2 calculated or albumin-creatinine ratio o f >30 mg/g.
Participants missing data for CKD were assumed to be negative.
1 Unweighted sample size.
** An answer of "yes” to the question, "Are you currently taking medication to lower your blood pressure?” Asked of those with hypertension.
Average blood pressure <140/90 mmHg on examination among all persons with hypertension.
§§ Average blood pressure o f <140/90 mmHg on examination among all persons reporting current use of medications.
11 Participants of other racial/ethnic groups included in analysis, but are not reported.
*** Poverty-Income Ratio is an index for the ratio of family income to poverty as defined by the U.S. Census Bureau. Available at http://www.census.gov/hhes/www/poverty/methods/ 
definitions.html#ratio of income to poverty.
Participants were asked, "Is there a place that you usually go when you are sick or need advice about your health?” "Yes” responses include those who answered "yes” or "there 
is more than one place.”
§§§ participants were asked, "During the last 12 months how many times have you seen a doctor or other health professional about your health at a doctor's office, a clinic, hospital 
emergency room, at home, or some other place? Do not include times you were hospitalized overnight.”
111 Medicare includes all participants who had Medicare. Private does not include those participants with Medicare. Public insurance includes participants who reported only Indian 
Health Service. Uninsured includes participants with single service plan only.
**** Participants were asked, "What kind o f place do you go to most often: is it a clinic, doctor>s office, emergency room, or some other place?”
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Affordable Care Act [ACA]) expands insurance coverage, 
consumer protections, and access to primary care (11,12). The 
law expands Medicaid to cover persons with incomes up to 
133% of the federal poverty level (ACA §2001). Starting in 
2014, state-based insurance exchanges'"'"'' will provide access 
to health insurance for small employers and to persons and 
families not eligible for Medicaid or the Children’s Health 
Insurance Program, and federal tax credits will help those living 
at 100%—400% of the federal poverty level (ACA §1311). 
The Affordable Care Act also provides for guaranteed issue of 
insurance, ending denials of coverage for preexisting conditions 
(hypertension is considered a preexisting condition by certain 
insurers) (ACA §1201), and prohibits rescission (dropping 
coverage), lifetime coverage limits, and limits on emergency 
room use. The law also expands access to primary care by 
increasing funding to community health centers, which provide 
primary health-care services to uninsured and underserved 
populations (ACA §5601.) The primary care workforce will 
be strengthened through provisions that increase funding for 
the National Health Service Corps to increase the number of 
providers in underserved areas; provide incentives to expand 
the number of primary care physicians, nurse practitioners, and 
physician assistants; and offer scholarships and loan repayments 
for those working in underserved areas. Increasing access to 
primary care and increasing the proportion of persons with 
a usual care provider can lead to better diagnosis, treatment, 
and control of hypertension.
Hypertension screening in adults aged >18 years is a grade 
A recommendation from USPSTF (6) and therefore is covered 
without cost sharing as ofJanuary 1, 2011, by Medicare (ACA 
§4104) and will be covered by the new health exchanges that go 
into effect starting in 2014 (ACA §1001). Beginning January 
1, 2013, state Medicaid programs that offer U.S. Preventive 
Services Task Force grade A or B services at no cost sharing 
will receive an enhanced federal matching rate. Currently, 
the U.S. Preventive Services Task Force has not given a grade 
A or B recommendation to existing clinical guidelines for 
hypertension treatment and management, which means that 
hypertension treatment and management are subject to cost 
sharing. However, provisions of the Affordable Care Act might 
reduce patient out-of-pocket costs for clinician visits and 
hypertension medications. These include an essential health 
benefits package (ACA §1302) that limits cost sharing and 
includes preventive and wellness services, prescription drugs,
Beginning in 2014, a competitive insurance marketplace will be set up in 
the form of state-based insurance exchanges. These exchanges will allow 
eligible persons and small businesses with up to 100 employees to purchase 
health insurance plans that meet criteria outlined in the Affordable Care Act 
(ACA §1311). I f  a state does not create an exchange, the federal government 
will operate it.
and chronic disease management. Each state will determine 
which evidenced-based clinical services will be included in the 
state’s essential health benefits package. Clinical services for 
controlling hypertension (e.g., team-based coordination of care 
and reducing or eliminating cost-sharing for medications and 
other services such as lifestyle counseling) might be beneficial 
because studies indicate that hypertension control is one of the 
preventive services with the greatest potential for preventing
deaths (13—15).
Persons aged >65 years accounted for 38% of persons with 
hypertension in this study. For such persons, the Affordable 
Care Act makes several changes to Medicare Part D to reduce 
patient out-of-pocket costs for prescription drugs. In 2010, 
Medicare beneficiaries who reached the coverage gap (the 
difference of the initial coverage limit and the catastrophic 
coverage) in expenses were eligible to receive a $250 rebate from 
Medicare. Beginning in 2011, Medicare beneficiaries reaching 
the coverage gap will be given a 50% discount on the total 
cost of brand name drugs while in the gap and pay a reduced 
rate for generic medications. Medicare will phase in additional 
discounts on the cost of both brand name and generic drugs. By 
2020, these changes will effectively close the coverage gap and 
rather than paying the full cost of prescription drugs while in 
the gap, a senior’s responsibility will be 25% of the costs (16).
The American College ofCardiology and the American Heart 
Association recommend that patients have a comprehensive 
cardiovascular health assessment at least every 5 years starting 
at age 18 years, and that those with cardiovascular risk factors 
such as diabetes or hypertension or those who smoke cigarettes 
should have their cardiovascular health risk assessed more 
frequently (17). A health risk assessment is provided for in the 
annual wellness visit for Medicare, as are counseling services 
aimed at reducing risk factors for chronic disease, including 
hypertension, heart disease, and stroke (ACA §4103). In 
December 2011, CDC issued a framework for patient-centered 
health risk assessments for persons aged >65 years (18).
The management of hypertension is also likely to benefit 
from provisions of the Affordable Care Act that call for 
improving health-care quality and making system-level changes 
to health-care delivery. The National Strategy to Improve 
Health Care Quality (ACA §3011) calls for promoting 
the most effective prevention and treatment practices for 
the leading causes of mortality, starting with CVD, and 
includes efforts to decrease preventable hospitalizations and 
readmissions (19). Hospitalization for hypertension, also 
referred to as an ambulatory-care—sensitive condition, is 
preventable; such hospitalization could be avoided if patients 
were to receive early and continued access to quality health 
care (20). Other quality improvement initiatives that might 
promote treatment according to guidelines for hypertension
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control include the Physician Quality Reporting System 
(ACA §3002), the development of quality measures (ACA 
§3013) and meaningful use of clinical data (21), incentives 
for physicians to join accountable care organizations to better 
coordinate patient care and improve quality, creation of 
community health teams that can coordinate prevention and 
disease management and support primary care providers (ACA 
§3502), and the development of medication management 
services by pharmacists that can increase patient adherence to 
prescribed medications (ACA §3503). Quality improvement 
efforts that improve the care of patients with hypertension 
can have substantial public health impact because even small 
improvements in blood pressure control can reduce the risk 
of cardiovascular disease. Health system changes might be of 
particular value to persons with hypertension who also have 
diabetes or CKD as the complexity of the therapeutic regimes 
for these patients might benefit from better coordinated 
disease management. In September 2011, as part of national 
health quality improvement efforts, the U.S. Department of 
Health and Human Services launched the Million Hearts 
national initiative (22) to prevent 1 million heart attacks and 
strokes over the next 5 years. Led by CDC and the Centers 
for Medicare and Medicaid Services, the Million Hearts 
initiative aims to improve heart disease and stroke prevention 
by improving access to effective care, improving the quality 
of care, focusing more clinical attention on heart attack and 
stroke prevention, increasing public awareness of how to lead 
a heart-healthy lifestyle, and increasing the consistent use of 
high blood pressure and cholesterol medications.
Improving the management of hypertension will require 
further efforts. For example, standardization of health 
information technology that allows exchange of clinical data 
between health-care providers could increase awareness of 
hypertension diagnosis and control among all of a patient’s 
providers. A doption o f electronic health records that 
include decision support tools that prompt clinicians to ask 
patients about medication adherence also could improve the 
management of hypertension (23). Barriers to hypertension 
medication adherence should be addressed (e.g., costs, health 
literacy, lack of perceived benefit, and multiple comorbidities) 
and nonpharmacologic approaches that can reduce blood 
pressure should be emphasized (e.g., adoption of a healthy diet 
that includes reduction of dietary sodium intake, increased 
physical activity, weight loss, smoking cessation, and reduction 
of alcohol intake) (7).
The findings in this report are subject to at least three 
limitations. First, the population of persons with hypertension 
in this study might underestimate the U.S. population of 
persons with hypertension because older persons residing 
in nursing homes and other institutions, who have a higher
prevalence of age-related hypertension, are not included in 
NHANES. Second, although data collection is standardized, 
NHANES self-reported data on the use of blood pressure 
medications and diagnosis of diabetes from interviews and 
questionnaires are subject to inaccuracies or recall bias. Finally, 
the estimated prevalence of adults with hypertension might 
be underestimated because only persons who had measured 
high blood pressure during the examination and those who 
reported taking pharmacologic treatment to achieve control of 
hypertension were included in the analysis. Certain participants 
who might have received a diagnosis of hypertension previously 
but who had normal blood pressure measurements during the 
examination, perhaps as a result of life-style habits (e.g., diet 
and exercise), were not included as having hypertension in 
the analysis.
Conclusion
Hypertension control has the potential to prevent a 
substantial number of deaths because although hypertension 
is common (affecting approximately 30% of the U.S. adult 
population), therapeutic interventions are effective, and control 
rates are below achievable levels (13). If implementation of 
health-care reform increases the number of people with regular 
access to primary care and access to affordable medications, it 
could have a substantial impact on control of hypertension in 
the U.S. population.
R eferences
1. Roger V L , Go AS, Lloyd-Jones DM , et al. Heart disease and stroke 
statistics— 2011 update: a report from the American Heart Association. 
Circulation 2011;123:e18-209.
2. C D C . Vital signs: prevalence, treatment, and control of hypertension— 
United States, 1999-2002 and 2005-2008. M M W R 2011;60:103-8.
3. Neal B , McMahon S, Chapman N . Effects of A C E inhibitors, calcium 
antagonists, and other blood pressure-lowering drugs. Lancet 
2000;356:1955-64.
4. Heidenreich PA, Trogdon JG , Khavjou OA, et al. Forecasting the future 
of cardiovascular disease in the United States: a policy statement from 
the American Heart Association. Circulation 2011;123:933-44.
5. National Heart, Lung, and Blood Institute. Seventh report of the Joint 
National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
6. US Preventive Services Task Force. Screening for high blood pressure: 
U.S. Preventive Services Task Force reaffirmation recommendation 
statement. Ann Intern Med 2007;147:783-6.
7. Institute of Medicine. A  population-based policy and systems change 
approach to prevent and control hypertension. Washington, D C : The 
National Academic Press; 2010.
8. Levey AS, Stevens LA, Schmid CH , CKD-EPI (Chronic Kidney Disease 
Epidemiology Collaboration), et al. A  new equation to estimate 
glomerular filtration rate. Ann Intern Med 2009;150:604-12.
9. American Diabetes Association. Standards of medical care in 
diabetes— 2011. Diabetes Care 2011;34:S11—61.
24 MMWR / June 15, 2012 / Vol. 61
Supplement
10. National Kidney Foundation. Clinical practice guidelines and clinical 
practice recommendations for diabetes and chronic kidney disease. Am
J Kidney Dis 2007;49:S13-119.
11. Patient Protection and Affordable Care Act of 2010. Pub. L. No. 114—48 
(March 23, 2010), as amended through May 1, 2010. Available at http:// 
www.healthcare.gov/law/full/index.html. Accessed May 17, 2012.
12. Steinbrook R. Health care and the American Recovery and Reinvestment 
Act. N  Engl J Med 2009;360:1057-60.
13. Farley TA, Dalal MA, Mostashari F, Frieden TR . Deaths preventable in 
the US by improvements in use of clinical preventive services. Am J Prev 
Med 2010;38:600-9.
14. Silverstein M D, Ogola G, Mercer Q, et al. Impact of clinical preventive 
services in the ambulatory setting. Proc (Bayl Univ Med Cent) 
2008;21:227-35.
15. Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman 
MJ, Solberg LI. Priorities among effective clinical preventive services: 
results of a systematic review and analysis. Am J Prev Med 
2006;31:52-61.
16. US Department of Health and Human Services. What is the donut hole? 
Available at http://www.healthcare.gov/news/blog/donuthole.html.
Accessed May 17, 2012.
17. Redberg RF, Benjamin E J, Bittner V, et al. A H A /A C C F 2009 
performance measures for primary prevention of cardiovascular disease 
in adults. Circulation. 2009;120:1296-336.
18. Goetzel RZ, Staley P, Ogden L, et al. A  framework for patient-centered 
health risk assessments: providing health promotion and disease 
prevention services to Medicare beneficiaries. Available at http://www. 
cdc.gov/policy/opth/hra. Accessed May 17, 2012.
19. US Department of Health and Human Services. National strategy to 
improve health-care quality. Available at http://www.hhs.gov/news/reports/ 
quality/nationalhealthcarequalitystrategy.pdf. Accessed May 17, 2012.
20. Agency for Healthcare Research and Quality. Guide to prevention quality 
indicators, hospital admission for ambulatory care sensitive conditions 
(version 3.1). Available at http://www.qualityindicators.ahrq.gov. 
Accessed May 17, 2012.
21. Blumenthal D , Tavenner M. The “meaningful use” regulation for 
electronic health records. N Engl J Med 2010;363:501^.
22. Frieden TR , Berwick DM. The “Million Hearts” initiative— preventing 
heart attacks and strokes. N  Engl J Med 2011;365:e27.
23. Hill MN, Miller N H, Degeest S, American Society of Hypertension 
Writing Group. Adherence and persistence with taking medication to 
control high blood pressure. J Am Soc Hypertens 2011;5:56-63.
MMWR / June 15, 2012 / Vol. 61 25
Supplement
Screening for Lipid Disorders Among Adults —  National Health and 
Nutrition Examination Survey, United States, 2005-2008
Cathleen D. Gillespie, M S1 
Nora L. Keenan, PhD1 
James B. Miner, MPH, MA2 
Yuling Hong, M D, PhD1
1D ivision fo r  Heart Disease and Stroke Prevention, National Center fo r  Chronic Disease Prevention and Health Promotion 
2Financia l Management Office, Office o f  the C h ie f Operating Officer
Corresponding author: Cathleen D. Gillespie, National Center for Chronic Disease Prevention and Health Promotion, CD C , 4770 Buford Hwy, MS F-72, 
Atlanta, GA 30341. Telephone: 770-488-5855; Fax: 770-488-8334; E-mail: CGillespie@cdc.gov.
In troduction
Cardiovascular disease (CVD) is the leading cause of 
preventable death in the United States (1), a major contributor 
to adult disability (2), and one of the most expensive 
conditions treated in U.S. hospitals (3). Lipid disorders (e.g., 
high blood cholesterol and triglycerides) increase the risk 
for atherosclerosis, which can lead to coronary heart disease 
(CHD), which accounts for a substantial proportion of 
cardiovascular mortality (1). Screening for lipid abnormalities 
is essential in detecting and properly managing lipid disorders 
early in the atherogenic process, thereby preventing the 
development of atherosclerotic plaques and minimizing 
existing plaques. Based on evidence-based studies, the United 
States Preventive Services Task Force (USPSTF) concluded that 
lipid measurement can identify asymptomatic adults who are 
eligible for cholesterol-lowering therapy (4).
According to USPSTF, the preferred screening tests for 
dyslipidemia or lipid disorders are total cholesterol (TC) and 
high-density lipoprotein cholesterol (HDL-C) on fasting 
or nonfasting samples. Screening recommendations are 
classified as having a rating of A (strongly recommended) or 
B (recommended) on the basis of sex, age, and risk factors 
for CHD (Box). USPSTF also stated that a complete fasting 
lipoprotein panel (i.e., TC, HDL-C, low-density lipoprotein 
cholesterol [LDL-C] and triglycerides [TG]) is useful for persons 
with dyslipidemia identified through TC and HDL-C screening 
tests, although they did not specify the numerical cut-points 
for determining lipid disorders (4). According to USPSTF, 
reasonable screening intervals include every 5 years with shorter 
or longer intervals depending on screening results (4).
In addition to the USPSTF guidelines, lipid disorder 
screening recommendations also have been published by the 
National Cholesterol Education Program (NCEP) (5), which 
recommends a complete fasting lipoprotein profile (TC, 
LDL-C, and TG) for all adults aged >20 years as the preferred 
screening test. In general, NCEP recommends target levels for 
fasting TC of <200 mg/dL, HDL-C of >60 mg/dL, TG of <100
BOX. U.S. Preventive Services Task Force recommendations for 
lipid disorders screening — United States, 2008
Age group Increased risk 









Abbreviation: CHD = coronary heart disease.
* Increased risk for CH D includes one or more of the following 
conditions: diabetes (determined by self-reported diabetes, fasting 
plasma glucose>126 mg/dL, or glycohemoglobin (A1c) >6.5%), history 
of CH D , family history of a heart attack or angina before age 50 years, 
current cigarette smoking (self-reported smoking every day or some 
days or a measured serum cotinine level of >10mg/ml), hypertension 
(average systolic blood pressure of >140 mmHg, average diastolic blood 
pressure of >90 mmHg, or self-reported currently taking blood 
pressure-lowering medication), and obesity (body mass index [weight 
(kg)/height m2] of >30).
' A = benefits of screening substantially outweigh the potential harms; 
B = benefits of screening moderately outweigh the potential harms.
mg/dL, and LDL-C of <100 mg/dL. NCEP treatment goals 
focus on LDL-C and vary depending on a history of, or the 
risk for, developing CHD: <100 mg/dL for those considered 
at high risk, <130 mg/dL for those considered at intermediate 
risk, and <160 mg/dL for those considered at low risk.
Recent population-based reports on the prevalence of 
screening for lipids (6), lipid levels (7,8), and the prevalence,
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treatment, and control o f high LDL-C using NCEP CHD 
risk categories have been published (9), but these reports did 
not address the outcomes in terms of USPSTF lipid disorder 
screening recommendations, i.e., by the groups recommended 
or eligible for screening.
This report analyzes 2005—2008 data from the National 
Health and N utrition Examination Survey (NHANES) 
to determine what proportion o f the adult population 
should be screened for cholesterol based on the USPSTF 
recommendations, the prevalence of lipid screening among 
those for whom screening is recommended, and the prevalence 
of high LDL-C, LDL-C treatment and control by screening 
recommendation category. The results o f this report will 
provide baseline estimates that researchers can use to track 
potential improvement over time in lipid screening as well 
as progress in LDL cholesterol treatment and control among 
those who are at increased risk for CVD.
M ethods
To determine 1) the percentage of adults aged >20 years 
w ithin each USPSTF-recommended screening category 
determined by sex, age, and CH D  risk factors (0 or >1); 2) 
the prevalence of lipid screening within the previous 5 years 
by sex, age, and USPSTF screening category; 3) the percentage 
of those within each USPSTF screening category for whom 
a fasting full lipid panel would be useful based on the NCEP 
guidelines for fasting or nonfasting mean TC or HDL-C; 
and 4) the prevalence, treatment, and control o f high LDL-C 
within each USPSTF screening category, CDC analyzed 
2005-2008 NHANES data.
NHANES is a nationally representative cross-sectional 
survey of the health and nutritional status of the U.S. civilian, 
noninstitutionalized population (10). Although NHANES 
data are collected continuously, the data are released in 
2-year cycles. The survey includes a household interview 
and a detailed physical examination. A subsample of study 
participants is selected randomly, and participants are asked to 
fast before the physical examination. Participants are included 
in the fasting subsample if they have fasted for 8-24 hours 
before blood is drawn for lipid testing. NHANES data were 
aggregated and analyzed from two survey periods (2005-2006 
and 2007-2008). During 2005-2008, the overall survey 
response rate for adults aged >20 years was 70.8%; 10,480 
adults aged >20 years took part in the home interviews and 
were examined at NHANES mobile examination centers. 
After exclusion of participants who were pregnant or for whom 
needed data were missing, the examination sample comprised 
8,485 adults and the fasting sample comprised 3,427 adults.
Participants were classified into USPSTF-recommended 
sex, age, and risk categories for lipid screening. In accordance 
with USPSTF guidelines and available NHANES data, 
participants with one or more of the following conditions 
were assessed as having an increased risk for CHD: diabetes 
(ever told they had diabetes, fasting glucose of >126 mg/dL, or 
glycohemoglobin [A1C] of >6.5%), personal history of CHD 
(ever told they had CHD, heart attack, or angina), family 
history of heart attack or angina before age 50 years in close 
relatives (blood relatives including father, mother, sisters, or 
brothers), current cigarette smoking (self-reported smoking 
every day or some days or a measured serum cotinine level of 
>10 ng/mL), hypertension (an average of up to three blood 
pressure measurements of >140/90 mmHg or self-reported 
current use o f antihypertensive medication), and obesity 
(body mass index [weight (kg)/height (m)2) >30). Detailed 
methods for using 2005-2008 NHANES data to categorize 
persons by level o f CH D  risk into one of the three NCEP 
risk groups for LDL-C-lowering therapy have been described 
elsewhere (9). In addition to estimating the proportion of 
the sample within each USPSTF recommendation group, 
researchers estimated the prevalence of cholesterol screening 
and the prevalence ofTC >200 mg/dL or HDL-C <40 mg/dL. 
The prevalence, treatment, and control of high LDL-C were 
estimated by sex and screening recommendation group among 
the fasting subsample. Treatment was defined as self-reported 
use of cholesterol-lowering medication among those with high 
LDL-C; prevalence of control was defined as having a fasting 
LDL-C below the NCEP treatment goals, depending on CHD 
risk, and was calculated among all persons with high LDL-C.
National estimates and 95% confidence intervals were 
calculated using SAS-callable SUDAAN (Research Triangle 
Institute, Research Triangle Park, North Carolina) and applying 
appropriate survey statistical weights for the examination 
sample or the fasting subsample to account for the probability 
of selection and nonresponse. Univariate chi-square tests of 
independence were used to assess differences in prevalence 
between the screening recommendation groups. Tests were 
considered statistically significant at the p<0.01 level.
Results
According to the USPSTF guidelines, 88.7% of the U.S. 
adult population aged >20 years should be screened for lipid 
abnormalities (Table 1). The USPSTF recommendation for 
screening applies to 94.4% of all adult men, including 76.2% 
of adult men being eligible under the grade A recommendation 
and 17.8% being eligible under the grade B recommendation. 
Among all adult women, the recommendation for screening
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TABLE 1. Prevalence of lipid screening* and estimated prevalence of elevated total or low high-density lipoprotein cholesterol (HDL-C) among 
adults+ aged >20 years, by U.S. Preventive Services Task Force (USPSTF) lipid screening recommendation categories5 — National Health and 
Nutrition Examination Survey, United States, 2005-2008
Screening recommendation group No.1
Sample
distribution Total screened
Elevated total or low 
HDL-C++
%** (95% CI) % (95% CI) % (95% CI)
Total 8,485 100.0 68.4 (66.6-70.3) 57.5 (56.0-59.0)
Recom mendation A or B 7,707 88.7 (87.6-89.8) 70.1 (68.3-71.8)§§ 59.4 (57.9-60.8)§§
Recom mendation A 5,914 64.8 (62.9-66.7) 77.7 (75.7-79.6) 62.4 (60.7-64.0)
Recom mendation B 1,793 23.9 (22.4-25.4) 49.3 (46.0-52.7)" 51.3 (48.1-54.5)"
No recom m endation 778 11.3 (10.2-12.4) 55.6 (51.8-59.3) 42.7 (38.5-47.1)
Men 4,537 52.2 (51.2-53.2) 64.4 (61.8-67.0) 59.8 (57.7-61.9)
Recom mendation A or B 4,326 94.4 (93.3-95.4) 66.6 (64.0-69.1)§§ 61.0 (58.9-63.0)§§
Recom mendation A 3,630 76.6 (74.4-78.7) 73.6 (70.9-76.2) 61.8 (59.7-64.0)
Recom mendation B 696 17.8 (16.2-19.5) 36.5 (32.4-40.8)" 57.3 (52.3-62.2)
No recom m endation 211 5.6 (4.6-6.7) 27.5 (20.4-35.9) 39.7 (32.1-47.7)
Women 3,948 47.8 (46.8-48.8) 72.8 (70.9-74.7) 55.0 (52.8-57.2)
Recom mendation A or B 3,381 82.5 (80.6-84.2) 74.4 (72.2-76.5)§§ 57.4 (55.0-59.7)§§
Recom mendation A 2,284 52.0 (49.3-54.6) 84.3 (82.3-86.1) 63.2 (60.8-65.5)
Recom mendation B 1097 30.5 (28.3-32.8) 57.6 (53.7-61.3)" 47.5 (43.3-51.7)"
No recom m endation 567 17.5 (15.8-19.4) 65.3 (61.4-69.1) 43.8 (38.8-48.9)
* Cholesterol screening w ith in  the  past 5 years de term ined by the  response to  the question "Have you ever had your blood cholesterol checked?” and response to 
the  question: "About how  long has it been since you last had your blood cholesterol checked? Has it been...Less than 1 year ago, 1 year bu t less than 2 years ago, 
2 years bu t less than 5 years ago?”
+ Excluding pregnant wom en.
§ USPSTF recommends screening for lip id disorders for all men aged >35 years (grade A recom m endation: benefits o f screening substantially ou tw eigh the potential 
harms) and men aged 20-34 years (grade B recom m endation: benefits o f screening m oderately ou tw eigh the potential harms), wom en aged 20-44 years (grade 
B recom m endation), and wom en aged >45 years (grade A recom m endation) w ho are at increased risk for coronary heart disease. Risks include diabetes (determ ined 
by self-reported diabetes, fasting plasma glucose>126 m g/dL, or g lycohem oglobin o f >6.5%), history o f coronary heart disease (CHD), fam ily history o f a heart 
attack or angina before age 50, current smoker, hypertension (average systolic blood pressure o f >140 mmHg, average diastolic blood pressure o f >90 mmHg, or 
self-reported currently taking blood pressure-lowering medication), and obesity (body mass index [BMI] [kg/m 2] o f >30).
I Unweighted sample size.
**  All estimates are calculated using the  exam ination sample weight.
++ Serum total cholesterol o f >200 m g/dL or serum HDL cholesterol o f <40 mg/dL.
§§ Univariate % tests o f independence significant (p<0.01): grade A or B recom m endation versus no recom m endation.
II  Univariate x 2 tests o f independence significant (p<0.01): grade A recom m endation versus grade B.
applies to 82.5%, including 52.0% being eligible under the 
grade A recommendation and 30.5% being eligible under 
the grade B recommendation. The grade A recommendation 
applies to the majority of adults aged >20 years (64.8%), with 
the remaining 23.9% for whom screening is recommended 
being eligible under the grade B recommendation. Among 
adults for whom screening is recommended, 70.1% reported 
having their cholesterol checked within the previous 5 
years. Two thirds (66.6%) of men for whom screening is 
recommended reported having their cholesterol checked 
within the previous 5 years; the prevalence among women 
recommended for screening was 74.4%. The prevalence 
of cholesterol screening was higher among those who were 
eligible under either the grade A or grade B recommendation 
compared with those for whom no recommendation is made 
(70.1% versus 55.6%, respectively; p<0.01); this pattern was 
observed among both men and women. The prevalence of 
screening was higher among the grade A-eligible participants 
than it was among the grade B—eligible participants (77.7% 
versus 49.3%, respectively; p<0.01); this pattern also was 
observed in both men and women. Although the prevalence
of elevated TC or low HDL-C was higher among those eligible 
for lipid screening based on the USPSTF recommendations, 
42.7% of those to whom the screening recommendations do 
not apply had cholesterol levels indicating that a full fasting 
lipid panel would be warranted. The prevalence of high TC or 
low HDL-C among men not eligible for screening under the 
USPSTF recommendations was 39.7%, and among women 
not eligible for screening the prevalence was 43.8%.
The prevalence of high LDL-C (LDL-C greater than the 
NCEP goal or current lipid-lowering medication use) was 
higher among those for whom screening is recommended, 
compared with those for whom the recommendations do not 
apply (40.5% versus 13.7%, respectively; p<0.01) (Table 2). 
This significant difference also was observed among women 
(41.6% versus 17.4%, respectively; p<0.01). The prevalence 
of high LDL-C also was higher among the grade A-eligible 
participants compared with the grade B-eligible participants 
(48.8% versus 18.0%, respectively; p<0.01); this pattern also 
was observed among both men and women. The prevalence of 
treatment among those with high LDL-C was higher among 
those eligible for screening compared with those not eligible
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TABLE 2. Estimated prevalence of high low-density lipoprotein cholesterol (LDL-C)*, treatment,+ and control5 of high LDL-C by eligibility for 
screening under U.S. Preventive Services Task Force recommendations,11 adults** aged >20 years — National Health and Nutrition Examination 








%§§ (95% CI) % (95% CI) % (95% CI)
Total 36.1 (33.2-39.1) 46.4 (42.6-50.2) 33.5 (30.2-36.9)
Men 36.0 (32.4-39.7) 43.5 (38.8-48.3) 31.8 (27.7-36.4)
Women 36.3 (32.6-40.1) 49.7 (44.5-54.9) 35.3 (30.6-40.2)
Recommendation A or B
Total 40.5 (37.5-43.5)*** 47.0 (43.0-51.0)*** 33.2 (29.5-37.1)***
Men 39.6 (35.9-43.5) 44.5 (39.7-49.4) 32.6 (28.3-37.2)
Women 41.6 (37.4-45.9)*** 50.1 (44.4-55.8)*** 34.0 (28.5-40.0)***
Recommendation A
Total 48.8 (45.7-52.0) 51.2 (47.5-54.8) 36.6 (33.0-40.4)
Men 45.6 (41.5-49.7) 47.6 (43.2-52.1) 34.9 (30.6-39.5)
Women 54.1 (50.0-58.0) 56.0 (49.8-62.0) 39.0 (32.9-45.4)
Recommendation B
Total 18.0 (13.7-23.3)+++ 16.6 (8.8-29.2)+++ —
Men 15.7 (11.1-21.9)+++ _ _
Women 19.7 (14.5-26.1)+++ _ _
No recommendation
Total 13.7 (10.1-18.5) 37.3 (24.3-52.4) 37.2 (24.2-52.2)
Men _ 11 _ _
Women 17.4 (12.9-23.2) 46.1 (31.1-61.8) 45.9 (31.0-61.7)
* The National Cholesterol Education Program's A dult Treatm ent Panel III risk categories based on the  risk for developing coronary heart disease (CHD) in the next 
10 years were used to  examine LDL-C levels. High LDL-C was defined as >100 m g/dL for the  high-risk group, >130 m g/dL for the  interm ediate risk group, and 
>160 m g/dL for the low-risk group, or self-reported currently taking cholestero l-lowering m edication. Additiona l in form ation available at h ttp ://w w w .nh lb i.n ih . 
gov/guide lines/cholesterol/index.htm
+ Self-reported currently taking cholesterol-lowering m edication am ong those w ith  high LDL-C (LDL-C >100 m g/dL for the high-risk group, >130 m g/dL for the 
interm ediate risk group, >160 m g/dL for the  low-risk group or reported current lip id -low ering m edication use).
§ Am ong those w ith  high LDL-C or currently taking lip id -low ering m edication, control was defined as having a LDL-C level <100 m g/dL for the high-risk group, 
<130 m g/dL for the  interm ediate risk group, and <160 m g/dL for the  low-risk group.
1 The U.S. Preventive Services Task Force recommends screening for lip id disorders for all men aged >35 years; men aged 20-34 years if they are at increased risk 
for CHD, and wom en aged >20 years if  they are at increased risk for CHD.
**  Pregnant wom en were excluded from analyses.
++ Unweighted sample size.
§§ All estimates are calculated using the m orning fasting sample weight.
11 Estimates unstable by NCHS standards (RSE>30%) are suppressed.
“  Univariate x 2 tests o f independence significant (p<0.01): grade A or B versus no recom m endation.
+++ Univariate x 2 tests o f independence significant (p<0.01): grade A versus grade B.
for screening (47.0% versus 37.3%, respectively; p<0.01). A 
similar pattern was observed among women (50.1% among 
those eligible for screening versus 46.1% among those not 
eligible for screening; p<0.01); however, the difference between 
men recommended for screening compared with men not 
recommended for screening could not be assessed as a result of 
small cell sizes and unstable estimates. A statistically significant 
difference was noted in prevalence of treatment observed 
between those in the grade A recommendation group compared 
with the grade B recommendation (51.2% for grade A versus 
16.6% for grade B; p<0.01). Sample sizes did not allow for 
comparisons in treatment prevalence between the specific 
recommendation grades within genders. The prevalence of 
LDL-C control was significantly lower among all persons with 
high LDL-C for whom screening is recommended compared 
with those for whom screening is not recommended (33.2%
versus 37.2%, respectively), and this pattern also was observed 
among women (34.0% among those eligible for screening 
versus 45.9% among those not eligible for screening; p<0.01). 
Sample sizes did not allow for comparisons in LDL-C control 
prevalence between the specific recommendation grades.
Discussion
The findings in this report indicate that 88.7% of U.S. 
adults aged >20 years are eligible for cholesterol screening per 
the USPSTF guidelines and that 68.4% of those eligible for 
screening reported being screened for cholesterol during the 
previous 5 years. National Health Interview Survey data for 
2008 indicated that 74.6% of adults aged >18 years reported 
having had their blood cholesterol checked within the preceding 
5 years (6). The distribution of persons into USPSTF groups by
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recommended lipid disorder screening status indicated that the 
highest percentages of persons screened (77.7%) were found 
in the two categories with a grade A recommendation (men 
aged >35 years and women aged >45 years at increased risk for 
CHD). On the basis of lipid levels, persons not recommended 
for lipid disorder screening were classified appropriately using 
the USPSTF guidelines. Similarly, a study using USPSTF 
recommendations to assess the proportion of persons exceeding 
their NCEP LDL-C goals indicated that 88% of the persons 
not recommended for screening had LDL-C levels at NCEP 
goals (11). A full lipid panel based on TC or HDL-C values 
would be useful for a sizeable proportion of participants in the 
groups not recommended for screening. Rates of treatment for 
high LDL-C cholesterol do not appear to be higher among 
those for whom screening is recommended compared with 
those that fall outside the criteria for recommended screening, 
indicating a potential need for improvement in treatment 
among patients at an increased risk for CHD.
Adults without health insurance are less likely than those 
with insurance to be tested for high cholesterol, and, if 
they have high cholesterol, they are less likely to receive a 
diagnosis and have their high cholesterol under control (12). 
Implementation of the provision in the Patient Protection and 
Affordable Care Act of 2010 (as amended by the Healthcare 
and Education Reconciliation Act of 2010 and referred to 
collectively as the Affordable Care Act [ACA]) (ACA §1001) 
that eliminates cost sharing for those persons enrolled in new 
plans who meet the USPSTF lipid disorder screening grade A 
and B recommendations would identify persons at increased 
risk for C H D  who would benefit from early detection of 
lipid disorders and early management of lipid disorders (13). 
Starting in 2014, these services will be covered at no cost 
sharing by newly qualified private health plans operating in 
state-based insurance exchanges.* Moreover, beginning in 
2013, state Medicaid programs that eliminate cost sharing 
for these clinical preventive services will receive enhanced 
federal matching funds for them (ACA §4106) (13,14). In 
addition, the Affordable Care Act ensures that preventive and 
wellness services be provided without cost-sharing to Medicare 
recipients (ACA §4104), a group comprising persons most in 
need of lipid management. However, recommendations for 
follow-up and lipid-lowering management after screening are 
not included in the USPSTF recommendations (15).
* Beginning in 2014, a competitive insurance marketplace will be set up in the 
form of state-based insurance exchanges. These exchanges will allow eligible 
persons and small businesses with up to 100 employees to purchase health 
insurance plans that meet criteria outlined in the Affordable Care Act (ACA 
§1311). I f  a state does not create an exchange, the federal government will 
operate it.
The findings in this report are subject to at least three 
limitations. First, this report might underestimate lipid levels 
of the U.S. population because NHANES does not include 
persons living in institutions such as nursing homes, and the 
prevalence of lipid disorders increases with age. Second, persons 
who received a diagnosis of a lipid disorder were not excluded 
from the study; the percentage of persons who were eligible for 
screening might be overestimated because the classification of 
participants was not restricted to asymptomatic persons when 
determining the USPSTF sex, age, and CH D  risk groups 
or the lipid levels. Finally, using the cut-points of TC >200 
mg/dL or HDL-C <40 mg/dL to estimate the percentage 
of persons for whom a full lipid panel would be useful is 
based on a combination of USPSTF and NCEP guidelines. 
USPSTF recommends complete lipid testing based on fasting 
or nonfasting TC or HDL levels without providing specific 
cut-points for estimating CHD risk. NCEP includes these 
cut-points but indicates that they are to be used when a fasting 
measure is not available. However, the combined measure has 
value for estimating the prevalence of being referred for a full 
lipid profile by USPSTF screening categories.
Conclusion
Approximately 70% of the U.S. adult population who 
meet the criteria for lipid screening reported having their 
cholesterol checked within the last 5 years, a percentage 
that is well below the Healthy People 2020 target of 82.1%. 
Because the Affordable Care Act reduces cost sharing for lipid 
screening, monitoring the prevalence of lipid screening among 
adults who meet the USPSTF or NCEP criteria is needed to 
determine if screening increases over time. Because lowering 
LDL cholesterol is associated with a decrease in the onset of 
subsequent CHD, and because the effectiveness of LDL-C 
drug therapy is well established, monitoring the treatment 
and control of LDL cholesterol in the population also will 
be important as a measure of improvements intended by the 
Affordable Care Act.
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In trod uctio n
Nationally representative estimates indicate that 18.8 million 
adults in the United States have received a diagnosis with 
diabetes mellitus (1). When glycemic control is not optimized, 
diabetes imposes additional burdensome care requirements, 
health-care costs, and high risk of disabling complications, 
and this has been especially evident in socioeconomically 
disadvantaged and minority populations (2). For example, 
higher levels of glycated hemoglobin (A1c) have been associated 
with increased risk of diabetic retinopathy (3), increased risk of 
chronic kidney disease (4), and increased risk of cardiovascular 
disease (5). Reducing A1c levels through combined clinical 
and effective self-management has demonstrated reduced risk 
for microvascular complications (6,7). Although the most 
appropriate target A1c levels to achieve optimal health impact 
might vary among persons, the majority of adults with diabetes 
will benefit from reduction of A1c levels to <7%; targets for 
patients with a history of severe hypoglycemia, or with limited 
life expectancy, or with advanced complications, or with certain 
comorbid conditions might be higher (8). Nevertheless, an A1c 
level of 9% constitutes a clearly modifiable, high level of risk 
that few, if any, persons with diabetes should be exposed to. 
Accordingly, the Healthy People 2020 objectives (9) include a 
10% reduction in the proportion of the diabetes population 
that has poor glycemic control (A1c >9%) as a target.
This report evaluates the levels of glycemic control achieved 
among U.S. adults with diagnosed diabetes by demographic, 
socioeconomic, clinical, and health-care access-related 
characteristics, and identifies the gaps in glycemic control 
nationally. These data also serve as a baseline for future evaluations 
of how ongoing expansions of access to health insurance will affect 
diabetes care and control.
M ethods
To estimate the proportions and characteristics o f U.S. 
adults aged >18 years with self-reported diagnosed diabetes 
experiencing inadequate glycemic control, CDC analyzed 
pooled data from the 2007-2008 and 2009-2010 cycles 
of the National Health and Nutrition Examination Surveys 
(NHANES). These serial cross-sectional surveys use stratified 
multistage probability cluster sampling to ensure adequate 
representation of the United States’ noninstitutionalized 
civilian population. NHANES data are collected through 
household interviews, standardized medical examinations, 
and blood sample collection in mobile examination centers 
(10). Overall survey exam response rates were 75.4% (for 
2007-2008) and 77.3% (for 2009-2010). This analysis 
included 1,350 nonpregnant adults aged >18 years with 
self-reported diabetes. Self-reported diagnosed diabetes was 
defined as a respondent’s positive response to the question of 
whether they had ever been told by a health-care provider or 
other health professional that they had diabetes other than 
during pregnancy.
Glycated hemoglobin was measured in all NHANES 
participants aged >12 years from whole blood samples 
and standardized to reference methods from the Diabetes 
Control and Complications Trial. In all adult participants 
with self-reported diagnosed diabetes, the proportion with 
poor glycemic control (represented by most recent A1c 
>9.0% reflecting National Diabetes Quality Improvement 
Alliance indicators) (11) was estimated. Crude estimates of 
the proportion of adults with poor glycemic control were then 
calculated, stratifying by demographic (age group, sex, race/ 
ethnicity, and marital status), socioeconomic position (e.g.,
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age group, sex, education, and poverty-income ratio*), clinical 
(e.g., time since diagnosis of diabetes, and glucose-lowering 
medication type) and health-care access-related characteristics 
(e.g., health insurance status^ number of times medical care 
was received in the previous year,§ and usual source of medical 
care*). All estimates were standardized to the age distribution 
of the population with diagnosed diabetes in NHANES 
2009-2010. Multivariable logistic regression was conducted 
to compute the adjusted prevalence of poor glycemic control 
(Alc >9.0%) in each category, adjusting for all other exposures 
(e.g., age and socioeconomic position). Categorical results were 
deemed statistically significant using the Satterthwaite-adjusted 
F-test if p<0.05.
Results
During 2007-2010, an estimated 12.9% of U.S. adults 
with self-reported diagnosed diabetes exhibited poor glycemic 
control (Table).
Poor glycemic control was least common among those 
aged >65 years (6.8%) and most common among adults aged 
18-39 years (24.2%). The proportion of non-Hispanic blacks 
(18.7%) and Hispanics (18.8%) with poor glycemic control 
was greater than the proportion of non-Hispanic whites with 
poor glycemic control (10.1%). No statistically significant or 
consistent patterns of association existed between education 
levels attained, poverty-income ratio group, or sex with poor 
glycemic control. However, unmarried persons (16.8%) 
were more likely than married persons (10.3%) to have poor 
glycemic control. Higher percentages of respondents using 
insulin therapy alone (20.8%) or combined with other oral 
glucose-lowering medications (22.3%) exhibited poor glycemic
* Poverty-income ratio is an index of household income in relation to family 
need, based on family size and annual changes in the cost of living using poverty 
thresholds that are federally established by the U.S. Census Bureau and track 
the Consumer Price Index. Missing data for poverty-income ratios (n = 150)
were imputed.
 ̂Uninsured includes those answering negatively to the following questions: “Are 
you covered by health insurance or some other kind of health care plan?” and 
“Do you have Medicare?” (>65 years only). Medicare recipients include all 
individuals who had Medicare (including those that have supplemental 
insurance of another kind). Non-Medicare public insurance recipients include 
those who reported having any government-sponsored health insurance 
excluding Medicare (e.g., Medicaid, Medi-Gap, military health care, Indian 
Health Service). Private insurance recipients include those who answered 
affirmatively to the question, “Are you covered by private insurance?”
§ Participants were asked, “During the last 12 months, how many times have 
you seen a doctor or other health professional about your health at a doctor’s 
office, a clinic, hospital emergency department, at home, or some other place? 
Do not include times you were hospitalized overnight.”
* Participants were asked, “Is there a place that you usually go when you are sick 
or need advice about your health?” Those answering “yes” were asked to specify 
the place (e.g., hospital/emergency department, clinic, or doctor’s office).
control compared with those reporting no medication use 
(5.3%) or oral medications only (10.1%). Prevalence of poor 
glycemic control was highest among the uninsured (28.5%) 
compared with non-Medicare publicly insured (13.0%), 
Medicare users (12.6%), and privately insured persons (7.2%). 
In addition, poor glycemic control was common among those 
without a usual source of medical care (22.4%) or among those 
using hospital or emergency departments for their health­
care needs (22.9%) compared with 11.2%—15.2% for those 
accessing clinics or doctors’ offices.
In a m ultivariable analysis controlling for all other 
sociodemographic, clinical, and economic covariates, adults 
aged >65 years were less likely to have poor glycemic control 
than young and middle-aged adults (7.3% versus 19.1% 
and 15.0%, respectively; p = 0.02). After controlling for all 
covariates, non-Hispanic blacks and Hispanics (17.6% and 
16.2%, respectively versus 9.7%; p <0.01) still exhibited higher 
prevalence of poor glycemic control compared to non-Hispanic 
white persons. Marital status also was associated with poor 
glycemic control (married [9.6%] versus not married [16.1%]; 
p = 0.05). Similarly, independent of all other demographic, 
socioeconomic, and clinical factors considered, poor glycemic 
control was more prevalent among the uninsured (20.7%) 
compared with those on non-Medicare public insurance 
plans (12.4%), those on Medicare (12.4%), and those with 
private insurance (9.5%)(p = 0.03). In a sensitivity analysis, in 
which age was excluded from the multivariable model, these 
relationships remained significant (p<0.001). The association 
between usual place of care and poor glycemic control was 
no longer statistically significant in the multivariable model.
Discussion
Among persons with self-reported diagnosed diabetes, young 
(aged 18-39 years) and middle-aged adults (aged 40-64 
years), non-Hispanic black or Hispanic respondents, those not 
married, those treated with insulin, and those lacking insurance 
exhibited substantially higher prevalence of poor glycemic 
control than their respective comparison groups. Adjusted 
for all other demographic and socioeconomic covariates 
considered, poor glycemic control remained persistently more 
prevalent among young and middle-aged adults, minority 
groups, those not married, those using insulin, and those with 
no health insurance coverage, compared with their respective 
comparison groups. These findings are encouraging because 
40.5% o f persons with diabetes are aged >65 years, and a 
substantial proportion of them maintain A1c levels of <9%. 
However, the data describe ongoing disparities, especially 
among high-risk groups that account for a large number
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TABLE. Prevalence* of poor glycemic control (glycated hemoglobin [A1c] >9.0%) among adults1" aged >18 years with diagnosed diabetes — 
National Health and Nutrition Examination Survey, United States, 2007-2010
Characteristic






Total 100.0 12.9 (11.1-15.0) 12.4 (10.6-14.2)
Age group (yrs)
18-39 8.3 (6.8-10.1) 24.2 (13.7-39.3) 19.1 (8.1-30.1)
40 -64 51.2 (48.2-54.1) 15.4 (13.2-18.0) 15.0 (12.5-17.5)
>65 40.5 (37.5-43.6) 6.8 (5.1-9.0) 7.3 (4.4-10.2)
Sex
Male 49.7 (45.3-54.1) 14.4 (11.4-17.9) 13.4 (10.5-16.3)
Female 50.3 (45.9-54.7) 11.5 (9.3-14.0) 11.4 (8.9-13.9)
Race/ethnicity**
White, non-Hispanic 62.7 (54.8-69.9) 10.1 (8.0-12.7) 9.7 (7.7-11.7)
Black, non-Hispanic 16.5 (12.6-21.3) 18.7 (15.7-22.0) 17.6 (14.5-20.7)
Hispanic 13.5 (9.2-19.4) 18.8 (14.7-23.7) 16.2 (10.9-21.5)
Education
<High school graduate 31.2 (28.4-34.1) 14.7 (11.1-19.1) 13.1 (9.2-17.0)
High school graduate 23.2 (19.0-27.9) 12.2 (8.0-18.0) 11.4 (7.3-15.5)
>High school graduate 45.6 (41.2-50.2) 12.8 (10.3-15.8) 12.4 (9.7-15.1)
Poverty-income ratio++
<100% 15.5 (12.8-18.5) 16.6 (12.9-21.2) 12.4 (8.5-16.3)
100%-200% 45.7 (41.6-49.9) 11.9 (9.1-15.4) 11.3 (8.9-13.7)
>200% 38.8 (34.8-43.0) 12.1 (8.5-17.0) 13.8 (8.9-18.7)
Marital status
M arried/partner 58.2 (54.4-62.0) 10.3 (7.1-14.6) 9.6 (6.5-12.7)
Not married 41.8 (38.0-45.6) 16.8 (13.5-20.6) 16.1 (12.0-20.2)
Time since diabetes diagnosis (yrs)
<10 55.5 (52.0-58.9) 10.1 (7.6-13.3) 10.6 (7.5-13.7)
10-15 17.8 (15.7-20.2) 21.5 (14.9-30.1) 21.0 (13.6-28.4)
>15 26.7 (23.9-29.8) 14.6 (10.6-19.8) 11.0 (7.1-14.9)
Medication
None 11.6 (9.0-14.9) 5.3 (2.8-10.0) 3.5 (1.3-5.7)
Oral m edication only 59.0 (54.7-63.1) 10.1 (7.6-13.2) 10.1 (7.6-12.6)
Insulin only 15.6 (12.9-18.7) 20.8 (14.0-29.8) 21.0 (12.2-29.8)
Oral m edication + insulin 13.8 (12.3-15.6) 22.3 (16.8-28.8) 22.5 (16.2-28.8)
Insurance status55
Uninsured 10.8 (8.6-13.4) 28.5 (19.5-39.4) 20.7 (14.0-27.4)
Medicare 45.7 (43.7-47.8) 12.6 (8.5-18.2) 12.4 (8.5-16.3)
Public 9.6 (7.8-11.9) 13.0 (9.0-18.5) 12.4 (6.7-18.1)
Private 33.9 (30.5-37.4) 7.2 (4.8-10.8) 9.5 (6.0-13.0)
Doctor visits in past year”
None 2.6 (1.8-3.7) 19.8 (11.5-32.0) 18.3 (4.6-32.0)
1-3 27.1 (24.3-30.2) 16.0 (12.0-21.1) 15.2 (10.9-19.5)
>4 70.3 (67.0-73.4) 11.4 (9.2-14.0) 11.0 (8.5-13.5)
Usual source of care***
No place 2.8 (1.9-4.1) 22.4 (16.0-30.6) 18.7 (7.7-29.7)
Hospita l/em ergency departm ent 3.7 (2.4-5.5) 22.9 (12.0-39.3) 13.7 (6.3-21.1)
Clinic 18.8 (16.0-22.0) 15.2 (10.5-21.4) 13.4 (8.3-18.5)
Doctor's office 74.7 (70.3-78.6) 11.2 (9.0-13.9) 11.6 (9.1-14.1)
* Weighted prevalence estimates (95% confidence intervals) are reported.
+ Sample (n = 1,350) represents U.S. population o f nonpregnant adults w ith  diabetes aged >18 years.
§ Estimates standardized to  the age distribution o f the population w ith  diagnosed diabetes in NHANES 2009-2010.
1 Adjusted prevalence was calculated from  multivariate logistic regression o f poor glycemic control adjusted for all covariates. The follow ing six categories were 
statistically significant at p <0.05 using the Satterthwaite-adjusted F-test: age group, race/ethnicity, marital status, tim e since diabetes diagnosis, medication, and 
insurance status.
** Because o f sample size, estimates for participants o f other racial/ethnic groups were not reported.
++ Missing poverty-income ratio values (n = 150) were imputed.
§§ Uninsured includes those answering negatively to  the follow ing questions: "Are you covered by health insurance or some other kind o f health-care plan?” and "Do 
you have Medicare?” (aged >65 years only). Medicare recipients include all persons who had Medicare (including those who have supplemental insurance o f another 
kind). Non-Medicare public insurance recipients include those who reported having any government-sponsored health insurance excluding Medicare (e.g., Medicaid, 
Medi-Gap, m ilitary health care, or Indian Health Service). Private insurance recipients include those who answered affirm atively to  the question, "Are you covered by 
private insurance?”
11 Participants were asked, "During the last 12 m onths how many times have you seen a health-care provider or other health professional about your health at a doctor's 
office, clinic, hospital em ergency departm ent, at home, or some other place? Do not include times you were hospitalized overnight.”
* **  Participants were asked, "Is there a place tha t you usually go when you are sick or need advice about your health?”
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(e.g., non-Hispanic black and Hispanic persons comprise up 
to 30%) o f adults with diabetes in the United States.
The sub-optimal glycemic control observed among young 
persons might reflect less interaction with the health system 
stemming from the vulnerable period of age-related transition 
between parents’ and independent insurance coverage. This 
finding also is consistent with 2007 employee benefit data 
demonstrating that approximately 23%-32% o f U.S. youths 
and young adults were uninsured (12). The association between 
young adulthood and poor glycemic control was attenuated 
but was still significant after controlling for demographic and 
socioeconomic characteristics, suggesting that other barriers to 
achieving better glycemic control might exist. Future studies 
are needed to explore this association.
The findings in this report support previous studies 
demonstrating that social, demographic, and economic 
exposures are linked closely to health outcomes and might 
be interconnected (2,13). For example, health insurance 
status influences the likelihood of having a usual health-care 
provider. Conceivably, the attenuated relationships between 
regular access to a provider and glycemic control noted in 
this analysis might be moderated by health insurance status. 
Our data confirm the importance of health insurance status 
because a much smaller proportion of persons with any public 
or private insurance exhibited poor glycemic control than 
uninsured persons. These data also support previous findings 
that outcomes for persons with diabetes are similar in publicly 
funded and commercially managed health systems (14). Finally, 
although insulin use was associated with poor glycemic control, 
this might more accurately reflect type 1 diabetes or more 
advanced stage of diabetes requiring aggressive therapy, rather 
than a causal link with poor glycemic control (6,15).
These findings also suggest that glycemic control among 
persons with diagnosed diabetes has steadily improved since 
1988- 2002 (16). Healthy People 2020 targets for glycemic 
control have already been reached for certain subgroups (e.g., 
whites, the elderly, and those with a high level o f education). 
The findings of this report can be used to track and evaluate 
the effects of national and state health reforms. The Patient 
Protection and Affordable Care Act of 2010 (as amended by 
the Healthcare and Education Reconciliation Act o f 2010 
and referred to collectively as the Affordable Care Act [ACA])
(17) includes a number of provisions that directly address 
gaps in diabetes prevention, screening, care, and treatment. 
The Catalyst to Better Diabetes Care Act of 2009 (ACA 
§10407) directs the U.S. Department of Health and Human 
Services and CDC to enhance diabetes surveillance and quality 
standards across the country. In particular, these agencies were 
responsible for emphasizing reengineering of vital statistics
systems, promoting more accurate classification and collection 
of diabetes mortality data, preparing biennial national reports 
that track trends in health outcomes for persons with diabetes 
and prediabetes that will be made publicly available and that 
can be used to inform policy and program development, and 
promoting licensing and certification for providers that care 
for persons with diabetes. In addition, diabetes is targeted 
specifically by provisions administering private health insurance 
wellness and prevention programs (ACA §2717), Medicaid 
Health Homes for enrollees with chronic conditions (ACA 
§2703), the Medicaid Incentives to Prevent Chronic Disease 
program (ACA §4108), and the Medicare Independence at 
Home Demonstration program (ACA §3024).
More broadly, the Affordable Care Act expands insurance 
coverage, consumer protections, and access to primary care. 
The law expands Medicaid to cover persons with incomes up 
to 133% o f the federal poverty level. State-based insurance 
exchanges** will provide access to health insurance for 
small employers and to persons and families not eligible for 
Medicaid or the Children’s Health Insurance Program, and 
federal tax credits will help those living at 100%-400% of the 
federal poverty level. By 2016, an estimated 95% of the U.S. 
population will have access to health insurance. Young adults 
>aged 26 years are now eligible to remain on their parents’ 
insurance, and the National Center for Health Statistics 
reported in December 2011 that 2.5 million additional 
young adults had been insured. The law also provides for 
guaranteed issue of insurance, ending denials o f coverage for 
preexisting conditions (diabetes is considered preexisting by 
certain insurers) and prohibits rescission (dropping coverage), 
lifetime coverage limits, and limits on emergency department 
use (12,17).
In the context o f these reforms, the findings in this report 
provide a benchmark for future and more detailed national 
diabetes report cards that focus on persons affected by diabetes. 
Increasing access to care through insurance and increasing 
the proportion of persons with a usual care provider might 
lead to better diagnosis, treatment, and control o f diabetes
(18). In addition, future reports might consider evaluations 
of system- and provider-focused policies and interventions 
and their impact on diabetes detection and control. The only 
empirical data associated with a number of national large-scale 
population-targeted policies and interventions are related to
** Beginning in 2014, a competitive insurance marketplace will be set up in the 
form of state-based insurance exchanges. These exchanges will allow eligible 
persons and small businesses with up to 100 employees to purchase health 
insurance plans that meet criteria outlined in the Affordable Care Act (ACA 
§1311). I f  a state does not create an exchange, the federal government will 
operate it.
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quality improvement strategies (e.g., structured team-based 
care, reminders, nonphysician health workers, peer support, 
and provision of feedback to patients) and how this affects 
efficiency, self-management support, physician responsibilities, 
and glycemic control (19).
The findings provided in this report are subject to at least 
four limitations. First, the analyses are cross-sectional, which 
do not provide information regarding temporal or causal 
association. Second, detailed analyses were confined to those 
with diagnosed diabetes because the profile and reasons for 
poor glycemic control would predictably be different between 
the groups with diagnosed and undiagnosed disease. For groups 
with undiagnosed diabetes, poor glycemic control is primarily 
related to lack of awareness of the condition; the public health 
solution should focus on better detection. Including persons 
with undiagnosed diabetes might cause the proportion of the 
population with poor glycemic control to be overestimated, 
but to potentially have overestimates or underestimates of 
the associations between poor control and sociodemographic 
characteristics. Third, the indicator used (A1c>9.0%) might 
overestimate poor control in African American persons, among 
whom A1c might be naturally higher (20). Finally, no attempt 
was made to disaggregate data regarding persons with type 1 
and type 2 diabetes because glucose control guidelines do not 
differ by type of diabetes mellitus.
Conclusion
Nationally, sociodemographic disparities in glycemic control 
among persons with self-reported diagnosed diabetes persist. 
Improvements in access to health care and benefits, quality of 
care delivery, and patient adherence might be achieved by more 
extensive translation of innovative, evidence-based system, 
provider, and patient-level policies and interventions. Routine 
surveillance also will be imperative to evaluate the intended and 
unintended impacts of system-level reforms on sociodemographic 
disparities in health utilization and diabetes control.
Further study is needed to examine the effects o f increasing 
emphasis on evidence-based guidelines and to monitor quality 
indicators to determine how incentives affect motivation and 
accountability among health-care providers. Evaluating the 
implementation o f health information technologies (e.g., 
electronic health records and computerized decision support 
systems that aim to motivate provider and patient adherence) 
will be essential in determining whether to extensively promote 
adoption. Finally, evaluating health system policies (e.g., 
assessments of the patient-centered medical home, reduction
of copayments for essential medications, and other initiatives)
will determine the sustainability of each initiative.
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In troduction
Tobacco use continues to be the leading cause of preventable 
disease and death in the United States; cigarette smoking 
accounts for approximately 443,000 premature deaths annually 
(1). In 2009, the prevalence of smoking among U.S. adults was 
20.6% (46 million smokers), with no significant change since 
2005 (20.9%) (2). In 2010, approximately 69% ofsmokers in 
the United States reported that they wanted to quit smoking
(3). Approximately 44% reported that they tried to quit in the 
past year for >1 day; however, only 4% -7%  were successful 
each year (4). Tobacco dependence has many features of a 
chronic disease: most patients do not achieve abstinence after 
their first attempt to quit, they have periods of relapse, and they 
often require repeated cessation interventions (4). At least 70% 
of smokers visit a physician each year, and other smokers visit 
other health-care professionals, providing key opportunities for 
intervention (4). The 2008 update to the U.S. Public Health 
Service (PHS) Clinical Practice Guideline: Treating Tobacco Use 
and Dependence recommends that clinicians and health-care 
delivery systems consistently identify and document tobacco 
use status and treat every tobacco user seen in a health-care 
setting using the 5 A’s model: 1) ask about tobacco use, 2) 
advise tobacco users to quit, 3) assess willingness to make a quit 
attempt, 4) assist in quit attempt, and 5) arrange for follow-up
(4). The PHS guideline also recommends the following as 
effective methods for increasing successful cessation attempts: 
individual, group, and telephone counseling; any of the seven 
first-line medications for tobacco dependence that are approved 
by the Food and Drug Administration (FDA); and provision of 
coverage for these treatments by health-care systems, insurers, 
and purchasers (4). However, clinicians and health-care systems 
often do not screen for and treat tobacco use consistently and 
effectively (4).
The Healthy People 2020  objectives for health systems 
changes related to tobacco cessation include increasing tobacco 
screening in office-based ambulatory care settings to 68.6%
from a baseline of 62.4% among persons aged >18 years in 
2007 (objective TU  9.1) and increasing tobacco cessation 
counseling in office-based ambulatory care settings to 21.1% 
from a baseline o f 19.2% among current tobacco users aged 
>18 years in 2007 (objective TU  10.1) (5). An overall Healthy 
People 2020 objective for adult cessation is increasing recent 
(i.e., within the past year) smoking cessation success by adult 
smokers to 8.0% among adults aged >18 years who have ever 
smoked 100 cigarettes, who do not smoke now, and who last 
smoked <1 year ago and among current smokers who initiated 
smoking at least 2 years ago from a baseline of 6.0% among 
adults aged >18 years in 2008 who ever smoked 100 cigarettes, 
who do not smoke now, and who last smoked <1 year ago and 
among current smokers who initiated smoking at least 2 years 
ago (objective TU  5.1) (5).
This report summarizes data from the National Ambulatory 
Medical Care Survey (NAMCS) and the National Health 
Interview Survey (NHIS) that address the three Healthy 
People 2020 objectives (increase screening, increase cessation 
counseling, and increase overall cessation success) and tobacco 
medication provision by patient- and physician-related 
characteristics and presents trends in recent successful cessation 
among adult smokers by whether they visited a doctor in 
the past year. These results can be used by researchers and 
health-care providers to track and improve adherence to the 
PHS clinical practice guideline on tobacco use and to learn of 
opportunities for tobacco cessation as a covered health benefit.
M ethods
To estimate the percentage of office-based physician visits 
made by adults aged >18 years with documentation ofscreening 
for tobacco use, tobacco cessation counseling in the form of 
health education ordered or provided during those visits, as 
well as tobacco cessation medications ordered or continued 
during those visits, CDC analyzed data from the combined
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2005-2008 NAMCS. NAMCS is a national probability sample 
survey of outpatient visits made to office-based physicians that 
measures health-care use across various health-care providers.
The NAMCS sample included 96,232 outpatient visits 
among persons aged >18 years, ranging from 21,220 visits in 
2005 to 27,169 in 2007. The NAMCS estimates for tobacco 
use screening and tobacco cessation counseling and medications 
among visits by adults aged >18 years were analyzed by patient 
demographics, tobacco use status, type of health insurance, 
counseling and education provided, medication continued or 
ordered, and other physician- or visit-related characteristics. 
Demographic characteristics include age, sex, and race/ 
ethnicity; length of visit; and type of health insurance (private 
insurance, Medicare, Medicaid or State Children’s Health 
Insurance Program [SCHIP], self-pay, or other [workers’ 
compensation; no charge or charity; other sources of payment 
not covered by private insurance, Medicare, Medicaid/SCHIP, 
workers’ compensation, self-pay, and no charge or charity; or 
unknown]). Physician-related characteristics include practice 
type (solo or other), specialty, and whether the physician was 
the patient’s primary care physician (determined by response 
to the question, “Are you the patient’s primary care physician/ 
provider?”).
For the 2005-2007 NAMCS, respondents who were 
eligible both for Medicare and Medicaid were categorized as 
Medicaid recipients for type o f health insurance; however, 
these respondents were classified as Medicare recipients in 
2008. To account for this change, the 2005-2007 payment 
type variable was recoded to be consistent with the 2008 
classification for primary expected source o f payment. For 
all survey years, nonphysician providers, federally employed 
physicians, and physicians in anesthesiology, pathology, and 
radiology specialties were excluded. The basic sampling unit for 
NAMCS is the physician-patient encounter or office visit. For 
physicians whose major professional activity was patient care, 
only visits classified by the American Medical Association or 
the American Osteopathic Association as office-based, patient 
care were included. The survey methods and sampling frame 
has been described elsewhere (available at http://www.cdc. 
gov/nchs/ahcd/ahcd_scope.htm#namcs_scope). Additional 
information on the NAMCS microdata file documentation 
also is available (ftp://ftp.cdc.gov/pub/Health_Statistics/ 
NCHS/Dataset_Documentation/NAMCS).
NAMCS defines tobacco use as documentation in the 
medical chart that the patient is a current user of tobacco, 
including cigarettes or cigars, snuff, or chewing tobacco. 
Tobacco cessation counseling is defined as information given 
in the form o f health education to the patient on topics 
related to tobacco use in any form, including cigarettes, cigars, 
snuff, and chewing tobacco, or on exposure to secondhand
smoke. Tobacco cessation counseling includes information 
on smoking cessation and prevention of tobacco use, as well 
as referrals to other health professionals for smoking cessation 
programs. Medication use includes medications that were 
ordered, supplied, administered, or continued during the 
visit. Only medications related to tobacco cessation were 
analyzed. These medications were entered as free text for each 
visit and were limited to no more than eight prescription 
and over-the-counter (OTC) medications. The tobacco 
cessation medications included nicotine replacement therapy 
(i.e., nicotine patch, gum, lozenge, nasal spray, and inhaler), 
bupropion, and varenicline.
To estimate recent smoking cessation success among persons 
aged >18 years, CDC analyzed data from the 2005-2009 
NHIS. NHIS is a periodic, nationwide, household survey 
about the health and health care of a representative sample of 
the U.S. civilian noninstitutionalized population. The NHIS 
sample during 2005-2009 included 128,608 adults aged >18 
years, ranging from 21,781 in 2008 to 31,428 in 2005. Recent 
smoking cessation success was defined using the Healthy People 
2020 definition (objective TU  5.1) (5): former smokers who 
had ever smoked 100 cigarettes, do not smoke now, and last 
smoked 6 months to 1 year ago were considered to have had 
recent smoking cessation success. Former smokers who had ever 
smoked 100 cigarettes, do not smoke now, and last smoked 
<6 months ago and current smokers who initiated smoking 
at least 2 years ago were considered to have had unsuccessful 
recent smoking cessation. Recent smoking cessation success was 
analyzed by whether the respondent had visited a physician 
within the last year.
All analyses were conducted using statistical software to 
account for the complex sample design of both NAMCS 
and NHIS. Data from NAMCS and NHIS were adjusted 
for nonresponse and weighted using the 2000 U.S. standard 
population to provide national estimates o f outpatient 
visits with tobacco screening, tobacco cessation counseling, 
cessation treatments and successful cessation, respectively; 95% 
confidence intervals were calculated for both surveys to account 
for the multistage probability sample design. For NHIS, linear 
trends were examined using orthogonal polynomial contrasts. 
Statistical significance of differences between those who saw 
a physician and those who did not was determined using a 
t-test, with significance set at p<0.05.
Results
During 2005-2008, adults aged >18 years made an estimated 
annual average of approximately 771 million outpatient visits 
(an estimated total of 3.08 billion visits during 2005-2008
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combined) to office-based physicians, ranging from 720 
million in 2006 to 799 million in 2007, of which an average 
annual estimate of approximately 483 million (62.7%) 
included tobacco screening, an estimated total of 1.93 billion
visits during 2005—2008 combined (66.9% in 2005, 61.6% 
in 2006, 58.7% in 2007, and 63.6% in 2008) (Table). O f 
the visits in 2005—2008 that included tobacco use screening, 
17.6% (340 million visits) were made by current tobacco
TABLE. Receipt of tobacco use screening, counseling, and cessation medication prescriptions during outpatient visits to office-based physicians 





Visits with current 
tobacco use§
(n = 11,376)
Visits with current 
tobacco use and 
tobacco counseling1 
(n = 2,258)
Visits with current 




Characteristic % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Total 62.7 (60.7-64.6) 17.6 (16.6-18.5) 20.9 (19.1-22.7) 7.6 (6.5-8.7)
Age group (yrs)
18-24 64.0 (60.9-67.0) 19.0 (16.7-21.3) 19.5 (15.6-24.0) t t —
25-44 64.8 (62.7-66.9) 21.8 (20.2-23.4) 17.9 (15.7-20.3) 8.0 (6.1-9.9)
45 -64 62.6 (60.4-64.8) 21.0 (19.8-22.2) 22.7 (20.4-25.2) 9.1 (7.3-10.9)
>65 60.8 (58.6-63.0) 9.9 (9.0-10.7) 22.6 (19.4-25.7) 5.0 (3.1-6.8)
Sex
Male 61.7 (59.6-63.7) 21.1 (19.8-22.4) 21.9 (19.8-24.1) 7.1 (5.5-8.8)
Female 63.3 (61.3-65.4) 15.5 (14.6-16.3) 20.0 (18.1-22.1) 8.0 (6.5-9.4)
Race/Ethnicity
W hite, non-Hispanic 64.1 (62.1-66.1) 18.1 (17.1-19.1) 21.2 (19.3-23.2) 7.8 (6.7-8.8)
Black, non-Hispanic 60.2 (56.7-63.7) 19.5 (17.5-21.4) 18.9 (15.3-23.1) — —
Hispanic 57.8 (54.4-61.1) 13.8 (12.2-15.3) 21.0 (17.0-25.7) 10.8 (5.3-16.3)
Asian/Pacific Islander 55.5 (47.3-63.6) 12.2 (10.0-14.4) 23.2 (15.6-33.1) — —
American Indian/Alaska Native 55.9 (48.2-63.6) 20.3 (14.0-26.6) — — — —
M ultip le  race 61.2 (47.8-74.7) 31.3 (20.1-42.5) — — — —
Health insurance
Private insurance 64.8 (62.8-66.9) 17.1 (16.0-18.1) 20.8 (18.7-22.9) 9.7 (8.2-11.2)
Medicare 62.0 (59.7-64.4) 12.5 (11.5-13.4) 22.4 (19.4-25.4) 5.5 (3.7-7.2)
Medicaid/SCHIP 63.4 (59.6-67.3) 33.2 (29.8-36.5) 22.8 (18.7-26.9) 6.2 (3.9-8.5)
Self-pay 63.7 (59.2-68.2) 26.6 (22.6-30.5) 23.5 (17.3-29.6) — —
Other§§ 50.2 (45.4-54.9) 24.3 (22.0-26.6) 12.5 (8.9-16.0) 8.6 (4.0-13.3)
Primary care physician
Yes 66.6 (63.9-69.3) 18.7 (17.4-20.1) 26.9 (24.2-29.7) 8.3 (6.6-10.0)
No 61.6 (59.7-63.6) 16.2 (15.3-17.1) 15.5 (13.7-17.3) 6.6 (5.3-8.0)
Solo practice11
Yes 61.1 (58.0-64.3) 17.7 (16.2-19.1) 22.0 (19.0-25.1) 7.9 (5.7-10.0)
No 63.5 (61.3-65.6) 17.6 (16.6-18.6) 20.2 (18.2-22.3) 7.5 (6.2-8.8)
Physician specialty
General and fam ily practice 66.4 (62.9-70.0) 21.9 (20.4-23.5) 23.5 (20.7-26.4) 7.6 (5.8-9.5)
Internal medicine 64.3 (60.0-68.6) 17.7 (15.3-20.0) 32.5 (26.7-38.2) 8.8 (5.8-11.7)
Obstetrics and gynecology 69.6 (65.8-73.5) 14.2 (12.3-16.1) 19.7 (14.9-24.5) — —
Cardiovascular disease 63.4 (57.3-69.4) 13.7 (11.7-15.7) 35.4 (28.1-42.8) 7.3 (3.9-10.7)
Psychiatry 58.9 (52.9-64.9) 23.4 (20.4-26.5) 20.7 (14.4-26.9) 17.7 (12.5-22.8)
All o ther specialties 58.2 (55.6-60.9) 15.5 (14.6-16.4) 10.5 (8.4-12.5) 4.5 (3.1-5.9)
Time spent with physician (mins)
<20 60.9 (58.5-63.3) 17.6 (16.6-18.6) 18.6 (16.8-20.4) 7.5 (6.3-8.8)
>20 64.9 (62.8-67.0) 17.6 (16.3-18.8) 23.6 (21.0-26.2) 7.7 (6.1-9.2)
Abbreviations: CI = confidence interval; SCHIP = State Children's Health Insurance Program.
* Visits during which current tobacco use (currently smoke cigarettes or cigars or use snuff or chewing tobacco) o r no current use was recorded.
+ Yearly visits w ith  tobacco screening: 13,721 in 2005; 15,324 in 2006; 16,176 in 2007; and 14,810 in 2008.
§ Visits during which current tobacco use (smoking cigarettes or cigars or using snuff or chewing tobacco) was recorded.
I Tobacco counseling refers to  any in form ation provided tha t related to  tobacco use in any form , including cigarettes, cigars, snuff, and chewing tobacco, and on 
exposure to  tobacco in the  form  o f secondhand smoke, smoking cessation, and prevention o f tobacco use, as well as referrals to  o ther health-care providers for 
smoking cessation programs.
**  Cessation m edications include n icotine replacement therapy (n icotine patch, gum , lozenge, nasal spray, and inhaler), buprop ion, and varenicline.
++ Data no t shown because sample size is <30, or the  relative standard error o f the estimate is >30%.
§§ Workers' com pensation; no charge or charity; other sources o f paym ent no t covered by private insurance, Medicare, Medicaid/SCHIP, workers' com pensation, 
self-pay, and no charge or charity; or unknown.
II  Medical practice run by an individual physician; a solo practitioner offering medical services on a person-to-person basis (i.e., no t a group  practice).
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users (17.2% in 2005, 18.3% in 2006, 19.6% in 2007, and 
15.4% in 2008).
The prevalence of respondents who received tobacco 
screening varied by race/ethnicity; Hispanic patients were less 
likely to receive screening for tobacco use (57.8%) during 
office-based physician visits than were non-Hispanic white 
patients (64.1%). Screening also varied by insurance status. 
Patients with private insurance (64.8%), Medicare (62.0%), 
Medicaid or SCHIP (63.4%), and self-payers (charges paid by 
the patient or patient’s family and not reimbursed by a third 
party) (63.7%) were more likely to receive tobacco screening 
than were patients with workers’ compensation, classified as 
no charge or charity, or covered by a source other than private 
insurance, Medicare, Medicaid/SCHIP, workers’ compensation, 
self-pay, and no charge or charity, or whose insurance status 
was unknown (50.2%). Patients who visited their primary 
care physician were more likely to receive tobacco screening 
(66.6% of visits) than patients who visited a physician who was 
not their primary care physician (61.6% of visits). Screening 
also varied by physician specialty. Patients visiting general or 
family practitioners (66.4%) and obstetricians/gynecologists 
(69.6%) were more likely to receive screening than patients 
who visited physicians in other specialties (58.2%), excluding 
internal medicine, cardiovascular disease, and psychiatry.
Patients aged <65 years, men, non-Hispanic whites, non- 
Hispanic blacks, and persons of multiple races were more 
likely to be current tobacco users than were Hispanics and 
Asians/Pacific Islanders. Patients who were identified as 
current tobacco users also varied by type of health insurance, 
with visits made by those with Medicaid/SCHIP (33.2%) and 
those who were self-payers (26.6%) more likely to be current 
tobacco users than those with private insurance (17.1%) or 
Medicare (12.5%). In addition, patients who were screened for 
tobacco use by their primary care physician were more likely 
to be current tobacco users (18.7% of visits) than patients who 
were screened by a physician who was not (16.2% of visits). 
Patients who visited certain physician specialists were more 
likely to be identified as current tobacco users (general or 
family practice, 21.9%, and psychiatry, 23.4%) than patients 
who visited other specialists, excluding specialists in internal 
medicine, cardiovascular diseases, and obstetrics/gynecology 
(15.5% of visits).
Among the patients who were classified as current tobacco 
users, 20.9% received tobacco counseling during their 
physician visit. Visits that included tobacco counseling varied 
by patient’s age, with patients aged 45—64 years receiving 
a higher percentage of counseling (22.7%) than patients 
aged 25—44 years (17.9%). Among all outpatient visits for
current smokers identified by screening, visits that included 
tobacco counseling also varied by type of health insurance; 
patients with private insurance (20.8%), Medicare (22.4%), 
Medicaid/SCHIP (22.8%), and self-payers (23.5%) were more 
likely to receive counseling than patients who had workers’ 
compensation, were classified as no charge or charity, were 
classified under other sources of payment (i.e., other than 
private insurance, Medicare, Medicaid/SCHIP, workers’ 
compensation, self-pay, and no charge or charity), or whose 
insurance status was unknown (12.5%). Visits that included 
tobacco counseling also varied by whether the physician was 
the patient’s primary care physician (26.9% of visits) or was 
not (15.5% of visits). Likewise, visits that included tobacco 
counseling varied by physician specialty; visits to internal 
medicine physicians (32.5%) and cardiovascular disease 
specialists (35.4%) were more likely to include counseling 
than visits to general or family practitioners (23.5% of visits) 
and obstetricians/gynecologists (19.7% of visits). Outpatient 
visits of >20 minutes were more likely to include counseling 
(23.6%) than those of <20 minutes (18.6%).
Among the patients who were identified as current tobacco 
users, 7.6% received a prescription or an order for a medication 
associated with tobacco cessation. An order for a cessation 
medication varied by health insurance, with patients who had 
private insurance more likely to receive a prescription or order 
for cessation medication (9.7%) than patients with Medicare 
(5.5%). An order for a cessation medication also varied by 
physician specialty; psychiatrists were more likely to include an 
order for a cessation medication (17.7%) than other specialists. 
(Psychiatrists had a higher proportion [95.2%] of orders for 
bupropion, which can be used both as an antidepressant and 
as a tobacco cessation medication, than all specialists [57.7%]). 
O f visits with a medication order, 95.4% of the visits had an 
order for one cessation medication, and 4.6% had an order for 
more than one cessation medication. Among patients who were 
identified as current tobacco users and received a prescription 
or order for a cessation medication, 97.3% of the medications 
were for prescription drugs (bupropion, 57.7%; varenicline, 
38.7%; and nicotine nasal spray and inhaler, 0.9%).
The prevalence of recent smoking cessation success increased 
significantly from 2005 to 2009 (p<0.05) among adult smokers 
aged >18 years overall and among those who visited a physician 
in the past year (Figure). No trend in recent smoking cessation 
success was observed among those who did not visit a physician 
in the past year. Overall, prevalence of recent smoking cessation 
success was 6.6% in 2009 (7.2% among those who visited a 
doctor in the past year and 3.9% among those who did not 
visit a doctor in the past year [p<0.001 by t-test]).
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FIGURE. Percentage of adult smokers* aged >18 years who recently 
quit smoking, by whether persons visited a physician in the past 
ye ar — N atio n a l H ealth  In te rv ie w  S u rve y , U n ite d  States, 
2005-2009
2005 2006 2007 2008 2009
Year
* Num ber o f adults w ho ever smoked 100 cigarettes, do no t smoke now, and 
last smoked 6 m onths to  1 year ago. The denom inator included num ber o f 
adults aged >18 years w ho have ever smoked 100 cigarettes, do no t smoke 
now, and last smoked <1 year ago and current smokers w ho initia ted smoking 
at least 2 years ago.
+ Age adjusted to the 2000 U.S. census population.
Discussion
This report indicates that although tobacco use screening 
occurred during the majority of adult visits to outpatient 
physician offices during 2005—2008 (62.7%), among patients 
who were identified as current tobacco users, only 20.9% 
received tobacco cessation counseling and 7.6% received 
tobacco cessation medication. The 2008 update to the 
PHS Clinical Practice Guideline for Treating Tobacco Use and 
Dependence concluded that to increase tobacco cessation rates, 
it is essential for clinicians and the health-care delivery system 
to consistently identify and document tobacco use status and 
treat every tobacco user with cessation counseling and any 
of the seven FDA-approved first-line medications (except 
when medically contraindicated or with specific populations 
for which evidence of effectiveness is insufficient, such as 
pregnant women, smokeless tobacco users, light smokers, 
and adolescents). The Healthy People 2020  objectives for 
health systems changes related to tobacco use include goals 
for increasing both tobacco screening and tobacco counseling 
among tobacco users in office-based ambulatory care settings 
(objectives TU-9.1 and TU-10.1).
The demographics of patients who were classified as current 
users of tobacco were similar to those among all U.S. adults 
who use tobacco (2). The findings in this report indicate that 
screening for tobacco use was lower among Hispanic patients 
than among non-Hispanic whites, a finding that is similar to 
findings from another study using 2001—2005 NAMCS data; 
in that study, lack of insurance did not explain the ethnic 
differences (6). Possible explanations for the lower prevalence 
of tobacco screening among Hispanic patients might include 
cultural and language differences between the patients and 
physicians, factors that have been identified as barriers to cancer 
screening (7). Medical school curricula should include training 
to address these barriers to preventive services for Hispanic 
patients as well as other patient populations whose members 
are underrepresented among physicians (8,9).
Tobacco counseling among adults aged 25—44 years was less 
prevalent than among older patients. This finding is notable 
because younger smokers are more likely than older smokers to 
have tried to quit in the past year and are less likely to succeed 
in quitting (10). Successful quit attempts begin to occur, on 
average, at age 40 years, and the percentage of former smokers 
among those who ever smoked >100 cigarettes (an indicator 
of successful cessation) also increases with age (10). Some 
physicians might believe that younger patients are not seriously 
interested in quitting (10). However, tobacco information also 
should be provided to patients who seem unwilling to quit as a 
way to encourage them to think about quitting (4). Although 
tobacco cessation is beneficial at any age, intervening as early 
as possible is important because quitting at age 50 decreases 
by half the smoking-related health effects, and quitting at 
age 30 prevents almost all of the effects to the level of a never 
smoker (11,12).
During 2005—2008, patients who were current users of 
tobacco who had an unknown health insurance status or other 
selected types of health insurance (workers’ compensation, 
no charge or charity, or other sources of payment not covered 
by private insurance, Medicare, Medicaid/SCHIP, workers’ 
compensation, self-pay, and no charge or charity) were less 
likely to be screened for tobacco use (all visits) or receive 
counseling than self-pay patients and those with all other types 
of insurance (i.e., private insurance, Medicaid, and Medicare/ 
SCHIP). The PHS guideline concluded that persons who 
have insurance that covers treatment for tobacco use are more 
likely to receive treatment than those who do not (4). Tobacco 
dependence treatments (both counseling and medication), 
whether provided as paid or covered benefits by health insurance 
plans, have been shown to increase the proportion of smokers 
who use cessation treatment, attempt to quit, and successfully 
quit (4). Neither private insurers nor state Medicaid programs 
consistently provide comprehensive coverage of evidence-based
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tobacco interventions (4). For example, in 2009, although 47 
(92%) of 51 Medicaid programs offered coverage for some 
form of tobacco-dependence treatment to some Medicaid 
enrollees, only five states offered coverage of all recommended 
pharmacotherapies and individual and group counseling for 
all Medicaid enrollees (13). A Healthy People 2020 objective 
(TU-8) is to increase Medicaid insurance coverage of all 
evidence-based treatments for nicotine dependency to all 50 
states and the District of Columbia (5).
The Patient Protection and Affordable Care Act of 2010 
as amended by the Healthcare and Education Reconciliation 
Act of 2010 (referred to collectively as the Affordable Care 
Act [ACA]) and other national initiatives will increase 
tobacco cessation treatment coverage (14). As of October 1, 
2010, as part of the Affordable Care Act (ACA §4107), state 
Medicaid programs were required to provide tobacco cessation 
coverage to pregnant women enrollees with no cost sharing. 
Effective January 1, 2013, state Medicaid programs that cover 
prevention services recommended as grade A or B by the U.S. 
Preventive Services Task Force with no cost sharing will receive 
an enhanced federal matching rate (ACA §4106 ); evidence- 
based smoking cessation services are grade A recommendations 
(14,15). Effective January 1, 2014, the Affordable Care Act 
will also bar state Medicaid programs from excluding FDA- 
approved cessation medications, including OTC medications, 
from Medicaid drug coverage (ACA §2502). As of July 2011, 
Medicaid began allowing states to apply for 50% administrative 
match funds for telephone quitline services provided to 
Medicaid enrollees. Also as a part of the Affordable Care Act 
(ACA §1001), as of January 1, 2014, newly qualified health 
insurance plans operating in the exchanges* are required to 
offer their members cessation coverage without cost sharing 
(16). This requirement also applies to grandfathered plans that 
were in existence before that date if they undergo substantial 
changes (17). As ofAugust 25, 2010, Medicare began offering 
cessation counseling as a covered benefit to all its members; 
previously, only Medicare enrollees who had already developed 
tobacco-related disease were eligible for counseling. Effective 
January 1, 2011, the Affordable Care Act (ACA §4104) also 
ended Medicare coinsurance requirements for any covered 
preventive service that is recommended with a grade of A 
or B by the U.S. Preventive Services Task Force, including 
cessation services (14). In addition, as of January 1, 2011, all 
federal employees began receiving comprehensive cessation
* Beginning in 2014, a competitive insurance marketplace will be set up in the 
form of state-based insurance exchanges. These exchanges will allow eligible 
persons and small businesses with up to 100 employees to purchase health 
insurance plans that meet criteria outlined in the Affordable Care Act (ACA 
§1311). I f  a state does not create an exchange, the federal government will run 
one in that state.
coverage through the Office of Personnel Management and 
the Federal Employees Health Benefit Program. (Additional 
information on this benefit is available at http://www.opm. 
gov/quitsmoking.) This new benefit can serve as model for 
comprehensive tobacco cessation coverage for state and private 
insurers. Given the decrease in smoking prevalence that 
occurred after implementation of mandated tobacco cessation 
coverage for the Massachusetts Medicaid program (18), 
expanded access to tobacco cessation services and treatments 
are likely to reduce the prevalence of current smoking among 
U.S. adults and the related adverse effects.
Other substantial barriers interfere with clinician assessment 
and treatment of smokers, including lack of knowledge, 
lack of time, inadequate payment for treatment, and lack of 
institutional support for routine assessment and treatment of 
tobacco use (4). The findings in this report indicate that both 
physician and visit characteristics were related to the likelihood 
of screening and counseling for tobacco use occurring during 
a visit. Patients visiting their primary care physician had a 
higher likelihood of receiving tobacco use screening and 
cessation counseling than patients who visited a physician 
who was not their primary care physician, perhaps because 
the primary care physicians were providing more routine 
care than specialized care, and tobacco cessation counseling 
might have been provided as part of a wellness or preventive 
care visit. In addition, primary care physicians might have 
had a more established relationship with their patients and 
felt more comfortable addressing tobacco use than other 
physicians. General and family practitioners and obstetricians/ 
gynecologists were more likely to screen for tobacco use during 
patient visits than physicians in other specialties; however, they 
were less likely to provide tobacco counseling than internal 
medicine physicians and cardiologists. These differences might 
be related to the reasons patients visit cardiologists and internal 
medicine physicians; they might be more willing to make a 
quit attempt as a result of an acute medical event or a smoking- 
related health problem (4). More research is needed to identify 
factors that affect the provision of tobacco screening and 
counseling in various medical specialties, particularly among 
obstetricians/gynecologists because of the substantial effects 
of tobacco on reproductive health, as well as the associated 
costs (19,20).
The frequency of tobacco counseling was higher among 
physicians who spent >20 minutes with a patient. Lack of 
time has been noted as a barrier to clinical interventions, and 
total treatment time is an important determinant of tobacco 
cessation success. Although clinicians can increase quit rates 
among patients with even minimal interventions (<3 minutes), 
the effectiveness of counseling increases with the intensity of 
the intervention (i.e., session length) up to a total contact
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time (which might span multiple visits) of 90 minutes (4). 
Health-care systems can support physician interventions by 
instituting effective systems-level changes that make screening 
and brief cessation intervention a standard part of every office 
visit. According to the Guide to Community Preventive Services 
(21), provider-reminder systems increase health-care providers’ 
assessment and treatment of tobacco use in a range of clinical 
settings and populations. Provider reminder systems remind or 
prompt providers to screen and treat patients for tobacco use 
and can be implemented as chart stickers, vital sign stamps, 
medical record flow sheets, check lists, or as part of electronic 
medical records. The PHS guideline further recommends that 
health-care providers offer medication and counseling referrals 
such as quitlines for patients who are willing to make a quit 
attempt or offer additional treatment to help patients quit (4). 
Other patient characteristics, such as educational attainment 
and language preference, which were not included in NAMCS, 
might play a role in delivery of health-care services such as 
tobacco screening and counseling that could be examined in 
future studies.
The findings in this report are subject to at least five 
limitations. First, tobacco counseling might have included any 
information on tobacco or exposure to secondhand tobacco 
smoke as well as referrals to tobacco cessation programs. 
Because most adult established smokers (>80%) begin smoking 
before age 18 years (22), the assumption that most information 
provided to adults focused on cessation is reasonable. However, 
separately assessing both the provision of actual tobacco 
cessation counseling (i.e., problem solving and patient skills 
training) and referrals to smoking cessation programs would 
have enabled tracking the use of the of 5 A’s more effectively 
(4). The lack of documentation might be a particular problem 
in the provision of advice to use OTC medications. Among 
visits by tobacco users during which a cessation medication was 
provided, the majority were prescription medications (97.3%). 
In contrast, OTC medications were the most commonly used 
cessation therapy that was effective among U.S. adults smokers 
who made a serious attempt to quit in the past year in 2005
(23). This difference might have resulted from a lack of advice 
to use OTC medications or lack of documentation of this 
advice. Some medications that were recommended by the 
physician might not have been documented. Therefore, OTC 
medications might be underreported. Second, data collection 
was limited to entry of eight medications. However, this did 
not seem to be a barrier to listing all the cessation medications 
a patient was offered among those who were identified as 
current tobacco users; tobacco users had, on average, 2.5 
medications listed during each visit. Third, because bupropion 
can be prescribed as an antidepressant, whether a prescription 
for bupropion was for tobacco cessation or a mental illness
is unclear. Bupropion accounted for a larger proportion of 
the cessation medications among psychiatrists (95.2%) than 
among all physicians (57.7%); therefore, it is more likely these 
prescriptions were to treat mental illness rather than tobacco 
use. Fourth, this analysis might be limited because quality 
and completeness of reporting varied over time, and changes 
in recommended tobacco cessation medications changed; for 
example, varenicline was approved first by FDA in May 2006. 
In addition, the differences from year to year in the quality of 
reporting and persons who completed the form might have 
resulted in differences in the percentage of patients screened 
for tobacco use. For example, using 2001—2004 NAMCS 
data, a previous study (24) reported that outpatient screening 
for tobacco use is 68.2%, higher than the 62.7% in this 
report. These findings might underestimate or overestimate 
the prevalence of tobacco screening, cessation counseling, 
and successful quit rates. Additional research is needed 
to understand differences in reporting over time. Finally, 
NAMCS data are primarily obtained through self-reporting 
by physicians and include no record validation.
Conclusion
Tobacco use screening and intervention is one of the most 
effective clinical preventive services, both in terms of cost 
and success (4,25), and is an important component of a 
comprehensive strategy for increasing tobacco use cessation. 
As part of its National Tobacco Control Program, CDC 
recommends that states implement policies and other effective 
community-based strategies that increase tobacco cessation, 
in addition to working with health-care systems, insurers, 
and purchasers of health insurance to expand coverage for 
tobacco cessation and implement health system changes that 
support these effective clinical interventions (12,21). Other 
effective community-based interventions for increasing 
cessation include increasing the unit price of tobacco products, 
conducting mass media campaigns combined with other 
community interventions, providing telephone counseling, 
and implementing smoke-free legislation (12,21). These 
interventions are critical for decreasing tobacco use among 
adults because most persons who try to quit typically do 
not use any effective services (18,26). Therefore, public 
health programs should implement a comprehensive tobacco 
cessation strategy by using policy and media interventions to 
promote cessation among tobacco users while simultaneously 
providing affordable, available, and effective services (including 
counseling and medication) to those who want help to quit 
(12,21,27).
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Th is report is based, in part, on contributions by Stephen D . Babb,
Office on Smoking and Health, C D C .
References
1. C D C . Smoking-attributable mortality, years of potential life lost, and 
productivity losses— United States, 2000—2004. M M W R 2008; 
57:1226-8.
2. C D C . Vital signs: current cigarette smoking among adults aged >18 
years— United States, 2009. M M W R 2010;59:1135—40.
3. C D C . Quitting smoking among adults— United States, 2001—2010. 
M M W R 2011;60:1513-19.
4. Fiore M C , Jaen CR , Baker T B , et al. Treating tobacco use and 
dependence: 2008 update. Clinical practice guideline. Rockville, MD: 
US Department of Health and Human Services, Public Health Service; 
2008. Available at http://www.surgeongeneral.gov/tobacco/index.html. 
Accessed March 30, 2012.
5. US Department of Health and Human Services. Tobacco use objectives. 
Healthy People 2020. Washington, D C : US Department of Health and 
Human Services; 2011. Available at http://www.healthypeople. 
gov/2020/topicsobjectives2020/objectiveslist.aspx?topicid=4. Accessed 
March 30, 2012.
6. Sonnenfeld N , Schappert SM, Lin SX. Racial and ethnic differences in 
delivery of tobacco-cessation services. Am J Prev Med 2009;36:21-8.
7. Garbers S, Chiasson MA. Inadequate functional health literacy in Spanish 
as a barrier to cervical cancer screening among immigrant Latinas in 
New York City. Prev Chronic Dis 2004;1:A07.
8. Manetta A, Stephens F, Rea J, Vega C. Addressing health care needs of 
the Latino community: One medical school’s approach. Acad Med 
2007;82:1145-51.
9. Monroe AD , Shirazian T. Challenging linguistic barriers to health care: 
students as medical interpreters. Acad Med 2004;79:118-22.
10. Messer K , Trinidad DR, Al-Delaimy W K, Pierce JP Smoking cessation 
rates in the United States: a comparison of young adult and older 
smokers. Am J Pub Health 2008;98:317-22.
11. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to 
smoking: 50 years’ observations on male British doctors. BM J 
2004;328:1519.
12. CDC . Best practices for comprehensive tobacco control programs— 2007. 
Atlanta, GA: US Department of Health and Human Services, CDC; 
2007. Available at http://www.cdc.gov/tobacco/stateandcommunity/ 
best_practices/index.htm. Accessed March 30, 2012.
13. C D C . State Medicaid coverage for tobacco-dependence treatments— 
United States, 2009. M M W R 2010;59:1340-3.
14. University of Wisconsin Center for Tobacco Research and Intervention. 
Summary of selected tobacco, prevention, and public health previsions 
from H .R . 3590 and H .R . 4872. Madison, W I: University ofWisconsin 
Center for Tobacco Research and Intervention; 2010. Available at http:// 
www.ctri.wisc.edu/Insurers/HeathReformTobaccoSummary.pdf. 
Accessed March 30, 2012.
Acknowledgments 15. US Preventive Services Task Force. Counseling and interventions to 
prevent tobacco use and tobacco-caused disease in adults and pregnant 
women. Rockville, M D: US Preventive Services Task Force; 2009. http:// 
www.uspreventiveservicestaskforce.org/uspstf/uspstbac2.htm. Accessed 
March 30, 2012.
16. Cassidy A. Health policy brief: preventive services without cost sharing. 
Health Affairs, December 28, 2010. Available at http://www. 
healthaffairs.org/healthpolicybriefs/brief.php?brief_id=37. Accessed 
April 6, 2012.
17. Merlis M. Health policy brief: ‘grandfathered’ health plans. Health 
Affairs. October 29, 2010. Available at http://www.healthaffairs.org/ 
healthpolicybriefs/brief.php?brief_id=29. Accessed April 6, 2012.
18. Land T, Warner D, Paskowsky M, et al. Medicaid coverage for tobacco 
dependence treatments in Massachusetts and associated decreases in 
smoking prevalence. PLoS One 2010;5:e9770.
19. US Department of Health and Human Services. How smoking causes 
disease: the biological and behavioral basis for smoking-attributable 
disease: a report of the Surgeon General. Atlanta, GA: US Department 
of Health and Human Services, CD C ; 2010. Available at http://www. 
surgeongeneral.gov/library/tobaccosmoke/report/index.html. Accessed 
March 30, 2012.
20. Adams E K , Miller VP, Ernst C, Nishimura BK, Melvin C, Merritt R. 
Neonatal health care costs related to smoking during pregnancy. Health 
Econ 2002;11:193-206.
21. Task Force on Community Preventive Services. The guide to community 
preventive services: tobacco use prevention and control. New York, NY: 
Oxford University Press; 2005. Available at http://www.cdc.gov/tobacco/ 
stateandcommunity/comguide/index.htm. Accessed March 30, 2012.
22. Substance Abuse and Mental Health Services Administration. Results 
from the 2008 National Survey on Drug Use and Health: national 
findings. Rockville, M D: Substance Abuse and Mental Health Services 
Administration, Office of Applied Studies; 2009. N SDUH Series H-36, 
HHS Publication No. SMA 09-4434.
23. Curry SJ, Sporer AK, Pugach O, Campbell RT, Emery S. Use of tobacco 
cessation treatments among young adults smokers: 2005 National Health 
Interview Survey. Am J Public Health 2007;97:1464-69.
24. Ferketich AK , Khan Y, Wewers ME. Are physicians asking about tobacco 
use and assisting with cessation? Results from the 2001-2004 National 
Ambulatory Medical Care Survey (N A M C S). Prev Med 2006; 
43:472-6.
25. Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman 
MJ, Solberg LI. Priorities among effective clinical preventive services: 
results of a systematic review and analysis. Am J Prev Med 2006; 
31:52-61.
26. Shiffman S, Brockwell SE, Pillitteri JL , Gitchell JG . Use of smoking- 
cessation treatments in the United States. Am J Prev Med 2008; 
34:102-11.
27. US Department of Health and Human Services. Ending the tobacco 
epidemic: a tobacco control strategic action plan for the U.S. Department 
of Health and Human Services. Washington, DC : Office of the Assistant 
Secretary for Health; 2010. Available at http://www.hhs.gov/ash/ 
initiatives/tobacco/tobaccostrategicplan2010.pdf. Accessed April 10,
2012.
MMWR / June 15, 2012 / Vol. 61 45
Supplement
Breast Cancer Screening Among Adult Women —  Behavioral Risk 
Factor Surveillance System, United States, 2010
Jacqueline W. Miller, MD 
Jessica B. King, MPH 
Djenaba A. Joseph, MD 
Lisa C. Richardson, MD
D ivision o f  Cancer Prevention and Control, National Center fo r  Chronic Disease Prevention and
Health Promotion
Corresponding author: Jacqueline W. Miller, M D, National Center for Chronic Disease Prevention and Health Promotion, CDC , 2858 Woodcock Boulevard, 
MS K-57, Atlanta, GA 30341. Telephone: 770-488-5061; Fax: 770-488-3230; E-mail: aci8@cdc.gov.
In troduction
Breast cancer continues to have a substantial impact on the 
health of women in the United States. It is the most commonly 
diagnosed cancer (excluding skin cancers) among women, with 
more than 210,000 new cases diagnosed in 2008 (the most 
recent year for which data are available) (1). Incidence rates are 
highest among white women at 122.6 per 100,000, followed 
by blacks at 118 per 100,000, Hispanics at 92.8, Asian/Pacific 
Islanders at 87.9, and American Indian/Alaskan Natives at 65.6
(1). Although deaths from breast cancer have been declining 
in recent years (2,3), it has remained the second leading cause 
of cancer deaths for women since the late 1980s with >40,000 
deaths reported in 2008 (1). Although white women are more 
likely to receive a diagnosis of breast cancer, black women are 
more likely to die from breast cancer than women of any other 
racial/ethnic group (1). In addition, studies have demonstrated 
that nonwhite minority women tend to have a more advanced 
stage of disease at the time of diagnosis (4,5). Breast cancer also 
occurs more often among women aged >50 years, those with 
first-degree family members with breast cancer, and those who 
have certain genetic mutations (4,5). Understanding who is at 
risk for breast cancer helps inform guidelines for who should 
get screened for breast cancer.
In 2002, the U.S. Preventive Services Task Force (USPSTF) 
recommended screening mammography, with or without a 
clinical breast exam, every 1-2 years for women aged >40 
years (6). Mammography has been demonstrated to reduce 
breast cancer mortality by detecting breast cancer early, when 
treatment is most effective (7,8). Mammography use increased 
in the 1990s, when it became a widely accepted practice for 
decreasing breast cancer mortality, but its use decreased during 
2000-2005 (9,10). Studies that assessed this decline noted that 
women with insurance and higher annual incomes had the 
highest decrease in mammography use. In a follow up study, the 
overall prevalence of receiving mammography within the past 2 
years rose slightly in 2006 to approximately the 2000 level (11). 
The latest report using 2008 data indicated that mammography
use among women aged 50-74 years has essentially leveled off 
since 2000 (12). During 2000- 2006, although non-Hispanic 
white women and those with insurance had a substantial overall 
decline in mammography use, women who were uninsured, 
those who had lower annual income or education levels, and 
members of certain minority racial/ethnic groups persistently 
reported lower prevalence of mammography use (11,12). 
Moreover, substantial geographic variation in screening rates 
exists across the United States (13).
In November 2009, USPSTF changed its breast cancer 
screening recommendations to biennial mammography for 
women aged 50-74 years and stated that women aged 40-49 
years do not need to be screened routinely (6). However, 
the Patient Protection and Affordable Care Act of 2010 (as 
amended by the Healthcare and Education Reconciliation Act 
of 2010 and referred to collectively as the Affordable Care Act 
[ACA]) specifically designates coverage of the breast cancer 
screening according to the recommendations issued before 
November 2009 (ACA §2713) (14).
This report summarizes the 2010 national mammography 
use prevalence estimates for women aged >40 years, by 
dem ographic characteristics and state-level prevalence 
estimates, based on the 2002 USPSTF recommendations. 
This information can be used by providers, public health 
practitioners, and other stakeholders as baseline data for 
assessing progress and gaps in breast cancer screening as the 
Affordable Care Act is implemented.
M ethods
To estimate the prevalence of breast cancer screening using 
mammography among women aged >40 years in the United 
States, CDC analyzed 2010 data from the Behavioral Risk 
Factor Surveillance System (BRFSS). BRFSS is an ongoing, 
state-based, random-digit-dialed telephone survey of the 
civilian, noninstitutionalized adult population aged >18 years. 
The survey gathers information on health behaviors, chronic
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diseases, and preventive health practices from all 50 states, 
the District of Columbia (DC), Guam, Puerto Rico, and the 
U.S. Virgin Islands. In every even year, the survey contains a 
women’s health module that includes two questions related to 
mammography use. Participants are asked whether they have 
ever had a mammogram, and those who respond affirmatively 
are asked how long it has been since their last mammogram. 
Missing, refused, and “don’t know” responses were excluded 
from analyses. In 2010, among the 276,995 female survey 
participants, 228,871 were aged >40 years and were asked 
the questions regarding mammography use, accounting for a 
total sample of 221,241 participants included in this analysis.
All data were weighted to the respondents’ probability 
of selection, and sex, age, and race/ethnicity for each state’s 
population using intercensal estimates. Percentages were age- 
adjusted to the BRFSS female population aged >40 years. 
Percentages and 95% confidence intervals were calculated 
using SAS (SAS Institute Inc., Cary, North Carolina) and 
SUDAAN (Research Triangle Institute, Research Triangle 
Park, North Carolina) software. The median response rate for 
the Council of American Survey and Research Organizations 
(CASRO) was 54.6% (range: 39.1%-68.8%) and the CASRO 
cooperation rate was 76.9% (range: 56.8%—86.1%).* Current 
use of mammography was defined as having a mammogram 
within the past 2 years.
Results
In 2010, an estimated 75.4% women aged >40 years 
and 79.7% of women aged 50-74 years reported having a 
mammogram within the past 2 years (Table 1). Women who 
reported the highest prevalence of mammography use were 
those aged 60-69 years (81.3%) and 70-74 years (82.4%), 
non-Hispanic blacks (78.6%), those with college graduate 
or higher level of education (80.8%), those whose annual 
household income was >$75,000 (83.8%), those with health 
insurance (78.6%), and those with a usual source of health 
care (78.3%). Women who reported the lowest prevalence 
of mammography use were those aged 40-49 years (68.8%), 
American Indian/Alaska Natives (63.9%), those who did not 
graduate from high school (65.9%), those whose annual 
household income was <$15,000 (63.2%), those with no
* The CASRO response rate is the product of three other rates: 1) the resolution 
rate, which is the proportion of telephone numbers that can be identified as 
either for a business or residence; 2)the screening rate, which is the proportion 
of qualified households that complete the screening process; and 3) the 
cooperation rate, which is the proportion of contacted eligible households for 
which a completed interview is obtained. CASRO response and cooperation 
rates reported by different surveys are not strictly comparable because of 
differences in how disposition catagories are defined.
TABLE 1. Number and percentage* of U.S. adult women aged >40 
years who reported having a mammogram within the past 2 years, 
by demographic characteristics— Behavioral Risk Factor Surveillance 
System, United States, 2010
Characteristic No. % (95% CI)
Total 221,241 75.4 (75.0-75.7)
Age (yrs)
40-49 41,398 68.8 (68.0-69.6)
50-74 136,278 79.7 (79.3-80.1)
>75 43,565 73.0 (72.3-73.7)
Race/Ethnicity
White, non-Hispanic 179,827 75.4 (75.0-75.7)
Black, non-Hispanic 17,852 78.6 (77.5-79.7)
Hispanic 11,199 75.4 (74.0-76.8)
Asian/Pacific Islander 3,127 73.7 (70.8-76.5)
American Indian/Alaska Native 2,514 63.9 (59.4-68.1)
Other 4,267 67.0 (64.4-69.4)
Education level
Less than high school graduate 20,998 65.9 (64.5-67.3)
High school graduate 70,164 71.8 (71.1-72.5)
Some college 61,468 75.2 (74.5-75.8)
College graduate or higher 68,247 80.8 (80.3-81.3)
Annual household income
<$15,000 25,914 63.2 (61.9-64.4)
$15,000-34,999 61,435 68.1 (67.3-68.9)
$35,000-49,999 28,093 74.7 (73.7-75.7)
$50,000-74,999 27,640 79.2 (78.3-80.0)
>$75,000 42,749 83.8 (83.2-84.4)
Health insurance coverage
Yes 202,529 78.6 (78.2-78.9)
No 18,351 50.4 (48.7-52.0)
Usual source of health care
Yes 203,719 78.3 (78.0-78.7)
No 17,047 43.6 (42.3-45.0)
Abbreviation: CI = confidence interval.
*  Age-adjusted to  the 2010 BRFSS female population.
health insurance (50.4%), and those with no usual source of 
health care (43.6%).
The age-adjusted prevalence of reported mammography use 
within the study period (i.e., past 2 years from the time of the 
2010 BRFSS interview) varied among the states, ranging from 
63.7% in Idaho to 84.2% in Massachusetts (Table 2). Although 
mammography use prevalence varies considerably across the 
United States, the majority of states with the highest prevalence 
are located in the northeast region. Many states with the lowest 
prevalence estimates have more rural, less populated areas.
Discussion
In 2010, approximately 25% of women aged >40 years 
were not current with their mammography use according to 
the 2002 USPSTF guidelines. Mammography use was lower 
among American Indian/Alaska Native women, women with 
lower levels of education and annual household income, and
MMWR / June 15, 2012 / Vol. 61 47
Supplement
TABLE 2. Number and percentage* of U.S. adult women aged >40 
years who reported having a mammogram within the past 2 years, 
by state — Behavioral Risk Factor Surveillance System, United States, 
2010
State No. % (95% CI)
Quartile 1 (63.7%-70.9%)
Idaho 3,333 63.7 (61.5-65.81
Nevada 1,788 66.9 (63.4-70.11
W yoming 2,888 66.9 (64.8-68.91
Montana 3,502 67.0 (64.9-69.11
Oklahoma 3,969 67.2 (65.4-68.91
Utah 4,209 67.2 (65.5-69.01
Mississippi 4,506 67.9 (66.1-69.81
Arkansas 2,095 68.2 (65.4-70.81
Kentucky 4,491 69.8 (67.6-72.01
New Mexico 3,454 70.3 (68.2-72.31
Colorado 5,366 70.4 (68.9-71.91
Texas 9,024 70.5 (68.8-72.11
Oregon 2,560 70.8 (68.6-72.91
Quartile 2 (71.0%-74.8%)
Missouri 2,752 71.2 (68.6-73.61
Indiana 5,105 71.2 (69.5-72.91
Illinois 2,648 71.7 (69.4-73.81
Nebraska 8,395 71.7 (69.9-73.31
West Virginia 2,235 71.9 (69.9-74.11
Alaska 765 72.8 (68.3-77.01
Ohio 5,019 73.9 (72.3-75.51
Pennsylvania 5,649 74.2 (72.6-75.71
South Carolina 4,836 74.2 (72.1-76.11
Arizona 2,999 74.2 (71.4-76.91
W ashington 9,796 74.4 (73.2-75.51
Alabama 4,188 74.8 (72.9-76.71
North Dakota 2,302 74.8 (72.7-76.81
Quartile 3 (74.9%-77.8%)
Kansas 4,287 75.8 (74.2-77.21
Tennessee 3,252 75.9 (73.7-77.91
Iowa 3,051 76.1 (74.2-77.91
Louisiana 3,805 76.2 (74.5-77.71
Hawaii 3,123 76.4 (74.3-78.41
South Dakota 3,313 76.6 (74.6-78.41
Florida 18,023 77.0 (75.5-78.41
North Carolina 6,076 77.2 (75.6-78.61
New Jersey 5,884 77.4 (75.9-78.81
Virginia 2,607 77.7 (75.3-80.01
Verm ont 3,392 77.8 (76.1-79.31
Georgia 2,907 77.8 (75.8-79.71
New York 4,399 77.8 (76.3-79.31
Quartile 4 (77.9%-84.2%)
Michigan 4,599 78.2 (76.6-79.71
California 7,767 78.4 (77.3-79.51
Wisconsin 2,275 78.6 (76.3-80.71
Maine 4,159 80.2 (78.6-81.61
District o f Columbia 1,814 80.3 (77.9-82.51
New Hampshire 3,112 80.5 (78.7-82.11
Minnesota 4,326 80.5 (78.8-82.21
Maryland 4,522 80.8 (79.2-82.21
Delaware 2,180 81.2 (79.0-83.21
Connecticut 3,375 81.5 (79.7-83.21
Rhode Island 3,441 81.5 (79.8-83.01
Massachusetts 7,678 84.2 (82.9-85.41
United States 221,241 75.4 (75.0-75.71
Abbreviation: CI = confidence interval.
* Age-adjusted to  the 2010 BRFSS female population.
women with no health insurance or usual source of health 
care. The geographic variation noted in mammography use 
ranged from 63.7% to 84.2%. Mammography use has not 
substantially changed since 2000 (76.5% [95% confidence 
interval (CI): 75.9-77.0]), consistent with previous reports 
examining 2006 (11) and 2008 (12) data. The geographic 
variation noted in these findings is similar to that noted in 
the 2000 and 2006 data (13). Multiple factors account for 
this variation, including the availability of large university 
hospital systems, geographic density of healthcare providers, 
level of insurance coverage in the population, accessibility 
to mammography facilities, and levels of annual income. 
The finding that women without health insurance or a usual 
source of health care have lower mammography use supports 
previous reports that a physician’s recommendation for 
mammography is the most important influence for a woman 
to obtain a mammogram (15). Persistent lower mammography 
use among certain minority populations will continue to 
result in patients receiving a diagnosis of breast cancer at later 
stages and a potentially slower decrease in breast cancer death 
rates. One study addressing preventable deaths in the United 
States has estimated that a 5% increase in mammography use 
could prevent 560 deaths from breast cancer each year (16). 
Therefore, increasing mammography use among women, 
especially those with low use prevalence, might decrease breast 
cancer mortality substantially . More research is needed to help 
understand why these disparities exist and provide appropriate 
interventions that reduce or eliminate them.
To help address disparities in mammography use, CDC 
administers the National Breast and Cervical Cancer Early 
Detection Program (NBCCEDP) (17). NBCCEDP provides 
free or low-cost screening and diagnostic breast and cervical 
cancer services to low-income, under- and uninsured women 
and provides access to state Medicaid programs for treatment 
if breast or cervical cancer are diagnosed. NBCCEDP has 
reduced mortality among the medically uninsured (18) and 
prevented 0.6 deaths for every 1,000 women screened (19).
As a result of provisions in the Affordable Care Act, Medicare 
now covers adult clinical preventive services graded A (strongly 
recommended) or B (recommended) by the USPSTF and 
immunizations recommended by the Advisory Committee on 
Immunization Practices with no cost sharing to beneficiaries 
(ACA §2713). Starting in 2014, these services, along with 
recommended preventive services for children, youth, and 
women, will be covered at no cost sharing by newly qualified 
private health plans operating in the state-based insurance
48 MMWR / June 15, 2012 / Vol. 61
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exchanges.'!' Beginning in 2013, state Medicaid programs that 
eliminate cost sharing for these clinical preventive services 
may receive enhanced federal matching funds for them 
(ACA §4106).
The Affordable Care Act focuses on reducing health 
disparities by removing barriers to preventive health screening 
such as reducing out-of-pocket costs and expanding access 
to care by increasing availability of health-care providers 
and services through provisions such as the essential health 
benefits package (ACA §1302), state health-care workforce 
developm ent grants (ACA §5102), and public health 
workforce recruitment and retention programs (ACA §5204). 
Implementation of the Affordable Care Act is expected to result 
in an increase in mammography use among many more women 
of appropriate screening age and in a decrease in disparities 
among underserved populations by vastly expanding insurance 
coverage among the uninsured population. Using evidence- 
based interventions to increase breast cancer screening by 
addressing other barriers to screening, as recommended by the 
Guide to Community Preventive Services, might further decrease 
breast cancer mortality nationwide (20,21). These evidence- 
based interventions target both clients and providers. Client- 
oriented interventions (e.g., client reminders, small media, 
group education, one-on-one education, reducing structural 
barriers, and reducing out-of-pocket costs) are directed toward 
educating clients and removing barriers that interfere with 
screening (20). Provider-oriented interventions (e.g., recall 
and reminder systems or assessment and feedback systems) 
are designed to increase knowledge and develop system-level 
approaches to increase provider recommendation and delivery 
of cancer screening services (21).
The findings provided in this report are subject to at 
least three limitations. First, the data are self-reported and 
not validated from medical or billing records. Studies have 
demonstrated that women often over-report having a recent 
mammogram. For example, a recent report indicated that black 
women tend to over-report twice as often as white women (22). 
Adjusting for this over-reporting resulted in a considerable 
decrease in reported mammography use of29 percentage points 
among black women compared with 12 percentage points 
among white women (22). Second, because the BRFSS survey 
questionnaire does not ask why a woman had a mammogram, 
whether the mammogram was for screening or diagnostic 
purposes can not be determined. Finally, because BRFSS
! Beginning in 2014, a competitive insurance marketplace will be set up in the 
form of state-based insurance exchanges. These exchanges will allow eligible 
persons and small businesses with up to 100 employees to purchase health 
insurance plans that meet criteria outlined in the Affordable Care Act (ACA 
§1311). I f  a state does not create an exchange, the federal government will 
operate it.
samples civilian, noninstitutionalized persons by telephone, 
and only those with landlines are represented in this sample, 
these data might not be nationally representative.
Conclusion
Reducing personal costs and expanding insurance coverage 
are important factors that will help to ensure that more 
women receive mammography screening (20). Developing 
new and effective interventions to increase mammography 
use relies upon better understanding of who is not receiving 
recommended breast cancer screening and the reasons for lack 
of screening. Although clear communication for individualized 
decision-making is difficult, helping women to understand 
their personal risk (e.g., family history of breast cancer, 
menstrual history, use of estrogen, and genetic abnormalities) is 
also important for changing a woman’s behavior and acceptance 
of the need to undergo screening (23—25).
Public health efforts to monitor the use of clinical preventive 
services such as mammography screening will be necessary as 
the Affordable Care Act is fully implemented over the next 
few years. Understanding the interaction between individual, 
community-level, and federal-level activities will help identify 
promising practices and unsuccessful efforts that require 
modification. In particular, close monitoring of mammography 
screening will help to identify potential concerns regarding low 
use of this early detection test, which could lead to negative 
outcomes such as an increase in late stage breast cancer 
diagnoses and breast cancer mortality. The ACA includes the 
Prevention and Pubic Health Fund (ACA §4002) to increase 
the use of clinical preventive services at the community level. 
The establishment of additional interventions such as cancer 
screening registries to monitor outcomes of abnormal screening 
results, patient navigation services (i.e., assistance to help 
patients facilitate access to services and overcome barriers), and 
electronic health records could help ensure the U.S. population 
gets all the appropriate clinical preventive services.
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In troduction
Among cancers that affect both men and women, colorectal 
cancer is the second leading cause of cancer death (1). In 2007 
(the most recent year for which data are available), >142,000 
persons received a diagnosis for colorectal cancer and >53,000 
persons died (1). Screening for colorectal cancer has been 
demonstrated to be effective in reducing the incidence of and 
mortality from the disease (2). In 2008, the U.S. Preventive 
Services Task Force (USPSTF) recommended that persons aged 
50-75 years at average risk for colorectal cancer be screened by 
using one or more of the following methods: high-sensitivity 
fecal occult blood testing (FOBT) every year, sigmoidoscopy 
every 5 years with FOBT every 3 years, or colonoscopy every 
10 years (2).
The effectiveness of screening in reducing the incidence 
and mortality of colorectal cancer has been well established
(2). Colorectal cancer screening has been identified as a high­
impact, cost-effective service (3,4). An estimated 10,000 
additional deaths could be prevented each year if all adults 
aged >50 years were offered colorectal cancer screening, at an 
estimated cost of $11,900 per life year saved (3). Modeling 
studies have suggested that increasing colorectal cancer 
screening would have the greatest impact in reducing colorectal 
cancer mortality, compared with reducing risk factors or 
increasing treatment use (5,6). Despite strong evidence of its 
effectiveness, colorectal cancer screening prevalence continues 
to lag behind that of other screening-amenable cancers (i.e., 
breast and cervical cancer) (7,8).
This report summarizes the prevalence of colorectal cancer 
screening test use that can be used as a baseline by providers, 
public health practitioners, and other stakeholders to assess 
progress in colorectal cancer screening rates as the Patient 
Protection and Affordable Care Act (ACA) of 2010 (as 
amended by the Healthcare and Education Reconciliation Act 
of 2010 and referred to collectively as the Affordable Care Act 
[ACA]) is fully implemented (9).
M ethods
To determine the state-based prevalence of colorectal cancer 
screening among U.S. adults, CDC analyzed 2010 data from 
the Behavioral Risk Factor Surveillance System (BRFSS). 
BRFSS is an ongoing, state-based, random-digit-dialed 
telephone survey of the U.S. civilian, noninstitutionalized 
adult population aged >18 years that collects information on 
health risk behaviors, preventive health practices, and health­
care access in the United States, the District of Columbia 
(DC), Guam, Puerto Rico, and the U.S. Virgin Islands. Every 
2 years (in even-numbered years) respondents aged >50 years 
are asked whether they have ever used a “special kit at home 
to determine whether the stool contains blood (FOBT),” 
whether they have ever had “a tube inserted into the rectum 
to view the colon for signs of cancer or other health problems 
(sigmoidoscopy or colonoscopy),” and when these tests were 
last performed. Starting in 2008, respondents also were asked 
whether their most recent test had been a sigmoidoscopy or 
a colonoscopy. Percentages were estimated for persons who 
reported receiving an FOBT within 1 year, or sigmoidoscopy 
within 5 years with FOBT within 3 years, or colonoscopy 
within 10 years preceding the survey. Based on the USPSTF 
recommended screening age, the analysis was restricted to 
persons aged 50-75 years.
Survey data were available for all 50 states and DC. Based 
on Council of American Survey and Research Organizations 
(CASRO) guidelines,* in 2010, the median response rate was 
54.6% (range: 39.1%-68.8%), and the median cooperation 
rate was 76.9% (range: 56.8%—86.1%). Respondents who 
refused to answer, had a missing answer, or did not know 
the answer to a question were excluded from analysis of that
*The CASRO response rate is the product of three other rates: 1) the resolution 
rate, which is the proportion of telephone numbers that can be identified as 
either for a business or residence; 2)the screening rate, which is the proportion 
of qualified households that complete the screening process; and 3) the 
cooperation rate, which is the proportion of contacted eligible households for 
which a completed interview is obtained. CASRO response and cooperation 
rates reported by different surveys are not strictly comparable because of 
differences in how disposition catagories are defined.
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specific question. O f 236,186 persons aged 50-75 years who 
responded, approximately 12,206 (5.2%) were excluded from 
the results, yielding a final sample of 223,980. Data were 
weighted to the age, sex, and racial/ethnic distribution of each 
state’s adult population using intercensal estimates and were 
age-standardized to the 2010 BRFSS population.
Results
In 2010, an estimated 64.5% of respondents aged 50-75 
years reported having had one of the following colorectal 
screening tests recommended by USPSTF: FOBT within 1 
year, sigmoidoscopy within 5 years with FOBT within 3 years, 
or colonoscopy within 10 years preceding the survey (Table
1). The proportion of respondents who reported having had 
a colorectal cancer test within the recommended interval 
increased with age, increasing education level, and increasing 
annual household income. The proportion was also greater 
for those with health insurance than for those without, those 
with a regular care provider than those without, and slightly 
greater for women than for men. A slightly greater proportion 
of whites reported being up-to-date with colorectal cancer 
testing compared with all other racial/ethnic groups.
The proportion of respondents who had colonoscopy as their 
most recent test (60.3%) was much greater than the proportion 
that had FOBT (11.7%) or sigmoidoscopy in combination 
with FOBT (1.3%) as their most recent test. The proportion 
reporting use of any of the three test options increased with 
age and was greater among those with insurance and those 
with a regular care provider. Although a very small proportion 
of respondents reported having had a sigmoidoscopy within 5 
years with FOBT within 3 years, a slightly greater proportion 
reported having had a sigmoidoscopy alone within 5 years (5.7% 
[95% confidence interval (CI) 5.4%—5.9%]; data not shown). A 
greater proportion of blacks reported receiving FOBT within 1 
year compared with all other members of racial/ethnic groups; 
a greater proportion of whites reported colonoscopy within 10 
years compared with all other racial/ethnic groups. Minimal 
variation was noted in reported FOBT use by education level 
and household income, whereas the proportion of respondents 
reporting colonoscopy within the past 10 years increased 
substantially with increasing education level and increasing 
annual household income.
The proportion of respondents who reported having 
received any colorectal cancer test within the recommended 
interval was highest in Massachusetts (75.2%) and in New 
Hampshire (75.1%) and lowest in Oklahoma (54.1%) (Table
2). Connecticut had the largest proportion of respondents 
who reported colonoscopy within 10 years (72.5%), and West
Virginia had the smallest (49.7%). California had the largest 
proportion of respondents who reported FOBT within 1 year 
(19.4%), and Utah had the smallest (4.7%). All states had <5% 
ofrespondents reporting receiving sigmoidoscopy within 5 years 
and FOBT within 3 years.
Discussion
Approximately two thirds of the U.S. population aged 50-75 
years was up-to-date with colorectal cancer screening according 
to USPSTF recommendations. As noted in previous reports, 
certain populations had a lower prevalence of colorectal cancer 
screening, including those with a lower socioeconomic status, 
lower education levels, Hispanics, and those without health 
insurance or a regular health care provider (10—12). These 
populations also had a lower prevalence of screening with 
colonoscopy, despite evidence that colonoscopy has rapidly 
become the predominant method of colorectal cancer screening 
in the United States (8). This might reflect variation in access 
to colonoscopy by traditionally underserved populations. 
Substantial variation existed by state in the proportion of 
respondents who were up-to-date with colorectal cancer 
screening. In general, states with the highest proportion 
of residents who were current with screening also had the 
highest proportion of residents who reported colonoscopy as 
their most recent test. Use of FOBT and sigmoidoscopy with 
FOBT was low in all states. Variation in colonoscopy use by 
state might result from variations in the level of insurance 
coverage, proportion of underserved populations in the state, 
and availability of endoscopists (13,14).
An understanding of what factors influence the use of 
colorectal cancer screening is necessary to make improvements. 
Lack of insurance has been cited frequently as a barrier to 
colorectal cancer screening (12,15,16). Multiple studies have 
noted significantly lower colorectal cancer screening prevalence 
among the uninsured (10—12). The cost o f a screening 
colonoscopy can range between $400 and $1,600 (17,18). 
FOBT kits themselves are relatively inexpensive, but additional 
costs incurred by office visits and any potential follow up 
testing with colonoscopy could be cost prohibitive. Further, 
the uninsured might not have a regular health care provider 
from whom to receive a recommendation or referral for testing. 
Full implementation of the Afforable Care Act will potentially 
provide millions of currently uninsured persons with coverage 
of clinical preventive services graded A or B by the USPSTF, 
such as colorectal cancer screening (graded A for adults aged 
50—75 years), without additional copays, thereby removing a 
substantial financial barrier. Colorectal cancer screening for 
those currently insured by Medicare also should increase, as the 
Afforable Care Act removed cost-sharing for USPSTF grade A
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TABLE 1. Percentage of respondents aged 50-75 years who reported colorectal cancer test use, by test type and by selected characteristics 
— Behavioral Risk Factor Surveillance System, United States, 2010*
Characteristic
Up-to-date with CRC 
screening+ FOBT within 1 year
Sigmoidoscopy 
within 5 years with 
FOBT within 3 years
Colonoscopy within 
10 years
% (95% CI) % (95% CI) % (95% CI) % (95% CI)
Overall 64.5 (64.1-64.9) 11.7 (11.5-12.0) 1.3 (1.2-1.4) 60.3 (59.9-60.7)
Age (yrs)
50-59 55.1 (54.6-55.8) 9.1 (8.8-9.5) 0.9 (08-1.0) 51.0 (50.4-51.6)
60-69 72.9 (72.3-73.4) 14.0 (13.6-14.4) 1.6 (1.5-1.8) 68.5 (67.9-69.0)
70-75 76.9 (76.1-77.6) 15.4 (14.8-16.0) 2.1 (1.8-2.4) 72.8 (72.0-73.5)
Sex
Men 63.9 (63.3-64.5) 12.4 (12.0-12.8) 1.4 (1.3-1.5) 59.5 (58.9-60.1)
Women 65.0 (64.6-65.5) 11.2 (10.9-11.5) 1.2 (1.1-1.3) 61.0 (60.5-61.5)
Race/Ethnicity
White 66.3 (65.9-66.7) 11.3 (11.1-11.6) 1.3 (1.2-1.4) 62.5 (62.1-62.9)
Black 65.0 (63.8-66.3) 15.1 (14.2-16.2) 1.4 (1.1-1.8) 60.0 (58.7-61.3)
Hispanic 51.6 (49.7-53.4) 10.8 (9.8-11.9) 1.2 (0.9-1.7) 46.0 (44.1-47.8)
Asian/Pacific Islander 55.1 (51.8-58.4) 13.0 (10.9-15.3) 1.7 (0.9-2.9) 49.9 (46.6-53.2)
American Indian/Alaska Native 55.3 (51.4-59.2) 14.6 (12.0-17.7) 0.9 (0.4-1.8) 48.9 (45.1-52.8)
Other 61.3 (58.7-63.9) 13.5 (11.9-15.4) 2.2 (1.5-3.1) 55.2 (52.5-57.8)
Education level
<High school 45.4 (44.0-46.9) 9.6 (8.8-10.5) 0.8 (0.6-1.1) 40.6 (39.2-42.0)
High school graduate/GED 59.5 (58.8-60.2) 11.1 (10.7-11.5) 0.9 (0.8-1.1) 55.1 (54.5-55.8)
Some college/tech school 65.6 (64.9-66.3) 12.3 (11.9-12.8) 1.4 (1.3-1.6) 61.2 (60.5-61.8)
College graduate 71.9 (71.3-72.5) 12.4 (12.1-12.9) 1.7 (1.5-1.9) 68.2 (67.6-68.9)
Annual household income
<$15,000 47.6 (46.3-48.9) 11.2 (10.4-12.0) 0.9 (0.7-1.2) 42.2 (41.0-43.5)
$15,000-34,999 55.8 (55.0-56.5) 11.5 (11.1-12.0) 1.1 (1.0-1.3) 50.8 (50.0-51.5)
$35,000-49,999 64.6 (63.6-65.5) 11.9 (11.3-12.6) 1.5 (1.3-1.9) 60.2 (59.2-61.2)
$50,000-74,999 68.8 (68.0-69.7) 11.9 (11.4-12.5) 1.3 (1.1-1.6) 65.1 (64.2-66.0)
>$75,000 73.8 (73.1-74.5) 12.3 (11.8-12.8) 1.7 (1.5-1.9) 70.4 (69.7-71.1)
Health insurance
Yes 67.5 (67.2-67.9) 12.2 (11.9-12.4) 1.4 (1.3-1.5) 63.3 (62.9-63.7)
No 36.1 (34.3-38.0) 7.9 (6.9-9.1) 0.5 (0.3-0.7) 32.5 (30.7-34.3)
Regular care provider
Yes 67.9 (67.5-68.3) 12.3 (12.1-12.6) 1.4 (1.3-1.5) 63.6 (63.2-64.0)
No 31.7 (30.5-33.0) 5.7 (5.1-6.3) 0.5 (0.3-0.7) 28.4 (27.2-29.6)
Abbreviations: CI = confidence interval; FOBT = fecal occu lt blood test; GED = general equivalency diplom a.
* Data were weighted to  the age, sex, and racia l/ethnic d is tribu tion  o f each state's adult popula tion using intercensal estimates and were age-standardized to  the 
2010 Behavioral Risk Factor Surveillance System (BRFSS) population.
+ FOBT w ith in  1 year, or sigm oidoscopy w ith in  5 years w ith  FOBT w ith in  3 years, or colonoscopy w ith in  10 years (United States Preventive Services Task Force, 2008).
or B services as well as Advisory Committee on Immunization 
Practices (ACIP)-recommended immunizations as ofJanuary 1, 
2011 (ACA §2713). The law provides for an enhanced federal 
match rate to state Medicaid programs that offer these services 
at no cost sharing, beginning January 1, 2013 (ACA §4106) .
Although substantial gains in colorectal cancer screening 
rates have been made over the past 10 years (from 54% in 
2002 to approximately 65% in 2010), for the full potential 
of screening to be reached, additional work is needed to 
increase the uptake of screening among the currently insured 
and soon-to-be insured (10). Access to a regular health-care 
provider and having health insurance were each associated with 
a substantially higher prevalence of colorectal cancer screening; 
however, the prevalence of colorectal cancer screening has
remained lower than screening rates achieved with breast and 
cervical cancer screening, even among the currently insured 
(7,8). Participation in screening is influenced by multiple 
factors at the individual, physician, and organizational levels
(19). Individual level barriers include lack of a physician 
recommendation, lack of knowledge, fear, embarrassment, 
lack of symptoms or current health problems, cost, and 
competing demands (20,21). Barriers also might vary by test 
type. Reported barriers to FOBT include not wanting to handle 
stool or keep stool cards in the house (20,22). Colonoscopy- 
specific barriers include fear or avoidance of bowel preparation, 
fear of having a tube inserted through the rectum, and fear of 
pain or discomfort (20). Providers also might preferentially 
recommend a particular test to patients, which might deter
MMWR / June 15, 2012 / Vol. 61 53
Supplement
TABLE 2. Percentage of respondents aged 50-75 years who reported colorectal test use, by test type and by state* — Behavioral Risk Factor 
Surveillance System, United States, 2010
State
Up-to-date with CRC 
screening+ FOBT within 1 year
Sigmoidoscopy 
within S years with 
FOBT within B years
Colonoscopy within 
10 years
% (9S% Ci) % ( 9S% Ci) % (9S% Ci) % (9S% Ci)
United States 64.S (64.1-64.9) 11.7 (11.S-12.0) 1.B (1.2-1.4) 60.B (S9.9-60.7)
Quartile 1
Oklahoma 54.1 (52.3-56.0) 9.2 (8.3-10.3) 0.4 (0.2-0.7) 50.6 (48.7-52.4)
West Virginia 54.5 (52.1-56.8) 12.8 (11.3-14.4) 0.3 (0.1-0.7) 49.7 (47.4-52.0)
Idaho 55.9 (53.9-57.9) 8.1 (7.2-9.2) 0.8 (0.5-1.1) 52.4 (50.4-54.4)
W yoming 56.7 (54.7-58.6) 8.3 (7.3-9.4) 0.5 (0.3-0.9) 53.2 (51.2-55.2)
Nevada 56.8 (53.4-60.1) 9.9 (8.1-12.1) 0.9 (0.5-1.7) 52.5 (49.1-55.9)
North Dakota 57.0 (54.8-59.2) 11.2 (9.9-12.6) 1.4 (1.0-2.0) 52.2 (50.0-54.5)
Mississippi 57.1 (55.1-59.0) 11.0 (9.9-12.2) 0.9 (0.5-1.6) 52.8 (50.8-54.7)
Montana 58.0 (56.0-60.0) 8.8 (7.8-10.0) 1.3 (0.8-2.0) 53.9 (51.9-55.9)
Alaska 58.B (53.9-62.6) 8.0 (5.6-11.3) 0.2 (0.0-0.8) 57.0 (52.5-61.4)
Arkansas 58.6 (55.9-61.2) 10.2 (8.8-11.9) 0.1 (0.0-0.4) 54.2 (51.5-56.9)
Illinois 58.6 (56.1-61.1) 7.4 (6.2-8.7) 0.4 (0.2-0.9) 56.1 (53.6-58.6)
Texas 58.8 (56.7-60.7) 8.7 (7.8-9.8) 0.5 (0.3-0.7) 55.1 (53.1-57.1)
New Mexico 59.2 (57.2-61.1) 9.9 (8.7-11.2) 0.7 (0.5-1.0) 55.1 (53.1-57.1)
Quartile 2
Nebraska 59.8 (58.0-61.5) 8.7 (7.8-9.7) 0.6 (0.4-1.0) 56.2 (54.4-58.0)
Louisiana 60.2 (58.3-62.0) 12.7 (11.4-14.1) 0.5 (0.3-0.9) 55.2 (53.3-57.1)
Hawaii 60.4 (58.1-62.6) 16.5 (14.8-18.2) 2.9 (2.3-3.8) 51.3 (49.0-53.6)
Tennessee 60.8 (58.3-63.2) 12.7 (11.2-14.4) 1.5 (1.0-2.4) 56.4 (53.9-58.9)
Indiana 61.2 (59.4-62.9) 10.0 (8.9-11.1) 0.9 (0.5-1.5) 57.5 (55.7-59.3)
Kentucky 61.8 (59.6-63.9) 8.6 (7.5-9.9) 0.4 (0.2-0.9) 59.4 (57.2-61.5)
California 62.2 (60.8-63.6) 19.4 (18.3-20.5) 4.4 (3.9-5.0) 52.7 (51.3-54.2)
Alabama 62.5 (60.4-64.6) 10.2 (9.0-11.5) 0.6 (0.4-0.9) 58.3 (56.2-60.4)
Ohio 62.8 (61.0-64.5) 11.8 (10.7-12.9) 1.2 (0.8-1.7) 58.1 (56.3-59.9)
Kansas 6B.1 (61.4-64.7) 11.3 (10.4-12.4) 0.9 (0.6-1.3) 58.9 (57.2-60.5)
Missouri 6B.2 (60.5-65.8) 8.4 (7.0-10.2) 0.8 (0.4-1.6) 59.9 (57.2-62.5)
Iowa 6B.4 (61.4-65.3) 10.9 (9.7-12.2) 0.5 (0.3-0.9) 60.4 (58.4-62.4)
Quartile 3
Oregon 6B.6 (61.4-65.7) 11.4 (10.1-12.8) 3.6 (2.8-4.6) 57.8 (55.6-60.0)
Arizona 6B.7 (60.7-66.6) 11.5 (9.9-13.3) 1.0 (0.6-1.8) 60.2 (57.1-63.1)
South Dakota 64.0 (61.9-66.0) 10.1 (8.9-11.4) 0.6 (0.4-1.1) 60.9 (58.8-63.0)
South Carolina 64.4 (62.3-66.5) 9.3 (8.1-10.6) 0.7 (0.4-1.2) 61.3 (59.1-63.5)
New Jersey 64.7 (62.3-66.4) 11.6 (10.5-12.9) 1.1 (0.7-1.7) 60.5 (58.8-62.3)
Colorado 65.2 (63.7-66.7) 12.0 (11.0-13.0) 1.6 (1.3-2.1) 59.6 (58.0-61.1)
Florida 66.0 (64.2-67.6) 13.6 (12.6-14.7) 0.8 (0.7-1.1) 61.6 (59.8-63.3)
Georgia 66.4 (64.2-68.5) 14.2 (12.7-15.8) 1.5 (1.0-2.2) 62.5 (60.3-64.7)
Pennsylvania 66.5 (64.8-68.1) 8.9 (8.0-9.9) 0.8 (0.5-1.2) 63.3 (61.5-65.0)
Virginia 67.0 (64.4-69.5) 12.6 (10.9-14.6) 1.5 (0.7-3.0) 63.1 (60.4-65.7)
Utah 67.B (65.6-68.9) 4.7 (4.0-5.5) 0.4 (0.2-0.8) 65.9 (64.2-67.6)
Wisconsin 68.2 (65.7-70.5) 8.7 (7.4-10.1) 0.9 (0.5-1.6) 64.4 (61.9-66.8)
North Carolina 68.4 (66.7-70.1) 14.0 (12.8-15.3) 1.0 (0.8-1.3) 64.7 (63.0-66.5)
Quartile 4
New York 69.2 (67.5-70.9) 9.8 (8.8-10.9) 0.7 (0.4-1.1) 66.7 (65.0-68.4)
Michigan 69.2 (67.6-70.8) 11.5 (10.5-12.6 1.2 (0.8-1.6) 65.7 (64.0-67.3)
Minnesota 69.6 (67.6-71.6) 6.4 (5.4-7.4) 1.4 (0.9-2.0) 67.8 (65.8-69.8)
Delaware 70.4 (67.9-72.8) 8.6 (7.3-10.1) 0.5 (0.2-1.0) 68.5 (66.0-71.0)
District o f Columbia 70.5 (67.9-73.0) 16.4 (14.5-18.5) 2.3 (1.6-3.4) 65.4 (62.7-68.0)
W ashington 71.0 (69.9-72.1) 13.9 (13.1-14.7) 2.7 (2.3-3.2) 66.9 (65.8-68.1)
Verm ont 71.4 (69.7-73.0) 8.2 (7.3-9.2) 1.0 (0.7-1.5) 68.7 (66.9-70.3)
Maryland 72.4 (70.6-74.1) 14.7 (13.4-16.2) 1.1 (0.7-1.7) 68.8 (66.9-70.6)
Maine 7B.4 (71.8-74.9) 11.5 (10.5-12.6) 1.1 (0.8-1.6) 70.4 (68.8-72.0)
Rhode Island 74.1 (72.2-76.0) 9.6 (8.4-10.9) 0.6 (0.3-1.1) 71.8 (69.8-73.6)
Connecticut 74.9 (72.9-76.9) 11.5 (10.2-13.0) 1.1 (0.6-1.9) 72.5 (70.5-74.5)
New Hampshire 75.1 (73.2-76.9) 10.2 (9.1-11.5) 1.0 (0.6-1.5) 72.2 (70.3-74.0)
Massachusetts 75.2 (73.7-76.7) 11.9 (10.9-13.0) 0.8 (0.6-1.2) 72.4 (70.8-73.9)
Abbreviations: CRC = colorectal cancer; CI = confidence interval; FOBT = fecal occu lt blood test; GED = general equivalency diplom a.
* Data were weighted to  the age, sex, and racia l/ethnic d is tribu tion  o f each state's adult population using intercensal estimates and were age-standardized to  the 
2010 Behavioral Risk Factor Surveillance System (BRFSS) population.
+ FOBT w ith in  1 year, or sigm oidoscopy w ith in  5 years w ith  FOBT w ith in  3 years, or colonoscopy w ith in  10 years (United States Preventive Services Task Force, 2008).
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patients who would prefer an alternate test option from 
following through with screening (21).
Provider barriers to colorectal cancer screening include lack 
of knowledge of current screening guidelines, forgetfulness, 
competing priorities in the care of the patient (e.g., active 
comorbid diseases), patient refusal, lack oftime, lack ofa reminder 
system, and lack of tracking and follow up systems (15,23). 
Physicians also might overestimate the frequency with which 
they recommend colorectal cancer screening to their patients 
because patients often cite lack of a physician recommendation 
as the reason they did not complete screening (19,23).
Health-care system and organizational barriers, other 
than financial barriers, also exist. Absence of office systems 
that facilitate identification and referral of patients eligible 
for screening, insufficient access to primary care providers, 
insufficient access to or misdistribution of endoscopists, and 
structural barriers (e.g., lack of transportation, lack of translation 
services, or availability ofscreening services only during working 
hours) can impede access to screening even if provider- and 
patient-level barriers have been addressed (24—26).
Evidence-based interventions that address many of these 
barriers exist. The Guide to Community Preventive Services 
(known as the Community Guide) (available at http://www. 
thecommunityguide.org/cancer/index.html) has identified 
client- and provider-oriented interventions that have been 
demonstrated to increase cancer screening rates (26). Client- 
oriented interventions (e.g., client reminders, small media, 
and reducing structural barriers) can address a variety of 
barriers by, for example, augmenting or replacing a physician 
recommendation with a reminder, providing patient education 
about test choices, increasing knowledge about the importance 
of colorectal cancer screening, or providing screening services 
after working hours. Provider-oriented interventions (e.g., 
assessment and feedback or reminder and recall systems) 
can increase knowledge of current screening guidelines, 
inform actual screening rates among patients, and create 
institutionalized systems for screening recommendations.
Other interventions also have demonstrated promise for 
increasing colorectal cancer screening rates. Patient navigation, 
which uses laypersons or health professionals from the 
community to guide patients through the health-care system, 
has been demonstrated to be effective at increasing screening, 
particularly among those of lower socioeconomic status and 
racial/ethnic minorities (27—29). Patient navigators can be used 
to assist in obtaining transportation to appointments, provide 
one-on-one education, assist with understanding and following 
colonoscopy preparation and FOBT kit instructions, provide 
reminder calls, and address patient fears (27—29). Although
patient navigation programs have been gaining in popularity, 
the efficacy and cost-effectiveness of these programs has not 
been well established (30,31). Additional research is needed 
to define more clearly what constitutes an effective patient 
navigation program and to assess its cost effectiveness.
In July 2009, to address known barriers to colorectal cancer 
screening, CDC established the Colorectal Cancer Control 
Program (CRCCP), and currently funds 25 states and four 
tribal organizations with the stated goal of increasing colorectal 
cancer screening prevalence among those aged >50 years to 
80% in funded states and tribal areas by 2014. CRCCP, which 
provides colorectal cancer screening services to low-income 
underinsured and uninsured persons aged 50-64 years, focuses 
primarily on screening promotion to increase population- 
level screening. The screening promotion portion of the 
program encourages grantees to implement evidence-based 
interventions at an organizational, community, and policy 
level, where the impact will reach a larger proportion of the 
target population. Successful implementation of these strategies 
requires partnership and collaboration with nontraditional 
public health partners, including health systems, insurers, 
employers, and professional organizations. For example, a 
grantee might partner with a health system to implement 
client or provider reminders in all of its affiliated primary care 
practices or partner with an employer to implement policies 
that encourage screening. CD C also funds the National 
Comprehensive Cancer Control Program, which helps states, 
tribes, and territories to form coalitions that pool resources 
through partnerships with multiple organizations to reduce 
cancer burden in their communities.
The findings provided in this report are subject to at least 
five limitations. First, colorectal cancer screening rates might 
be overestimated or underestimated because BRFSS does not 
specify whether a test was for screening or diagnosis. Second, 
the survey was conducted only among households with a 
landline telephone, which might result in certain populations 
being underrepresented. Third, responses are self-reported and 
not validated by a review of medical records. Fourth, results 
might differ from other recent reports of colorectal cancer 
screening prevalence using BRFSS data (10,11,32). Questions 
that allow the analysis of screening with colonoscopy or 
sigmoidoscopy separately were instituted in BRFSS in 2008. 
In previous reports, sigmoidoscopy and colonoscopy rates 
were measured and reported as a combined measure (lower 
endoscopy) to allow analysis of trends in colorectal cancer 
screening over time (10,11,32). Finally, response rates were low 
(54.6%), although the BRFSS weighting procedure corrects 
for nonresponse.
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Given the strong association between having health 
insurance and being up-to-date with colorectal cancer 
screening, expanding insurance coverage is an important 
first step to ensuring access to colorectal cancer screening 
services. Other aspects of the Afforable Care Act also might 
contribute to increasing access and the use of preventive care 
services in general, including policies that support expansion 
of the primary care workforce (ACA §5201—5210), increased 
funding to community health centers(ACA §10503), and 
establishment of the Prevention and Public Health Fund 
(ACA §4002). Additional policies support use of electronic 
medical records (ACA §4103) and formation of Accountable 
Care Organizations (ACA §3022), which might lead to better 
patient care coordination and improved quality. Continued 
efforts by public health, through partnerships with a wide 
variety of stakeholders, will be necessary to maximize the 
potential of these initiatives to increase access to and ensure the 
equitable distribution and use of colorectal cancer screening 
services.
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In trod uctio n
In the United States, approximately 1.1 million adults and 
adolescents are living with human immunodeficiency virus 
(HIV) infection and, each year, another 50,000 become 
infected (1). At the end of 2008, approximately 20% of the 
persons living with HIV had an undiagnosed infection (2). O f 
those living with HIV at the end of 2008, nearly two thirds 
were racial/ethnic minorities and half were men who have sex 
with men (MSM) (2). In 2007, HIV ranked fifth as a leading 
cause of death among persons aged 35—44 years in the United 
States but third among blacks or African Americans in this age 
group (3). In 40 states with longstanding confidential name- 
based HIV surveillance systems, 33% of the estimated 41,768 
adults and adolescents diagnosed with HIV infection in 2008 
developed acquired immunodeficiency syndrome (AIDS) 
within 1 year (4) and, of these, 44% received their initial 
diagnosis in an acute care setting, suggesting that they received 
HIV testing late in the course of the infection. HIV-infected 
persons who are unaware of their infection or who receive a late 
diagnosis cannot benefit fully from timely initiation of therapy 
and are more likely to experience HIV-related morbidity and 
premature mortality (5). In addition, persons unaware of their 
infection are more likely to transmit HIV to others because 
of a higher prevalence of high-risk sexual behaviors (6) and 
higher levels of viral RNA that continue to replicate without 
appropriate antiretroviral treatment (7).
This report describes prevalence trends in HIV infection in 
the United States during 1985—2008 among persons aged >13 
years who were aware of their infection (i.e., diagnosed HIV 
infection) and unaware of their infection (i.e., undiagnosed 
HIV infection) and the characteristics of persons living with 
diagnosed and undiagnosed HIV infection in 2008. For 
local and state public health officials and for providers, these 
estimates can serve as the baseline for focusing efforts and 
monitoring progress of interventions designed to increase
HIV testing, expand HIV screening in health-care settings, 
and increase early diagnoses of HIV infection.
M ethods
To examine the prevalence trends of both diagnosed and 
undiagnosed HIV infection during 1985-2008 among persons 
aged >13 years and to describe the characteristics of persons 
aged >13 years estimated to be living with diagnosed and 
undiagnosed HIV infection in 2008, CDC analyzed data from 
the National HIV Surveillance System, a population-based 
surveillance system that collects data on persons who have 
received a diagnosis of HIV infection in the United States. 
HIV infection is notifiable in all 50 states and the District of 
Columbia (DC). CDC uses HIV data from states that have 
had confidential name-based HIV infection reporting for at 
least 4 years to allow sufficient time to elapse for the calculation 
of accurate estimates of reporting delays and the reliable 
determination of trends. Consistent with this requirement, this 
report includes HIV and AIDS data reported through June 
2010 for persons aged >13 years at diagnosis from 40 states 
that had confidential name-based HIV infection reporting as 
of January 2006 and AIDS data from DC and the 10 other 
states (California, Delaware, Hawaii, Maryland, Massachusetts, 
Montana, Oregon, Rhode Island, Vermont, and Washington).
The estim ates for the overall H IV  prevalence and 
undiagnosed HIV prevalence at the end of 2008 were obtained 
in four steps. First, HIV and AIDS data were statistically 
adjusted to mitigate the effects of 1) delays in reporting new 
cases and deaths (4), 2) incomplete reporting of diagnosed 
cases (8), and 3) cases reported without sufficient risk factor 
information to be classified into an HIV transmission category
(4). Second, based on the estimated annual number of HIV 
diagnoses and the severity of disease at diagnosis (i.e., whether 
the person received an AIDS diagnosis in the same calendar
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year as the HIV diagnosis), an extended back-calculation model 
was fitted to estimate the cumulative number of persons aged 
>13 years who had been infected with HIV by the end o f2008 
(8). Third, the estimated overall HIV prevalence was calculated 
by subtracting the estimated cumulative number of deaths that 
had occurred among those infected by the end of 2008 from 
the estimated cumulative number of HIV infections. Finally, 
the undiagnosed HIV prevalence was calculated by subtracting 
the estimated number of diagnosed HIV infections in living 
persons from the estimated overall HIV prevalence.
Rates per 100,000 population were calculated based on 
postcensal estimates from the U.S. Census Bureau. The type 
of facility where persons were initially diagnosed with HIV 
infection in 2008 in the 40 states was examined using univariate 
and multivariate log-binomial regression models. Prevalence 
ratios and 95% confidence intervals (CIs) were calculated to 
identify factors that were associated with receiving a diagnosis 
in an acute care setting; an acute care setting included hospital
inpatient rooms and emergency departments. Factors included 
in the models were age at diagnosis, sex, race/ethnicity, HIV 
transmission category, and timeliness of HIV testing. Persons 
were classified as testing late in the course of HIV infection (i.e., 
late testers) if AIDS was diagnosed within 1 year of the initial 
HIV infection diagnosis. A chi-square test for homogeneity was 
used to determine whether the characteristics of persons whose 
type of facility of diagnosis was known differed significantly 
from those of persons whose type of facility of diagnosis was 
unknown. Statistical significance was set at p<0.05.
Results
In the United States, the estimated number of persons aged 
>13 years living with HIV infection, including those whose 
infection had not been diagnosed, increased from 420,153 in 
1985 to 1,178,250 in 2008 (Figure). HIV prevalence increased
FIGURE. Estimated number of persons aged >13 years living with diagnosed and undiagnosed HIV infection* and percentage with undiagnosed 
HIV infection1 — National HIV Surveillance System, United States, 1985-2008
Y ear
* HIV prevalence estimates were based on national HIV surveillance data for persons aged >13 years at diagnosis reported through June 2010 using extended 
back-calculation.
+ The num ber o f undiagnosed HIV infections was calculated by subtracting the  estimated num ber o f diagnosed HIV infections in liv ing persons from  the estimated 
overall HIV prevalence.
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by an estimated 55.4% between 1996 (758,283), when highly 
active antiretroviral therapy became widely available in the 
United States, and 2008. Although the estimated percentage of 
undiagnosed HIV infections has decreased substantially, from 
87.9% in 1985 to 20.1% in 2008, the percentage persisted at 
approximately 20% from 2004 to 2008.
The majority of the 1,178,250 persons aged >13 years living 
with HIV infection at the end of 2008 were male (75%), 
racial/ethnic minorities (66%), and aged 35-54 years (63%) 
(Table 1). MSM represented 66% of the 883,300 males 
estimated to be living with HIV infection, and black or African 
American females represented 64% of the 294,800 females. 
At the end of 2008, a total of 2,536.1 per 100,000 black or 
African American males and 897.3 per 100,000 Hispanic or 
Latino males were living with HIV infection, compared with 
419.4 per 100,000 white males. Correspondingly, the rate of 
HIV prevalence among black or African American females 
(1,184.9 per 100,000) and Hispanic or Latino females (263.1 
per 100,000) were 18 times and 4 times the rate among white 
females (66.4 per 100,000), respectively. Compared with the 
overall 20.1% undiagnosed HIV infection prevalence, greater 
percentages of undiagnosed HIV infection were observed 
among persons aged <35 years (13—24 years: 58.9%; 25—34 
years: 31.5%), black or African American MSM (25.7%), men 
with high-risk heterosexual contact (24.9%), American Indians 
or Alaska Natives (25.0%), and Asians or Pacific Islanders 
(25.9%). The prevalence rate of undiagnosed HIV infection 
was highest among black or African American males (570.7 
per 100,000), black or African American females (228.8 per
100.000), and Hispanic or Latino males (177.8 per 100,000) 
and lowest among Asian or Pacific Islander females (12.6 per
100.000) and white females (10.9 per 100,000).
The type of facility of initial diagnosis was known for 
32,647 (78.1%) of the estimated 41,768 persons aged >13 
years whose HIV infection was diagnosed in 2008 in the 40 
states (Table 2). The majority (74.3%) of diagnoses occurred 
in a clinical setting, almost one fourth each in an acute care 
setting (24.8%) and at a private doctor’s office or health 
maintenance organization (HMO) (24.3%). The probability 
of initial diagnosis in an acute care setting was significantly 
higher among persons aged >55 years at diagnosis compared 
with persons aged 35—44 years (55—64 years: prevalence ratio 
[PR] =1.22, 95% CI = 1.15—1.29; >65 years: PR = 1.39, 95% 
CI = 1.28—1.51), blacks or African Americans (PR = 1.21, 
95% CI = 1.15—1.26), and Hispanics or Latinos (PR = 1.17, 
95% CI = 1.10—1.23) compared with whites, persons with a 
history of injection drug use compared with MSM (PR = 1.36, 
95% CI = 1.29—1.44), and late testers compared with persons 
who were not late testers (PR = 2.53, 95% CI = 2.43—2.63).
Discussion
HIV diagnosis is essential as the entry point for a lifelong 
continuum of care and treatment that benefits the health, 
quality of life, and life expectancy of the infected person and 
reduces the likelihood of HIV transmission to others (5—7). 
However, in the United States, the engagement of HIV-infected 
persons in this continuum of care for HIV infection needs 
improvement. As indicated by the findings in this report, 
approximately 80% of persons infected with HIV are aware 
of their infection. Furthermore, only approximately 77% of 
HIV-diagnosed persons are linked to care within 3—4 months 
after diagnosis, and only approximately 51% of those with a 
diagnosis of HIV infection are engaged in long-term care (9). 
Among persons in care, approximately 89% are prescribed 
antiretroviral medications and of these, approximately 77% 
achieve plasma viral load suppression (<200 copies/mL) (9). 
Overall, only approximately 28% of HIV-infected persons in 
the United States are aware of their infection, are in care, are 
receiving antiretroviral therapy, and have a suppressed HIV 
viral load (9).
To increase HIV testing and promote early detection of 
HIV infection, in 2006, CDC recommended routine HIV 
screening for all patients aged 13—64 years in health-care 
settings with a prevalence of undiagnosed HIV infection of 
>0.1%, all pregnant women, and patients initiating or seeking 
treatment for tuberculosis or sexually transmitted infections 
(10). The U.S. Preventive Services Task Force (USPSTF) 
also released recommendations in 2005 (rated as strongly 
recommended, or grade A recommendations, by USPSTF) 
for HIV screening of all pregnant women and all adults and 
adolescents at increased risk for HIV infection and those seen 
in health-care settings with >1% prevalence of infection (11). 
CDC further recommended in 2006 that persons at high risk 
for HIV infection should be screened at least annually (10). 
However, among the 7,271 MSM who were surveyed and 
tested for HIV infection by the National HIV Behavioral 
Surveillance System (NHBS) in 21 U.S. cities in 2008 and who 
did not report having received a diagnosis of HIV infection 
in the past, only 61% had been tested during the preceding 
12 months and of these, 7% received their first HIV-positive 
result as part of NHBS (12).
To guide local, state, and national efforts to increase the 
percentages of persons engaged in the continuum  from 
HIV diagnosis to viral load suppression, the 2010 National 
H IV /A ID S Strategy (13) emphasizes prevention and 
intervention service provision at clinics, community centers, 
and nontraditional settings (e.g., mental health centers). 
These services include HIV testing, as well as linkage to and 
retention in long-term quality care that seeks to sustain viral
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TABLE 1. Estimated number and rate of persons aged >13 years living with HIV infection and number, percentage, and rate of persons aged
>13 years with undiagnosed HIV infection, by selected characteristics — National HIV Surveillance System, United States,* 2008
Persons living with HIV infection Persons with undiagnosed HIV infection
No. (9S% CI) Rate+ (9S% CI) No. (9S% CI) % Rate (9S% CI)
Total 1,178,2S0 (1,128,2S0-1,228,400) 469.4 (449.S-489.4) 236,2S0 (224,7S0-247,7S0) 20.1 94.1 (89.S-98.7)
Age group (yrs)
13-24 68,600 (56,000-80,600) 134.1 (109.5-157.6) 40,400 (35,400-45,400) 58.9 79.0 (69.2-88.7)
25-34 180,600 (160,600-200,600) 440.9 (392.1-489.8) 56,800 (51,300-62,300) 31.5 138.7 (125.3-152.1)
35-44 357,500 (327,500-387,500) 846.3 (775.3-917.4) 64,300 (58,300-70,300) 18.0 152.2 (138.0-166.4)
45 -54 385,400 (353,400-417,400) 871.3 (798.9-943.6) 53,200 (48,200-58,200) 13.8 120.3 (109.0-131.6)
55-64 147,700 (132,770-162,770) 439.3 (394.9-484.1) 17,600 (15,600-19,600) 11.9 52.3 (46.4-58.3)
>65 38,400 (34,400-42,400) 99.0 (88.7-109.3) 4,100 (3,600-4,600) 10.7 10.6 (9.3-11.9)
White
MSM 275,400 (247,400-303,400) — — 53,300 (47,800-58,800) 19.4 — —
IDU
Male 27,200 (19,500-34,900) — — 4,150 (2,600-5,700) 15.3 — —
Female 20,400 (14,600-26,200) — — 3,250 (1,900-4,600) 15.9 — —
MSM and IDU 26,600 (19,600-33,600) — — 3,200 (1,750-4,650) 12.0 — —
Heterosexual5
Male 16,350 (10,600-22,100) — — 4,700 (3,050-6,350) 28.7 — —
Female 36,750 (27,700-45,800) — — 6,100 (4,200-80,000) 16.6 — —
O ther1 3,400 (2,500-4,300) — — 500 (150-900) 14.7 — —
Total
Male 348,100 (320,100-376,100) 419.4 (38S.7-4S3.1) 6S,600 (61,000-70,100) 18.8 79.0 (73.S-84.S)
Female S8,000 (47,S00-68,S00) 66.4 (S4.4-78.S) 9,SS0 (7,900-11,100) 16.S 10.9 (9.0-12.7)
Black/African American
MSM 187,400 (164,400-210,400) — — 48,200 (43,000-53,400) 25.7 — —
IDU
Male 74,400 (61,600-87,200) — — 12,200 (9,550-14,850) 16.4 — —
Female 42,700 (34,300-51,100) — — 6,400 (4,500-8,300) 15.0 — —
MSM and IDU 19,300 (13,400-25,200) — — 1,900 (800-3,000) 9.8 — —
Heterosexual
Male 73,300 (61,100-85,500) — — 17,300 (14,100-20,500) 23.6 — —
Female 144,000 (126,100-161,900) — — 29,800 (25,600-34,000) 20.7 — —
Other 3,900 (2,900-4,900) — — 800 (250-1,350) 20.5 — —
Total
Male 3S6,400 (328,400-384,400) 6.3,S2, (2,336.9-2,73S.4) 80,200 (72,100-88,300) 22.S S70.7 (S13.1-628.3)
Female 188,S00 (170,000-207,000) 1,184.9 (1,068.6-1,301.2) 36,400 (31,900-40,900) 19.3 228.8 (200.S-2S7.1)
Hispanic/Latino
MSM 104,800 (87,800-121,800) — — 24,000 (20,300-27,700) 22.9 — —
IDU
Male 28,800 (20,800-36,800) — — 2,200 (1,100-3,300) 7.6 — —
Female 9,900 (5,900-13,900) — — 700 (200-1,200) 7.1 — —
MSM and IDU 8,200 (6,800-9,600) — — 950 (200-1,650) 11.6 — —
Heterosexual
Male 18,700 (12,500-24,900) — — 4,600 (3,000-6,200) 24.6 — —
Female 33,300 (24,700-41,900) — — 6,200 (4,300-8,100) 18.6 — —
Other 1,650 (1,000-2,300) — — 200 (125-400) 12.1 — —
Total
Male 161,S00 (14S,S00-177,S00) 897.3 (808.4-986.2) 32,000 (27,S00-36,S00) 19.8 177.8 (1S2.8-202.8)
Female 43,800 (33,800-S3,800) 263.1 (203.0-323.2) 6,800 (4,800-8,800) 1s.s 40.8 (28.8-S2.9)
American Indian/Alaska Native
MSM 2,200 (1,800-2,600) 500 (200-800) 22.7
IDU
Male 520 (370-700) — — 150 (70-300) 28.8 — —
Female 500 (350-680) — — 100 (50-200) 20.0 — —
MSM and IDU 480 (420-630) — — 60 (30-120) 12.5 — —
Heterosexual
Male 350 (200-500) — — 150 (80-250) 42.9 — —
Female 850 (600-1,100) — — 250 (120-500) 29.4 — —
Other 100 (50-200) — — 40 (20-100) 40.0 — —
Total
Male 3,SS0 (2,400-4,700) 389.8 (263.S-S16.0) 860 (460-1,260) 24.2 94.4 (S0.S-138.3)
Female 1,4S0 (900-2,000) 1S2.7 (94.8-210.7) 390 (140-6S0) 26.9 41.1 (14.7-68.S)
See footnotes on page 61.
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TABLE 1. (Continued) Estimated number and rate of persons aged >13 years living with HIV infection and number, percentage, and rate of 
persons aged >13 years with undiagnosed HIV infection, by selected characteristics — National HIV Surveillance System, United States,* 2008
Persons living with HIV infection Persons with undiagnosed HIV infection
No. (9S% CI) Rate+ (9S% CI) No. (9S% CI) % Rate (9S% CI)
Asian/Pacific Islander
MSM 10,200 (8,000-12,400) — — 2,400 (1,200-3,600) 23.5 — —
IDU
Male 760 (550-1,000) — — 200 (120-350) 26.3 — —
Female 340 (240-500) — — 60 (30-120) 17.6 — —
MSM and IDU 500 (400-700) — — 40 (20—  100) 8.0 — —
Heterosexual
Male 2,100 (1,100-3,100) — — 880 (480-1,280) 41.9 — —
Female 2,550 (2,000-3,000) — — 650 (400-1,100) 25.5 — —
Other 350 (225-500) — — 120 (50-210) 34.3 — —
Total
Male 13,7S0 (11,300-16,1S0) 2S2.2 (207.2-296.2) 3,600 (2,300-4,900) 26.2 66.0 (42.2-89.9)
Female 3,0S0 (2,1S0-4,0S0) S1.3 (36.2-68.1) 7S0 (400-1,100) 24.6 12.6 (6.7-18.S)
Abbreviations: CI = confidence interval; IDU = in jection-drug user; MSM = men w ho have sex w ith  men.
*  Estimates derived using extended back-calculation on HIV and AIDS data for persons aged >13 years at diagnosis from  40 states tha t had confidential name-based
HIV infection reporting as o f January 2006 and AIDS data from  10 states (California, Delaware, Hawaii, Maryland, Massachusetts, Montana, Oregon, Rhode Island,
Verm ont, and W ashington) and the D istrict o f Columbia.
+ Per 100,000 population. Rates for transmission category subgroups were no t calculated because popula tion  denom inators were unavailable.
§ Heterosexual contact w ith  a person known to  have, or to  be at high risk for, HIV infection.
1 Includes hem ophilia, blood transfusion, perinatal exposure, and risk factor no t reported or no t identified.
load suppression through prom otion of adherence after 
timely initiation of antiretroviral therapy and provision 
of coordinated care for therapy-associated complications, 
other coinfections, substance addiction, and mental health 
issues. HIV testing of all pregnant women and treatment 
of HIV-infected pregnant women is essential to prevent 
perinatal transmission. O ther prevention services that 
can be incorporated into health care include H IV  risk 
behavior assessment and risk reduction counseling, condom 
distribution for HIV-infected and -uninfected persons and a 
broad array of partner services. New and emerging preventive 
care in health-care settings includes preexposure prophylaxis 
for at-risk MSM and male circumcision (14—17).
The Patient Protection and Affordable Care Act of 2010 
as amended by the Healthcare and Education Reconciliation 
Act of 2010 (referred to collectively as the Affordable Care Act 
[ACA]), which was signed into law in March 2010, creates an 
opportune environment for implementing the National HIV/ 
AIDS Strategy and makes its goals more achievable. Under the 
new law, persons who are living with or at increased risk for 
HIV infection such as young minority men will be more likely 
to be screened for HIV and to receive life-saving treatment and 
services that strengthen their ability to adhere to treatment 
regimens. The law provides greater health-care access to those 
who are currently uninsured or underinsured by
• expanding Medicaid coverage to persons with incomes 
<133% of the federal poverty level (FPL) (ACA §2001);
• establishing state-based health insurance exchanges (ACA 
§1311) to make private health insurance available to small
employers and to individuals and families not eligible for 
Medicaid or the Children’s Health Insurance Program and 
providing tax credits for those at 100%—400% of FPL; 
and
• increasing funding to community health centers (ACA 
§5601).
The Affordable Care Act provides for no cost sharing for 
high-value clinical preventive services, including HIV testing 
for adolescents and adults at increased risk for HIV infection. 
Medicare now covers adult clinical preventive services graded 
A (strongly recommended) or B (recommended) by USPSTF 
and vaccinations recommended by the Advisory Committee on 
Immunization Practices, with no cost sharing to beneficiaries. 
These services, in addition to recommended preventive services 
for children, youths, and women, will be covered with no cost 
sharing by newly qualified private health plans operating in the 
state-based insurance exchanges beginning in 2014. Beginning 
in 2013, state Medicaid programs that eliminate cost sharing 
for these clinical preventive services may receive enhanced 
federal matching funds for them.
Furtherm ore, the new law dem ands more provider 
accountability for factors within their control and commences 
more improvements in the health outcomes of HIV-infected 
persons through well-timed, better, and safer care. The law 
calls for
• the National Strategy for Quality Improvement in Health 
Care (ACA §3011) to prioritize, guide, and coordinate 
local, state, and national efforts to promote the most 
effective prevention and treatment practices for the leading
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TABLE 2. Type of facility in which initial HIV diagnosis was received among persons aged >13 years who received an HIV diagnosis,* by selected 
characteristics — National HIV Surveillance System, United States,+ 2008
Clinical facilities




Private room or 
physician or em ergency Correctional Other clinical
HMO departm ent STD clin ic facility facility Subtotal
AIDS clin ic or 
counseling  




No. (%) No. (%) No. (%) No. (%)
Prevalence
ratio++ (95% CI)
Total 32,647 7,945 (24.3) 8,103 (24.8) 2,246 (6.9) 2,184 (6.7)
Age group (yrs)
1 3 -2 4 5 ,969 1,042 (17.5) 8 63  (14.5) 744(12.5) 3 30  (5.5)
2 5 -3 4 8,571 2 ,0 1 7  (23.5) 1 ,779  (20.8) 6 99 (8.2) 6 5 7  (7.7)
3 5 -4 4 8 ,734 2 ,330  (26.7) 2,311 (26.5) 4 84 (5.6) 661 (7.6)
4 5 -5 4 6,541 1,776  (27.2) 2,021 (30.9) 2 46 (3.8) 461 (7.0)
5 5 -6 4 2,272 6 13  (27.0) 8 73  (38.4) 65 (2.8) 73 (3.2)
>65 561 167  (29.8) 2 5 7  (45.9) 7 (1.3) 3 (0.6)
Sex
M a le 2 4 ,488 5 ,9 6 6  (24.4) 5 ,8 1 6  (23.8) 1,802 (7.4) 1 ,778  (7.3)
Fem ale 8 ,159 1,979  (24.3) 2 ,2 8 7  (28.0) 4 44 (5.4) 4 0 5  (5.0)
Race/Ethnicity
A m e ric a n  In d ia n / 161 31 (19.3) 4 2  (26.3) 11 (6.9) 4  (2.6)
A laska  N a tive
A sian 347 130 (37.4) 70 (20.0) 21 (6.1) 1 (0.3)
B la c k /A fr ic a n 16,596 3 ,1 9 4  (19.3) 4 ,3 7 7  (26.4) 1,318 (7.9) 1,391 (8.4)
A m e ric a n
H is p a n ic /L a tin o 5 ,760 1,332 (23.1) 1 ,498  (26.0) 4 15 (7.2) 3 55  (6.2)
N a tiv e  H a w a iia n / 30 2 (7.0) 5 (15.6) 2 (5.0) 2 (6.7)
O th e r  P acific  Is la n d e r
W h ite 9 ,325 3,151 (33.8) 1 ,986  (21.3) 4 5 7 (4.9) 4 0 5  (4.3)
M u lt ip le  races 4 2 7 104  (24.4) 126  (29.4) 22 (5.2) 2 4  (5.7)
Transm ission category
M SM 17,769 4 ,8 0 8  (27.1) 3 ,709  (20.9) 1,469 (8.3) 8 1 6  (4.6)
IDU 3 ,278 4 1 2  (12.6) 1 ,248  (38.1) 115 (3.5) 547(16.7)
M S M  a n d  IDU 934 158  (17.0) 2 32  (24.9) 52 (5.6) 137(14.7)
H e te ro se xu a l 10,574 2 ,5 4 7  (24.1) 2 ,872  (27.2) 6 09 (5.8) 6 80  (6.4)
contact§§
O th e r1111 92 2 0  (21.5) 4 2  (46.3) 1 (1.6) 3 (3.7)
Tim eliness of testing
N o t la te  te s te r 22,051 5,671 (25.7) 3 ,445  (15.6) 1,883 (8.5) 1 ,747  (7.9)
L a te  te s te r* * * 10,596 2 ,274  (21.5) 4 ,6 5 8  (44.0) 363 (3.4) 4 3 6  (4.1)
3,785 (11.6) 24,263 (74.3) 5,904 (18.1) 2,480 (7.6) 8,384(25.7) — —
8 80  (14.7) 3 ,8 5 8  (64.6) 1 ,464  (24.5) 6 4 7 (1 0 .8 ) 2 ,1 1 1 (3 5 .4 ) 0.70 (0 .6 4 -0 .7 4 )
1 ,018 (11.9) 6 ,1 7 0  (72.0) 1 ,709  (19.9) 6 92  (8.1) 2,401 (28.0) 0 .87 (0 .8 3 -0 .9 2 )
8 8 4  (10.1) 6 ,670  (76.4) 1 ,464  (16.8) 600  (6.9) 2 ,0 6 4  (23.6) 1.00 —
6 8 6  (10.5) 5 ,1 9 0  (79.4) 9 4 8  (14.5) 4 0 3  (6.2) 1,351 (20.7) 1.10 (1 .0 5 -1 .1 5 )
2 6 7  (11.8) 1 ,890  (83.2) 2 6 9  (11.9) 112 (4.9) 381 (16.8) 1.22 (1 .1 5 -1 .2 9 )
50 (9.0) 4 8 5  (86.5) 4 9  (8.8) 2 7  (4.8) 7 6 (1 3 .5 ) 1.39 (1 .2 8 -1 .5 1 )
2 ,580  (10.5) 17,942  (73.3) 4 ,6 4 4  (19.0) 1,902 (7.8) 6 ,5 4 6  (26.7) 1.00 —
1,205 (14.8) 6,321 (77.5) 1 ,260  (15.4) 5 79 (7.1) 1 ,8 3 8(22 .5 ) 1.05 (1 .0 0 -1 .1 0 )
2 7  (16.5) 116  (71.6) 31 (19.4) 15 (9.0) 4 6  (28.4) 1.17 (0 .9 2 -1 .4 7 )
4 7  (13.5) 2 6 8  (77.3) 5 8  (16.7) 21 (6.0) 79 (22.8) 0 .96 (0 .7 8 -1 .1 8 )
2 ,062  (12.4) 12,343  (74.4) 2 ,8 5 8  (17.2) 1,396 (8.4) 4 ,2 5 3  (25.6) 1.21 (1 .1 5 -1 .2 6 )
6 05  (10.5) 4 ,2 0 6  (73.0) 1 ,232 (21.4) 321 (5.6) 1 ,5 5 4(27 .0 ) 1.17 (1 .1 0 -1 .2 3 )
6  (20.8) 17 (55.0) 13 (41.6) 1 (3.4) 14 (45.0) 0 .79 (0 .3 6 -1 .7 3 )
9 95  (10.7) 6 ,994  (75.0) 1 ,636  (17.5) 695 (7.5) 2,331 (25.0) 1.00 —
4 3  (10.0) 3 1 9  (74.8) 76 (17.8) 31 (7.4) 108  (25.2) 1.23 (1 .0 7 -1 .4 1 )
1,965 (11.1) 12,766  (71.9) 3 ,6 2 8  (20.4) 1,374 (7.7) 5 ,003  (28.2) 1.00 —
3 2 7  (10.0) 2 ,6 4 9  (80.8) 4 3 7  (13.3) 192 (5.9) 6 2 9 (1 9 .2 ) 1.36 (1 .2 9 -1 .4 4 )
93 (9.9) 6 72  (72.0) 175 (18.8) 86 (9.2) 2 62  (28.0) 1.13 (1 .0 1 -1 .2 5 )
1 ,385 (13.1) 8 ,093  (76.5) 1 ,657  (15.7) 824 (7.8) 2 ,482  (23.5) 1.09 (1 .0 4 -1 .1 5 )
15 (16.9) 82  (89.1) 6  (6.5) 3 (3.5) 9 (1 0 .1 ) 1.23 (1 .0 1 -1 .5 0 )
2 ,6 8 7  (12.2) 1 5,4 34  (70.0) 4 ,5 5 6  (20.7) 2,061 (9.4) 6 ,6 1 7 (3 0 .0 ) 1.00 —
1 ,097 (10.4) 8 ,8 2 9  (83.3) 1 ,348  (12.7) 4 19 (4.0) 1 ,7 6 7(16 .7 ) 2.53 (2 .4 3 -2 .6 3 )
Abbreviations: AIDS =  a c q u ire d  im m u n o d e f ic ie n c y  s y n d ro m e ; CI =  c o n fid e n c e  in te rv a l;  IDU =  in je c t io n -d ru g  user; H IV  =  h u m a n  im m u n o d e f ic ie n c y  v iru s ; H M O  =  h e a lth  m a in te n a n c e  
o rg a n iz a tio n ; M S M  =  m e n  w h o  h a ve  se x  w ith  m e n ; STD =  se x u a lly  t ra n s m it te d  d isease.
*  D a ta  in c lu d e  p e rs o n s  w ith  a d ia g n o s is  o f  H IV  in fe c t io n  re g a rd le ss  o f  s ta g e  o f  d ise a se  a t d ia g n o s is . D a ta  h a ve  b e e n  s ta t is t ic a lly  a d ju s te d  fo r  re p o r t in g  d e la ys  a n d  m iss in g  risk  fa c to r
in fo rm a t io n  b u t  n o t  fo r  in c o m p le te  re p o r t in g .
In c lu d e s  d a ta  f ro m  4 0  s ta te s  th a t  h a d  c o n f id e n tia l n a m e -b a s e d  H IV  in fe c t io n  as o f  J a n u a ry  2 0 0 6  (w h ic h  e x c lu d e s  C a lifo rn ia , D e la w a re , H a w a ii, M a ry la n d , M a ssa chu se tts , M o n ta n a , O re g o n , 
R h o d e  Is lan d , V e rm o n t, W a s h in g to n , a n d  t h e  D is tr ic t  o f  C o lu m b ia ).
§ T o ta l e x c lu d e s  9,121 p e rs o n s  w h o s e  ty p e  o f  fa c i l i ty  o f  d ia g n o s is  w a s  u n k n o w n  o r  m iss in g  a n d  17 p e rso n s  w h o s e  m o n th  o f  d ia g n o s is  o f  H IV  in fe c t io n  w a s  u n k n o w n .
In c lu d e s  d ru g  t re a tm e n t  fa c ility ,  fa m ily  p la n n in g  c lin ic , p re n a ta l c lin ic , tu b e rc u lo s is  c lin ic , a n d  o th e r  c lin ic .
* *  In c lu d e s  e m p lo y e r  o r  in s u ra n c e  c o m p a n y  c lin ic , m il i ta ry  in d u c tio n  o r  m il i ta ry  s e rv ice  s ite , im m ig ra t io n  s ite , a n d  o th e r  n o n c lin ic a l s e ttin g .
n  P re va le n ce  ra t io  fo r  b e in g  d ia g n o s e d  in  an  a c u te  ca re  s e tt in g , w h ic h  in c lu d e s  h o s p ita l in p a tie n t  ro o m s  a n d  e m e rg e n c y  d e p a r tm e n ts .
H e te ro s e x u a l c o n ta c t  w ith  a p e rs o n  k n o w n  to  h ave  H IV  in fe c t io n  o r  t o  b e  a t h ig h  risk  fo r  a c q u ir in g  H IV  in fe c t io n .
In c lu d e s  h e m o p h il ia ,  b lo o d  tra n s fu s io n , p e r in a ta l e xp o su re , a n d  ris k  fa c to rs  n o t  re p o r te d  o r  n o t  id e n tif ie d .
* * *  In c lu d e s  p e rso n s  w h o  re c e iv e d  an A IDS d ia g n o s is  w ith in  1 y e a r o f  th e ir  in it ia l H IV  in fe c t io n  d ia g n o s is .
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causes of death in the United States and reduce health 
disparities;
• the development of standards to measure the performance 
o f clinicians, service providers, health plans, and 
population health (ACA §3013);
• the improvement of public reporting initiatives that enable 
consumers to review and compare clinician and service 
provider performance (ACA §3015);
• the establishment of community-based health teams to 
support primary care practices (ACA §3502); and
• the implementation of medication management through 
licensed pharmacists (ACA §3503).
The findings in this report are subject to at least four 
limitations. First, HIV data used in the extended back- 
calculation represent only a portion of persons in the United 
States who received a diagnosis of HIV infection; several 
high-morbidity areas such as California, DC, and Maryland 
contributed AIDS data but not HIV data because confidential 
name-based HIV infection reporting was not implemented 
in these areas until after January 2006. The availability of 
reported HIV data from these areas will increase the accuracy 
of future national prevalence estimates. Second, not all HIV- 
infected persons have received a diagnosis of infection and 
been reported to the public health surveillance systems; data 
must be estimated for persons whose infection is undiagnosed. 
Third, statistical uncertainties were introduced in the estimates 
because data were adjusted for reporting delays, incomplete 
reporting, and missing HIV transmission category information. 
Finally, the type of facility where HIV infection was diagnosed 
initially was unknown for 22% of persons aged >13 years who 
received their diagnosis in 2008 in the 40 states. However, 
except for a higher percentage of late testers among persons 
with unknown facility type (35% vs. 32%, p<0.001), no 
significant difference in demographic characteristics and HIV 
transmission category was found between persons whose type 
of facility of diagnosis was known and persons whose type of 
facility of diagnosis was unknown.
Conclusion
HIV diminishes quality of life and productivity, increases 
the number of preventable deaths, and increases health-care 
expenditures. Based on the estimated incidence of HIV 
infection in 2009 (1) and the adjusted lifetime cost of HIV care 
in the United States to reflect 2010 U.S. dollars (18), CDC 
estimates that the total cost for treating HIV infection in the 
United States is $18.3 billion per year. To reduce the number 
of new HIV infections and thereby the ultimate cost of HIV, 
the National HIV/AIDS Strategy intends to increase 1) the
percentage of persons living with HIV infection who know 
their serostatus to 90%; 2) the percentage of persons with a 
new HIV diagnosis who are linked into clinical care within 3 
months of their diagnosis to 85%; 3) the percentage of Ryan 
White HIV/AIDS program (19) clients who are in continuous 
care to 80%; and 4) the percentage of HIV-diagnosed MSM, 
blacks or African Americans, and Hispanics or Latinos with 
undetectable viral load by 20% by 2015. These targets will 
not be met without the expansion of HIV prevention and 
intervention service delivery in health care. Only by combining 
expertise and efforts can public health professionals and 
health-care providers ensure greater public awareness of HIV 
infection and risk reduction, eliminate HIV-related stigma and 
discrimination, expand opportunities for HIV testing, increase 
the frequency of testing in high-risk populations, and establish 
a seamless prevention, intervention, care, and treatment 
infrastructure through which every HIV-infected person is 
able to receive the right care and support at the right time.
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In troduction
In the United States, annual influenza epidemics typically 
occur during the late fall through early spring. During these 
epidemics, rates of serious illness and death are highest among 
adults aged >65 years, children aged <2 years, and persons of 
any age who have medical conditions that increase their risk for 
complications from influenza (1-4). Adults aged 50-64 years 
who have underlying medical conditions have a substantially 
increased risk for hospitalization during the influenza season
(5). Influenza illness among healthy adults aged 18-64 years 
typically is not as severe as the illness among adults aged >65 
years, pregnant women, or persons with chronic medical 
conditions and less frequently results in hospitalization. 
However, influenza among healthy adults aged 18-49 years 
is an important cause of outpatient medical visits and worker 
absenteeism. An economic analysis estimated an annual average 
of approximately 5 million illnesses, 2.4 million outpatient 
visits, 32,000 hospitalizations, and 680 deaths from influenza 
among adults aged 18-49 years who did not have a medical 
condition that increased their risk for influenza complications
(6). In this analysis, adults aged 18-49 years accounted for 10% 
of the total economic cost from influenza, or approximately 
$8.7 billion (6).
The most effective strategy for preventing influenza is annual 
influenza vaccination. Routine influenza vaccination has been 
recommended since the 2010-11 influenza season for all 
persons aged >6 months (4). Before this recommendation, the 
only group that was not recommended for routine vaccination 
was healthy nonpregnant adults aged 18-49 years who did 
not have an occupational risk for influenza exposure and who 
were not close contacts of persons at higher risk for influenza- 
related complications. According to the Patient Protection and 
Affordable Care Act of 2010 as amended by the Healthcare and 
Education Reconciliation Act of 2010 (referred to collectively 
as the Affordable Care Act [ACA]), as of January 1, 2014, all
newly qualified health plans operating in the exchanges* must 
provide coverage without cost sharing for all persons, including 
those aged 18—64 years, for vaccinations recommended by 
the Advisory Committee on Immunization Practices (ACIP)
(7). Influenza vaccination for adults aged >65 years has been 
a covered benefit for many years under Medicare (4). Adults 
aged >65 years have had higher influenza vaccination coverage 
(>62%) than persons in all other age groups (4). This report 
examines factors associated with influenza vaccination during 
the 2008—09 influenza season and suggests ways that the 
provisions of the Affordable Care Act might improve access 
to vaccination and influenza vaccination coverage. The 
information in this report is intended for all persons involved 
in annual influenza vaccination, as well as those for whom 
annual influenza vaccination is recommended. The results 
can serve as a baseline to monitor the progress and impact of 
clinical preventive services.
M ethods
To estimate seasonal influenza vaccination coverage among 
adults aged 18—64 years during the 2008—09 influenza season, 
CDC analyzed data from the 2009 National Health Interview 
Survey (NHIS). NHIS collects information about the health 
and health care of the noninstitutionalized, civilian population 
in the United States and is designed to produce nationally 
representative samples. The NHIS questionnaire includes a 
set of basic health and demographic questions and questions 
on access to health care and use. Interviews are conducted 
in respondents’ homes continuously throughout the year by 
interviewers of the U.S. Census Bureau for CDC.
* Beginning in 2014, a competitive insurance marketplace will be set up in the 
form of state-based insurance exchanges. These exchanges will allow eligible 
persons and small businesses with up to 100 employees to purchase health 
insurance plans that meet criteria outlined in the Affordable Care Act (ACA 
§1311). I f  a state does not create an exchange, the federal government will run 
one in that state.
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To ascertain coverage estimates, participants were asked the 
following questions: 1) “During the past 12 months, have you 
had a flu shot?” and 2) “During what year and month did 
you receive your flu vaccine?” To ascertain coverage among 
persons with higher risk for complications from influenza, 
respondents were asked whether they had ever been told by a 
physician or other health professional that they have diabetes, 
emphysema, cancer or a malignancy of any kind (excluding 
nonmelanoma skin cancer), lymphoma, leukemia, or blood 
cancer or had coronary heart disease, angina, a heart attack, or 
another heart condition. Respondents also were asked whether, 
in the past 12 months, they had experienced an asthma episode 
or attack or had been told by a physician they have chronic 
bronchitis or weak or failing kidneys. Covariates were selected 
to measure associations among influenza vaccination and 
selected demographic and health-care access characteristics: 
age group, sex, race and ethnicity, marital status, educational 
level, employment status, poverty level, health insurance status, 
primary provider status, physician contacts in the previous year, 
hospitalization within the past year, having certain high-risk 
conditions, and current employment as health-care personnel.
Poverty status was defined using 2009 poverty thresholds 
published by the U.S. Census Bureau; below poverty was 
defined as a total family income of <$21,756 for a family of 
four (available at http://www.census.gov/hhes/www/poverty/ 
data/threshld/thresh09.html). Respondents were classified as 
health-care personnel if they were currently employed in a 
health-care occupation or in a health-care industry setting, 
based on standard occupation and industry categories recoded 
into categories by CDC. Respondents were classified as 
having a regular physician if they answered affirmatively to 
the question, “Is there a place that you usually go to when 
you are sick or need advice about your health?” Although 
female respondents were asked whether they were pregnant at 
the time of the interview, estimates of influenza vaccination 
among pregnant women are not presented because they might 
be misleading. Women who became pregnant at other times 
during the influenza vaccination period would not be counted 
in the analysis, and information on the stage of pregnancy or 
estimated date of delivery was not available.
Kaplan-Meier survival analysis was used to determine the 
cumulative influenza vaccination coverage during August
2008-May 2009 using monthly interview data collected during 
September 2008-June 2009. Data weighting procedures are 
described in more detail elsewhere (8). Point estimates and 
estimates of corresponding variances for this analysis were 
calculated using statistical software to account for the complex 
sampling design of NHIS. Chi-square tests were used to 
examine significance between age groups, and t-tests were used
to determine significance within strata with multiple levels. 
Statistical significance was defined as p<0.05.
Results
A total of 11,963 adults aged 18—64 years were included in 
the analysis. An estimated 70.1% were aged 18—49 years, and 
29.9% were aged 50—64 years (Table 1). Most respondents 
(72.1%) indicated that they were employed; 13.4% of 
respondents had incomes below the poverty level. Most 
respondents (67.2%) had private insurance; however, 20.3% 
of respondents aged 18—64 years reported having no insurance, 
including 23.6% of those aged 18—49 years. A total of 81.4% 
of respondents reported having a regular physician, and 79.2% 
had at least one or more physician contacts within the past 
year. Among adults aged 18—64 years, 20.2% reported having 
a high-risk condition. Health-care personnel comprised 8.8% 
of respondents.
Influenza vaccination coverage overall during the 2008—09 
influenza season for adults aged 18—64 years was 28.2% 
(Table 2). Coverage was significantly higher among adults 
aged 50—64 years than among those aged 18—49 years, both 
overall and by most demographic and health-care access 
characteristics examined. Influenza vaccination coverage for 
Hispanic adults aged 18—49 and 50—64 years was significantly 
lower than coverage among non-Hispanic whites in those age 
groups. Influenza vaccination coverage among non-Hispanic 
blacks and non-Hispanic whites aged 18—49 and 50—64 years 
was similar. Respondents aged 18—49 years and 50—64 years 
who were at or above the poverty level had higher influenza 
vaccination coverage (23.6% and 42.8% , respectively) 
than those who were below poverty (16.7% and 34.9%, 
respectively). In both age groups (18—49 and 50—64 years), 
influenza vaccination coverage was higher among adults 
with high-risk conditions (31.9% and 51.2%, respectively) 
compared with those without identified high-risk conditions 
(20.8% and 37.2%, respectively). Respondents with diabetes 
had higher influenza vaccination levels (49.0%) than those with 
heart disease (42.5%) or asthma (38.7%). Overall, influenza 
vaccination coverage among adults with high-risk conditions 
was 41.4%. Respondents who were health-care personnel had 
significantly higher influenza vaccination coverage (53.0%) 
than those who were not health-care personnel (25.8%). 
Women aged 18—49 years and 50—64 years had statistically 
higher influenza vaccination coverage than men in the same age 
groups (26.7% vs. 18.0% and 44.2% vs. 39.3%, respectively).
Influenza vaccination coverage was substantially higher 
among younger (18—49 years) and older (50—64 years) 
adults who had health insurance (whether private or public)
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TABLE 1. Demographic characteristics, health insurance status, and selected health conditions among adults aged 18-64 years, by age group* 




No. (%) No. (%) No. (%)
Total 11,963 (100) 8,312 (70.1) 3,651 (29.9)
Sex
Male 5,335 (49.0) 3,686 (49.4) 1,649 (48.2)
Female 6,628 (51.0) 4,626 (50.6) 2,002 (51.8)
Race/Ethnicity
White, non-Hispanic 6,908 (67.2) 4,434 (63.9) 2,474 (74.9)+
Black, non-Hispanic 1,917 (12.3) 1,349 (12.9) 568 (10.8)
Hispanic 2,305 (14.9) 1,882 (17.1) 423 (9.7)
Other 833 (5.7) 647 (6.1) 186 (4.6)
Marital status
Married 5,510 (54.6) 3,614 (49.8) 1,896 (65.7)+
Widowed, divorced, or separated 2,337 (13.1) 1,147 (9.2) 1,190 (22.1)
Never married 4,087 (32.3) 3,529 (40.9) 558 (12.2)
Education
<High school diploma 1,767 (13.3) 1,243 (13.6) 524 (12.4)+
High school diploma 3,009 (26.0) 1,978 (24.5) 1,031 (29.3)
Some college, college graduate, or higher 7,135 (60.8) 5,058 (61.8) 2,077 (58.3)
Employment status
Employed 8,479 (72.1) 6,145 (75.0) 2,334 (65.6)+
Not employed 3,481 (27.9) 2,165 (25.0) 1,316 (34.4)
Poverty status§
At or above poverty level 8,948 (86.6) 6,131 (85.0) 2,817 (90.5)+
Below poverty level 1,877 (13.4) 1,464 (15.0) 413 (9.5)
Health insurance
Private 7,618 (67.2) 5,081 (64.7) 2,537 (73.1)+
Public 1,724 (12.5) 1,120 (11.7) 604 (14.3)
None 2,587 (20.3) 2,083 (23.6) 504 (12.7)
Regular physician
Yes 9,607 (81.4) 6,349 (77.5) 3,258 (90.5)+
No 2,275 (18.6) 1,915 (22.5) 360 (9.5)
Physician contacts within past year
None 2,492 (20.9) 2,006 (24.2) 486 (13.0)+
1 2,056 (17.5) 1,522 (18.7) 534 (14.5)
2-3 3,103 (27.0) 2,132 (26.1) 971 (29.0)
4-9 2,582 (21.9) 1,591 (19.4) 991 (27.6)
>10 1,578 (12.8) 964 (11.5) 614 (15.8)
Hospitalized within past year
Yes 1,026 (7.9) 656 (7.4) 370 (9.3)+
No 10,933 (92.1) 7,654 (92.6) 3,279 (90.7)
High-risk conditions^
Yes 2,444 (20.2) 1,227 (14.8) 1217 (32.8)+
No 9,502 (79.8) 7,075 (85.2) 2,427 (67.2)
Asthma
Yes 525 (4.2) 345 (4.2) 180 (4.2)
No 11,433 (95.8) 7,964 (95.8) 3,469 (95.8)
Diabetes
Yes 822 (7.1) 298 (3.8) 524 (14.7)+
No 11,133 (92.9) 8,008 (96.2) 3,125 (85.3)
Heart disease
Yes 996 (8.1) 418 (5.0) 578 (15.5)+
No 10,960 (91.9) 7,892 (95.0) 3,068 (84.5)
Health-care personnel
Yes 1,134 (8.8) 813 (9.2) 321 (7.8)+
No 10,826 (91.2) 7,497 (90.8) 3,329 (92.2)
* Respondents who answered "don't know" or refused to answer were excluded from the analysis.
+ Significant difference between adults aged 18-49 years and adults aged 50-64 years (p<0.05, by chi-square test).
§ Poverty status was defined using 2009 poverty thresholds published by the U.S. Census Bureau; below poverty was defined as a total family income of <$21,756 for a family of four 
(available at http://www.census.gov/hhes/www/poverty/data/threshld/thresh09.html).
^ Respondents were asked whether they had ever been told by a physician or other health professional that they have diabetes, emphysema, cancer or a malignancy o f any kind 
(excluding nonmelanoma skin cancer), lymphoma, leukemia, or blood cancer or had coronary heart disease, angina, a heart attack, or another heart condition. Respondents also 
were asked whether, in the past 12 months, they had experienced an asthma episode or attack or had been told by a physician they have chronic bronchitis or weak or failing 
kidneys.
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TABLE 2. Percentage of adults aged 18-64 years who received an influenza vaccination, by demographic characteristics, health insurance status, 
selected health conditions, and age group* — National Health Interview Survey, United States, 2008-09 influenza season
Age group (yrs)
18-64 18-49 50 -64
Characteristic % (95% CI) % (95%  CI) % (95% CI)
Total 28.2 (26.9-29.4) 22.4 (21.1-23.8) 41 .91 (39.5-44.3)1
Sex
(3 5 .6 -4 3 .0 )*M a le 5 24.2 (2 2 .5 -2 5 .9 ) 18.0 (1 6 .2 -1 9 .8 ) 3 9 .3 +
Fem ale 3 2 .0 ' (3 0 .2 -3 3 .7 )' 2 6 .7 ' (2 4 .7 -2 8 .7 )' 4 4 .2 * ' (4 0 .9 -4 7 .4 )*,'
Race/Ethnicity
(4 0 .5 -4 6 .1 )*W h ite , n o n -H is p a n ic 5 30.2 (2 8 .6 -3 1 .7 ) 23.7 (2 1 .9 -2 5 .6 ) 43.3*
B lack, n o n -H is p a n ic 2 6 .1 ' (2 3 .3 -2 9 .0 )' 21.1 (1 8 .2 -2 3 .9 ) 4 0 .3 + (3 3 .8 -4 6 .9 )*
H isp a n ic 2 0 .8 ' (1 8 .0 -2 3 .5 )' 1 7 .4 ' (1 4 .9 -2 0 .0 )' 3 5 .0 * ' (2 7 .2 -4 2 .7 )* '
O th e r 28.7 (2 4 .2 -3 3 .2 ) 25.5 (2 0 .6 -3 0 .4 ) 39.2* (2 7 .8 -5 0 .5 )*
Marital status
(3 9 .4 -4 5 .7 )*M a rr ie d 5 31.9 (3 0 .1 -3 3 .7 ) 26.0 (2 3 .9 -2 8 .1 ) 42.6*
W id o w e d , d iv o rc e d , o r  s e p a ra te d 29.8 (2 7 .2 -3 2 .5 ) 1 9 .7 ' (1 6 .5 -2 3 .0 )' 40.0* (3 6 .0 -4 4 .1 )*
N e ve r m a rr ie d 2 1 .2 ' (1 9 .2 -2 3 .3 )' 1 8 .6 ' (1 6 .5 -2 0 .8 ) ' 41.5* (3 5 .5 -4 7 .4 )*
Education
< H ig h  s c h o o l5 21.7 (1 8 .8 -2 4 .5 ) 16.7 (1 3 .3 -2 0 .0 ) 35.3* (2 9 .0 -4 1 .7 )*
H ig h  s c h o o l g ra d u a te 24.1 (2 1 .7 -2 6 .4 ) 16.8 (1 4 .1 -1 9 .5 ) 3 8 .1 * (3 3 .9 -4 2 .4 )*
S o m e  c o lle g e , c o lle g e  g ra d u a te , o r  h ig h e r 3 1 .3 ' (2 9 .7 -3 2 .8 )' 2 5 .8 ' (2 4 .1 -2 7 .5 )' 4 5 .2 *,' (4 2 .0 -4 8 .5 )*,'
Em ploym ent status
2 3.3 ' (2 1 .7 -2 4 .9 )' (3 7 .6 -4 3 .7 )*E m p lo y e d 5 28.0 (2 6 .6 -2 9 .5 ) 4 0 .7 *
N o t e m p lo y e d 28.5 (2 6 .2 -3 0 .8 ) 19.8 (1 7 .2 -2 2 .5 ) 4 4 .1 * (4 0 .5 -4 7 .6 )*
Poverty level
2 9.4 ' (2 8 .0 -3 0 .9 )' 2 3 .6 ' (2 1 .9 -2 5 .2 )' 4 2 .8 *,' (4 0 .0 -4 5 .6 )*,'A t o r  a b o v e  p o v e r ty
B e lo w  p o v e r ty 5 * * 20.2 (1 7 .6 -2 2 .8 ) 16.7 (1 3 .9 -1 9 .5 ) 3 4 .9 * (2 8 .5 -4 1 .3 )*
Health insurance
(4 1 .6 -4 7 .2 )*P riva te 5 32.7 (3 1 .1 -3 4 .2 ) 27.0 (2 5 .1 -2 8 .8 ) 4 4 .4 *
P ub lic 32.0 (2 8 .4 -3 5 .5 ) 2 2 .7 ' (1 9 .1 -2 6 .2 ) ' 5 0 .9 * (4 4 .6 -5 7 .2 )*
N o n e 12.1 ' (9 .9 -1 4 .2 )' 1 0 .5 ' (8 .2 -1 2 .8 )' 1 8 .9 * ' (1 4 .2 -2 3 .7 )*,'
Regular physician
4 4 .8 * (4 2 .2 -4 7 .5 )*Yes5 31.9 (3 0 .5 -3 3 .3 ) 25.5 (2 3 .9 -2 7 .1 )
N o 12.6 ' (1 0 .3 -1 4 .9 )' 12.1 ' (9 .5 -1 4 .7 )' 14.8 ' (9 .8 -1 9 .8 ) '
Physician contacts within past year
N o n e 5 11.6 (9 .6 -1 3 .6 ) 11.0 1 (8 .9 -1 3 .2 ) 14.4 (9 .8 -1 8 .9 )
1 2 2 .4 ' (1 9 .7 -2 5 .1 )' 2 0 .3 ' (1 7 .3 -2 3 .2 ) ' 2 9 .0 *,' (2 3 .5 -3 4 .5 )*,'
2 -3 3 0 .6 ' (2 8 .0 -3 3 .1 )' 2 4 .9 ' (2 1 .9 -2 7 .9 )' 4 2 .6 *,' (3 8 .0 -4 7 .1 )*,'
4 - 9 3 7 .3 ' (3 4 .5 -4 0 .2 )' 2 8 .5 ' (2 5 .2 -3 1 .9 )' 5 2 .3 *,' (4 7 .8 -5 6 .9 )*,'
>10 4 3 .3 ' (3 9 .4 -4 7 .2 )' 3 4 .8 ' (3 0 .3 -3 9 .3 )' 5 7 .7 *,' (5 1 .6 -6 3 .8 )* '
Hospitalization within past year
5 9 .6 * (5 1 .8 -6 7 .5 )*Yes5 4 1.6 (3 7 .1 -4 6 .0 ) 32.0 (2 6 .5 -3 7 .4 )
N o 2 7.0 ' (2 5 .7 -2 8 .2 )' 2 1 .7 ' (2 0 .3 -2 3 .1 )' 3 9 .9 *,' (3 7 .4 -4 2 .4 )* '
High-risk conditions1"1'
5 1 .2 * (4 7 .2 -5 5 .1 )*Yes5 4 1.4 (3 8 .6 -4 4 .3 ) 31.9 (2 7 .8 -3 6 .0 )
N o 2 4.8 ' (2 3 .5 -2 6 .1 )' 2 0 .8 ' (1 9 .3 -2 2 .2 )' 3 7 .2 *,' (3 4 .3 -4 0 .1 )*,'
Asthm a
5 2 .3 * (4 2 .3 -6 2 .2 )*Yes5 38.7 (3 2 .6 -4 4 .8 ) 32.3 (2 4 .5 -4 0 .1 )
N o 2 7.7 ' (2 6 .5 -2 9 .0 )' 2 2 .0 ' (2 0 .6 -2 3 .4 )' 4 1 .4 * ' (3 9 .0 -4 3 .9 )*,'
Diabetes
5 2 .2 * (4 4 .8 -5 9 .6 )*
5
sYes 4 9 .0 (4 2 .9 -5 5 .2 ) 44.2 (3 4 .6 -5 3 .9 )
N o 26.6 ' (2 5 .3 -2 7 .9 )' 2 1 .6 ' (2 0 .2 -2 3 .0 )' 4 0 .2 *,' (3 7 .6 -4 2 .7 )* '
Heart disease
5 0 .3 * (4 4 .0 -5 6 .6 )*Yes5 42.5 (3 7 .8 -4 7 .2 ) 32.1 (2 5 .0 -3 9 .2 )
N o 26.9 ' (2 5 .6 -2 8 .1 )' 2 1 .9 ' (2 0 .5 -2 3 .3 )' 4 0 .3 *,' (3 7 .7 -4 2 .9 )* '
Health-care personnel
Yes5 53.0 (4 8 .8 -5 7 .1 ) 51.5 (4 6 .1 -5 6 .9 ) 56.8 (4 9 .4 -6 4 .3 )
N o 2 5 .8 ' (2 4 .6 -2 7 .1 )' 1 9 .5 ' (1 8 .2 -2 0 .9 ) ' 4 0 .6 * ' (3 8 .0 -4 3 .2 )*,'
Abbreviation: CI =  c o n fid e n c e  in te rv a l.
*  R e s p o n d e n ts  w h o  a n s w e re d  " d o n 't  k n o w "  o r  re fu s e d  t o  a n s w e r w e re  e x c lu d e d  f ro m  th e  analysis.
p < 0 .0 5  b y  t - te s t  fo r  c o m p a ris o n s  o f  v a c c in a tio n  c o v e ra g e  b e tw e e n  p e rs o n s  a g e d  1 8 -4 9  ye ars  a n d  p e rs o n s  a g e d  5 0 -6 4  years.
§ R e fe re n t g ro u p .
p < 0 .0 5  b y  t - te s t  fo r  c o m p a ris o n s  w ith in  each  v a r ia b le  w ith  th e  in d ic a te d  re fe re n c e  leve l.
* *  P o v e rty  s ta tu s  w a s  d e f in e d  u s in g  2 0 0 9  p o v e r ty  th re s h o ld s  p u b lis h e d  b y  th e  U.S. C ensus B ureau; b e lo w  p o v e r ty  w a s  d e fin e d  as a to ta l  fa m ily  in c o m e  o f  < $ 2 1 ,7 5 6  fo r  a fa m ily  o f  fo u r  (a va ila b le  
a t h t tp : / /w w w .c e n s u s .g o v /h h e s /w w w /p o v e r ty /d a ta /th re s h ld / th re s h 0 9 .h tm l).
R e s p o n d e n ts  w e re  a sked  w h e th e r  th e y  h a d  e v e r b e e n  to ld  b y  a p h y s ic ia n  o r  o th e r  h e a lth  p ro fe s s io n a l t h a t  th e y  h ave  d ia b e te s , e m p h y s e m a , c a n c e r o r  a m a lig n a n c y  o f  a n y  k in d  (e x c lu d in g  
n o n m e la n o m a  sk in  ca nce r), ly m p h o m a , le u k e m ia , o r  b lo o d  c a n c e r o r  h a d  c o ro n a ry  h e a r t d isease, a n g in a , a h e a r t a tta c k , o r  a n o th e r  h e a r t c o n d it io n .  R e s p o n d e n ts  a lso  w e re  a sked  w h e th e r , 
in  th e  p a s t 12 m o n th s , th e y  h a d  e x p e rie n c e d  an a s th m a  e p is o d e  o r  a tta c k  o r  h a d  b e e n  to ld  b y  a p h y s ic ia n  th e y  h ave  c h ro n ic  b ro n c h it is  o r  w e a k  o r  fa il in g  k id n e ys .
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than adults who did not have insurance (Table 2). However, 
influenza vaccination coverage was higher among adults aged 
18—49 years who had private insurance than among those aged 
18—49 years who had public insurance. Those who had some 
type of health insurance were more likely to have a regular 
physician and to have had two or more provider contacts within 
the past year than those who did not have insurance (Table 3). 
Coverage was twofold to threefold higher among those who had 
a regular physician compared with those who did not (Tables 2 
and 3). In addition, influenza vaccination coverage was higher 
among persons who had any physician contacts within the 
past year compared with those who had none, with coverage 
increasing with increasing number of physician contacts (Tables 
2 and 3). However, most respondents (56.7%—77.6%) with 
one or more provider contacts were not vaccinated (Table 2).
Discussion
The most effective strategy for preventing influenza is 
annual influenza vaccination (4). The Healthy People 2020 
immunization and infectious diseases objective 12 (objective 
IID-12) is to increase the percentage of children and adults
who are vaccinated annually against seasonal influenza (9). 
The Healthy People 2020 objectives for influenza vaccination 
range from 80% to 90% for population groups including 
noninstitutionalized healthy adults aged 18—64 years and 
adults with high-risk conditions aged 18—64 years, health-care 
personnel, and pregnant women. The findings reported here 
indicate that influenza vaccination coverage is well below the 
Healthy People 2020 objectives (9). Substantial improvement 
in influenza vaccination coverage is needed to achieve Healthy 
People 2020 targets.
Although the influenza vaccination level of 41.4% for 
noninstitutionalized adults aged 18—64 years with high-risk 
conditions was higher than that for adults without high-risk 
conditions (24.8%), the percentage is well below the Healthy 
People 2020  target of 90%. Vaccination of healthy adults 
aged <65 years can decrease work absenteeism and use of 
health-care resources, including use of antibiotics, when the 
vaccine and circulating viruses are well matched (10—12). 
Vaccine effectiveness among adults aged <65 years with 
high-risk conditions is typically lower than that reported for 
healthy adults; however, substantial data exist regarding the 
benefits of influenza vaccination in persons with high-risk
TABLE 3. Percentage of adults aged 18-64 years with and without health insurance, by usual health-care provider, physician contacts, and 
receipt of influenza vaccination* — National Health Interview Survey, United States, 2008-09 influenza season
Total Received influenza vaccination+
Characteristic No. % (95% CI) % (95% CI)
With health insurance5
Regular physician 
Yes5 8,334 89.9 (89.0-90.8) 34.1 (32.6-35.6)
No 944 10.1' (9.2-11.0)' 18.7' (14.7-22.6)'
Physician contacts w ith in  past year 
None5 1,308 14.4 (13.5-15.4) 16.3 (13.3-19.3)
1 1,569 17.2' (16.2-18.3)' 24.8' (21.6-27.9)'
2-3 2,678 29.6' (28.4-30.8)' 32.8' (30.1-35.5)'
4 -9 2,276 24.5' (23.4-25.6)' 40.0' (37.0-43.0)'
>10 1,392 14.3 (13.5-15.2) 45.7' (41.6-49.9)'
Without health insurance
Regular physician
Yes5 1,252 48.6** (46.0-51.2)** 16.2** (13.1-19.3)**
No 1,318 51.4** (48.8-54.0)** 8.4' , ** (5.5-11.3)',**
Physician contacts w ith in  past year 
None5 1,175 46.0** (43.4-48.7)** 6.3** (3.8-8.7)**
1 480 18.3' (16.4-20.3)' 13.6',** (8.9-18.2)' , **
2-3 418 16.9',** (15.0-19.1)' , ** 16.6',** (9.3-23.9)' , **
4 -9 299 11.8',** (10.3-13.5)' , ** 17.8',** (12.0-23.5)' , **
>10 185 6.9' , ** (5.8-8.1)' , ** 25.5' , ** (15.9-35.0)' , **
Abbreviation: CI = confidence interval.
* Respondents w ho answered "don't know ” or refused to  answer were excluded from  the analysis.
+ Estimates based on the  responses o f participants in the respective categories who answered "yes” to  the question, "During the past 12 months, have you had a flu 
shot?” The sample sizes for the influenza vaccination estimates are not shown and m igh t be different from  the sample sizes for respondents w ith  or w ith o u t insurance, 
regular physicians, or physician visits shown in this tab le because persons w ho refused or did no t know the ir vaccination status were excluded from the analysis.
§ Referent group.
1 p<0.05 by t-test for com parisons w ith in  each set o f covariates w ith  the  referent group.
**  p<0.05 by t-test for com parison w ith  the  same variable w ith in  the  category o f respondents w ith  health insurance.
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conditions (4,13). The higher influenza vaccination coverage 
among persons with diabetes might reflect interventions to 
improve vaccination in this population, including support by 
professional organizations incorporating influenza vaccination 
recommendations into clinical care guidelines (4,13,14).
The findings in this report are consistent with previous 
reports indicating that persons who have insurance coverage, 
a usual place for health care or medical home, and who seek 
medical care one or more times during the year are more likely 
to be vaccinated against influenza and receive other preventive 
services, compared with those who are uninsured and do not 
have a usual place for health care (15—19). As indicated in this 
report and NHIS data for the 2005—06 influenza season (15), 
the likelihood of receiving an influenza vaccination increased 
with increasing numbers of health-care visits. However, many 
opportunities for vaccination likely are being missed; even 
among persons with health insurance and >10 physician 
contacts within the past year, approximately 57% were not 
vaccinated. Persons without insurance were less likely to receive 
influenza vaccination than their counterparts who had either 
private or public insurance. Uninsured persons who obtain 
insurance might not be able to rapidly catch up with their 
already-insured peers in regard to use of preventive services. 
Although insurance provides access to care, a relatively long 
period might elapse before appropriate prevention services are 
received (18). However, receipt of preventive services, including 
influenza vaccination, can increase substantially among adults 
who have insurance and a usual place for health care (19).
The lower seasonal influenza vaccination coverage for 
Hispanics and blacks compared with whites has been observed 
in previous influenza seasons among adults (20-22). Numerous 
factors play a role in these racial/ethnic disparities, including 
differences in attitudes toward vaccination and preventive 
care, propensity to seek and accept vaccination, variations 
in likelihood that providers recommend vaccination, and 
differences in quality o f care received by racial/ethnic 
populations (4,23-32). Broad use of interventions to remove 
barriers to access to care and to make vaccination services in 
health-care and other settings a routine practice are important 
components of efforts to reduce these disparities (33,34).
Pregnant women have an increased risk for complications 
from influenza (35-42) and are a priority group for vaccination
(4). Estimates for women who might have been pregnant during 
the 2008-09 influenza season are not included in this report 
because the estimates might be misleading. Pregnant women 
identified by NHIS were those who were pregnant at the time 
of the survey, and information on the stage of pregnancy or 
estimated date of delivery was not available. Some women 
who were pregnant during the vaccination period might have 
been missed, and some who were not pregnant during the
vaccination period might have been included. A more accurate 
estimate of the influenza vaccination status among pregnant 
women can be derived by ascertaining pregnancy status during 
the influenza vaccination period. Starting with the 2012 NHIS, 
this survey will collect information on influenza vaccination 
before, during, or after a recent or current pregnancy to 
ascertain whether a woman was pregnant during the influenza 
vaccination period. Other data sources that more specifically 
ascertain which women were pregnant during the influenza 
vaccination period are available (43-45).
ACIP recommends that all health-care personnel be 
vaccinated for influenza and certain other vaccine-preventable 
diseases to safeguard the health of personnel and protect 
patients from influenza virus infection through exposure 
to workers with influenza (4,46). Persons who should be 
vaccinated include all persons working in health-care settings, 
who have the potential for exposure to patients or residents or to 
infectious materials, including body substances, contaminated 
medical supplies and equipment, environmental surfaces, 
or contaminated air. Despite annual influenza vaccination 
being recommended by ACIP and being one of the standards 
for adult immunization practice (47), influenza vaccination 
coverage among health-care personnel is not optimal. The 
rate found in this report (53.0%) is well below the 90% 
Healthy People 2020 target. W ith moderate effort, organized 
campaigns can attain higher vaccination levels among health­
care personnel, and mandatory influenza vaccination policies 
for health-care personnel have been demonstrated to be a highly 
effective approach to achieving high vaccination coverage in 
this population (4).
The findings in this report are subject to at least two 
limitations. First, the determination of vaccination status 
and identification of high-risk conditions in NHIS were not 
validated by medical records; self-report of vaccination can 
introduce recall bias and might result in an overestimation of 
rates. However, adult self-reported influenza vaccination status 
has been shown to be sensitive and specific (48-50). Second, 
information was not available for certain high-risk conditions 
(such as chronic neurologic conditions) identified by ACIP
Conclusion
Substantial improvement in annual influenza vaccination of 
recommended groups is needed to reduce the health impact of 
influenza. Successful influenza vaccination programs combine 
education of potential vaccine recipients and publicity, 
increased access to influenza vaccination in medical and 
complementary settings such as workplaces and commercial 
establishments (e.g., pharmacies and chain stores), and use of
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practices shown to improve vaccination coverage, including 
reminder and recall systems, efforts to remove administrative 
and financial barriers to vaccination, use of standing orders 
programs for influenza vaccination, and assessment of 
practice-level vaccination rates with feedback to staff (4). The 
Affordable Care Act requires that certain clinical preventive 
services be provided without cost sharing in Medicare and by 
newly qualified health plans. The Affordable Care Act also 
encourages state Medicaid programs to offer selected clinical 
preventive services with no cost sharing (7). Beginning in 2013, 
state Medicaid programs that eliminate cost sharing for these 
preventive services may receive enhanced federal matching 
funds for them (7,51). The expanded enrollment in public 
and private insurance programs expected from provisions of 
the Affordable Care Act might improve access to health-care 
services, including vaccination, for persons who were previously 
uninsured. Although health insurance coverage can improve 
access to health-care services, insurance alone might not be 
sufficient to achieve optimal influenza vaccination levels (or 
coverage). The findings in this report indicate that even among 
those with health insurance and >10 contacts with physicians 
within the past year, influenza vaccination coverage did not 
meet the Healthy People 2020 target. Other provisions of 
the Affordable Care Act that create incentives for primary 
care, including increased payments for primary care services 
provided by primary care doctors and coverage without cost 
sharing (34) for vaccines recommended by ACIP, also should 
help to improve influenza vaccination coverage.
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The findings described in this supplement can help improve 
collaboration among public health and other stakeholders who 
influence population health, including employers, health plans, 
health professionals, and voluntary associations, to increase the 
use of a set of clinical preventive services that, with improved 
use, can substantially reduce morbidity and mortality in the 
U.S. adult population (1—19). This supplement highlighted 
that the use of the clinical preventive services in the U.S. adult 
population is not optimal and is quite variable, ranging from 
approximately 10% to 85%, depending on the particular 
service (Table). Use was particularly low for tobacco cessation, 
aspirin use to reduce risk of cardiovascular disease, and 
influenza vaccination; however, ample opportunity exists 
to improve use of all of these services. Among the specific 
populations least likely to have used the recommended services 
(2—10), persons with no insurance, no usual source of care, 
or no recent use of the health-care system (if included in the 
analysis) were the groups least likely to have used the services. 
Use among the uninsured was generally 10 to 30 percentage 
points below the general population averages, suggesting that 
improvements in insurance coverage are likely to increase use 
of these clinical preventive services. A randomized, controlled 
trial of an expansion of Medicaid coverage by Oregon in 2008 
supports this hypothesis by demonstrating improved use 
of clinical services with increased health insurance coverage 
(20). A recent survey among the uninsured found a low level 
of awareness of the provisions of the Patient Protection and 
Affordable Care Act of 2010 as amended by the Healthcare and 
Education Reconciliation Act of 2010 (referred to collectively 
as the Affordable Care Act [ACA]) (21). Therefore, improving 
opportunities for coverage might be insufficient, and focused 
efforts by governmental health agencies and other stakeholders 
are likely to be needed to enroll uninsured persons in health 
plans. In addition, although use of the preventive services in 
insured populations was greater than among the uninsured,
use among the insured was generally <75%, and often much 
less (2—10). Therefore, having health insurance coverage might 
not itself be sufficient to optimize use of clinical preventive 
services, and additional measures to improve use are likely to 
be necessary.
O pportun ities  Iden tified  by Key 
Findings
The suboptimal use of adult clinical preventive services 
reported in this supplement can be improved and morbidity 
and mortality substantially reduced. Public health, other 
stakeholders, and communities can make use of the strategies 
identified in the reports to improve service use, including 
increasing health insurance coverage through effective 
implementation of the Affordable Care Act, participating in 
quality ofcare improvement initiatives, increasing the integrated 
use of electronic health information systems, implementing 
the National Prevention Strategy, better coordinating and 
integrating public health and clinical care, and increasing use 
of evidence-based community interventions to improve service 
use. For use of these services to actually increase and for the 
related improvements in the health of the U.S. adult population 
to be realized, key stakeholders and communities will need 
to take advantage of the opportunities and act to implement 
these strategies. Public health surveillance reports, such as this 
supplement, can play a key role in promoting accountability 
among stakeholders by monitoring and reporting on progress 
both in the use of clinical preventive services and in the 
implementation of strategies to improve service use.
The reports in this supplem ent identified numerous 
evidence-based, effective community interventions and quality- 
of-care improvement initiatives that can be implemented by 
stakeholders to increase use of clinical preventive services
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TABLE. Percentage of adults who are receiving selected clinical preventive services — United States
Topic/Indicator (years received) % receiving service
Aspirin and other antiplatelet therapy (2005-2008)
Adults aged >18 years w ith  a history o f ischemic vascular disease w ho are prescribed aspirin or an tip la te let therapy to  prevent recurrent CVD 46.9*
Men aged 45 -79  years and wom en aged 55-79 years w ith o u t ischemic vascular disease w ho are prescribed aspirin when the  potential 17.1*
benefit o f a reduction in myocardial infarction or stroke, respectively, outw eighs the potential harm a ttribu tab le  to  an increase in
gastrointestinal hem orrhage
Hypertension management (2005-2008)
Adults aged >18 years w ith  hypertension whose blood pressure is under control 43.6+
Lipid management (2005-2008)
Men aged >20 years for whom  lip id screening is recommended w ho have been screened for lip id disorders in the  past 5 years 66.6§
Women aged >20 years for w hom  lip id screening is recommended w ho have been screened for lip id disorders in the  past 5 years 74.4§
Men and wom en aged >20 years for w hom  lip id screening is recommended w ho have been screened for lip id disorders in the  past 5 years 70.1§
Diabetes management (2007-2010)
Adults aged >18 years w ith  diagnosed diabetes whose g lycohem oglobin (A1c) is <9% 87.11
Tobacco cessation (2005-2008)
Office-based am bulato ry care setting visits w ith  screening for tobacco use am ong adults aged >18 years 62.7**
Office-based am bulato ry care setting visits w ith  tobacco cessation counseling am ong current tobacco users in adults aged >18 years 20.9**
Office-based am bulato ry care setting visits w ith  tobacco cessation m edication prescribed am ong current tobacco users in adults aged >18 7.6**
years
Breast cancer screening (2010)
Women aged >40 years w ho had a m am m ogram  w ith in  the  previous 2 years 75.4++
Women aged 50-74 years w ho had a m am m ogram  w ith in  the previous 2 years 79.7++
Colorectal cancer screening (2010)
Adults aged 50-75 years w ho have had an FOBT w ith in  the  past year, sigm oidoscopy w ith in  the  past 5 years and FOBT w ith in  the past 3 years, 64.5§§
or colonoscopy w ith in  the  past 10 years
HIV screening (2005-2008)
Persons aged >13 years living w ith  HIV w ho know  they are infected 79.911
Influenza vaccination (2009)
Adults aged 18-64 years w ho have received the seasonal influenza vaccine 28.0***
Abbreviations: CVD = cardiovascular disease; FOBT = fecal occu lt blood test; HIV = human im m unodeficiency virus.
* Source: CDC. Recommended use o f aspirin and other an tip la te let m edications am ong adults— National Am bula tory Medical Care Survey and National Hospital 
Am bulatory Medical Care Survey, United States, 2005-2008. In: Use o f selected clinical preventive services among adults— United States, 2012. MMWR 2012;61(Suppl; 
June 15, 2012):11-8.
t  Source: CDC. Control o f hypertension am ong adults— National Health and N utrition  Examination Survey, United States, 2005-2008. In: Use o f selected clinical 
preventive services am ong adults— United States, 2012. MMWR 2012;61(Suppl; June 15, 2012):19-25.
§ Source: CDC. Screening for lip id disorders am ong adults— National Health and N utrition  Examination Survey, United States, 2005-2008. In: Use o f selected clinical 
preventive services am ong adults— United States, 2012. MMWR 2012;61(Suppl; June 15, 2012):26-31.
11 Source: CDC. Characteristics associated w ith  poor glycemic control among adults w ith  self-reported diagnosed diabetes— National Health and Nutrition Examination 
Surveys, U nited States, 2007-2010. In: Use o f selected clin ical preventive  services am ong ad u lts— U nited States, 2012. MMWR 2012;61(Suppl; June 15, 
2012):32-7.
**  Source: CDC. Tobacco use screening and counseling during physician office visits am ong adults— National A m bula tory  Medical Care Survey and National Health 
Interview  Survey, United States, 2005-2009. In: Use o f selected clinical preventive services am ong adults— United States, 2012. MMWR 2012;61(Suppl; June 15, 
2012):38-45.
f t  Source: CDC. Breast cancer screening am ong adu lt w om en— Behavioral Risk Factor Surveillance System, United States, 2010. In: Use o f selected clinical preventive 
services am ong adults— United States, 2012. MMWR 2012;61(Suppl; June 15, 2012):46-50.
§§ Source: CDC. Prevalence o f colorectal cancer screening am ong adults— Behavioral Risk Factor Surveillance System, United States, 2010. In: Use o f selected clinical 
preventive services am ong adults— United States, 2012. MMWR 2012;61(Suppl; June 15, 2012):51-6.
11 Source: CDC. Prevalence o f undiagnosed HIV infection am ong persons aged >13 years— National HIV Surveillance System, United States, 2005-2008. In: Use of 
selected clinical preventive services am ong adults— United States, 2012. MMWR 2012;61(Suppl; June 15, 2012):57-63.
* **  Source: CDC. Influenza vaccination coverage am ong adults— National Health Interview  Survey, United States, 2008-09 influenza season. In: Use o f selected clinical 
preventive services am ong adults— United States, 2012. MMWR 2012;61(Suppl; June 15, 2012):64-71.
(2—10,19). Many of the community interventions have been 
found to improve service use among underserved populations 
(2—10,19). The specific interventions available vary somewhat 
depending on the service but commonly include reducing 
barriers to access to the service and integrating into health­
care systems the ability to easily track service use and prompt 
clinicians or patients when the service is needed.
Most of the reports identified aspects of recent health-care 
reform initiatives that should facilitate increased use of these
services (2—10). For example, when fully implemented, the 
Affordable Care Act is projected to extend health insurance 
coverage to approximately 93% of U.S. residents by 2016 
(11,22). In 2009, 19.5% of the population (58.7 million 
persons) lacked health insurance for at least some part of 
the previous 12 months (23). In addition, the Affordable 
Care Act requires that certain clinical preventive services be 
provided without cost sharing by Medicare and newly qualified 
private health insurance plans and encourages the provision
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of selected services at no cost by Medicaid (11). A February 
2012 analysis by the U.S. Department of Health and Human 
Services (HHS) reported that 54 million persons are receiving 
preventive services coverage without cost sharing as a result of 
the Affordable Care Act; 14.1 million of these are children aged 
<17 years, 20.4 million are women aged 18—64 years, and 19.5 
million are men aged 18—64 years (24,25). In addition, HHS 
reported that 35 million Medicare beneficiaries are receiving 
free preventive services (24,25).
H ealth  System Reforms a t State and  
Local Levels
The Affordable Care Act includes provisions to improve 
disease prevention and health prom otion, improve the 
quality of health care, and lower health-care costs (11,22). 
Implementation of those health system and public health 
provisions is largely the responsibility of states and communities, 
health insurers, and health-care providers, and choices made 
during implementation will directly affect use of clinical 
preventive services by those populations. Starting in 2014, 
Medicaid will expand to cover persons with incomes <133% of 
the federal poverty level (22). By 2016, an additional 16 million 
persons will be covered through Medicaid and the Children’s 
Health Insurance Program (CHIP) (22). In addition, starting 
in 2014, the law creates state-based health insurance exchanges 
to make private health insurance available to small employers 
and to individual persons and families not eligible for Medicaid 
or CHIP (26,27). W ithin broad parameters, the law affords 
states considerable discretion in how they structure features of 
the plans, which can affect the delivery of clinical preventive 
services: cost sharing, eligibility for additional low-income 
subsidies, whether the exchange will include all qualified plans 
or only those with which the state contracts, governance, 
rating rules, adjusting premiums for risk, the range of benefit 
options, how to facilitate comparison shopping among plans, 
and public protections (27). Each of these decisions can directly 
or indirectly affect use of clinical preventive services and receipt 
of needed treatment.
Opportunities for states and communities to increase the 
use of clinical preventive services also are provided by national 
legislation supporting increased use of health information 
technology and electronic health records in hospitals and 
clinics (1,28). Electronic health information systems have the 
potential to improve the identification of individual persons 
and populations in need of services (e.g., persons who have not 
had a cholesterol check within the recommended interval or 
who have not received their annual influenza vaccine), provide 
reminders to both the health-care providers and patients
about the need, and monitor and report on use of the services 
(1). State and local governments can play important roles in 
the implementation of such systems by providing leadership 
and governance, participating in the exchange of health 
information, and monitoring and reporting on adoption of 
health information systems to the public (28).
Public H ealth  and Clinical Care
Interaction between clinical and community preventive 
services is recognized as one of four core strategies in the first 
National Prevention Strategy (11,29). The Affordable Care Act 
called for the development of the National Prevention Strategy 
in recognition of the essential role of prevention in improving 
the health of persons in the United States (11,29). Making 
meaningful health improvements through prevention will 
require action both within and beyond the health-care sector. 
The National Prevention Strategy highlights the important 
role of preventive services, including both clinical preventive 
services and community services discussed in this supplement, 
and the responsibility of communities to support these services. 
The public health sector can play a critical role in informing 
the public and key stakeholders about the benefits of clinical 
preventive services and in promoting evidence-based strategies 
such as those identified in this supplement. The National 
Prevention Strategy recognizes that patients receive both 
clinical and community services when they receive appropriate 
clinical preventive care that is supported by community-based 
resources such as tobacco quitlines, physical activity programs, 
and community programs to address barriers to health-care 
access. The combination of clinical and community services can 
optimize health through preventive health services. In addition, 
public health data on the use of preventive services, such as 
those highlighted in these reports, are critical for planning 
and monitoring community and health system interventions 
to increase the use of these services.
In this context, state, tribal, local, and territorial public health 
agencies have new opportunities to improve use of the clinical 
preventive services discussed in this supplement by improving 
the coordination and integration of agency services with those 
sponsored by state Medicaid agencies and those delivered by 
the health-care system. In the United States, the medical and 
public health fields have historically been in separate, although 
occasionally overlapping, realms. Realizing the potential for 
the Affordable Care Act to address U.S. health challenges of 
the 21st century, such as the aging population, increasing rates 
of chronic illness, and fragmented delivery of health care, will 
require the coordinated and deliberate redesign of the health 
care and public health systems.
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Several steps might be considered by public health and 
other stakeholders to improve delivery of the clinical services 
identified in this supplement by better coordinating efforts 
and improving coordination of clinical care and public 
health. Health officials can share this report with their clinical 
community and convene meetings to discuss statewide and 
local strategies to support the optimal use of preventive 
services. They can work with employers and insurers to 
review health plan benefit language to improve coverage for 
all of the medical procedures required to implement a single 
clinical practice guideline and for appropriate populations 
to be covered (30,31). Health officials also can facilitate 
collaboration among hospital associations, medical staff 
leaders, professional trade associations, and residency program 
directors to improve access to preventive services. Medical 
practices that use electronic health records can assess individual 
practitioner or group practice performance on service delivery 
and work to improve office systems that increase rates of use. 
At the same time, public health officials can apply strategies to 
encourage members of the public to seek these services and help 
practitioners to understand the community services available to 
their patients to support health-promoting behaviors such as 
tobacco cessation. Claims data for state Medicaid and private 
insurance can be used locally to target attention to populations 
with the greatest service gaps. Public health professionals can 
work with leaders in business, voluntary associations, and 
faith-based organizations to use their leadership positions to 
increase awareness of the gap in services and encourage the use 
of clinical preventive services.
Im proving  Public H ealth  Surveillance
Ideally, public health surveillance systems would have the 
capacity to track, in a timely, comprehensive, and accurate 
manner, the effects of numerous efforts that might influence use 
of clinical preventive services, including implementation of the 
Affordable Care Act and electronic health information systems, 
as well as actions by public health and other stakeholders. These 
systems would have the ability to characterize persons who are 
eligible for specific services and those who do or do not receive 
them, examine the effects of legislation and other interventions, 
and assess resulting health outcomes at both the individual and 
population levels. The ability of current resources and public 
health surveillance systems to examine such relationships is 
limited. However, surveillance reports such as those in this 
supplement can be helpful by highlighting underuse of the 
services, identifying trends that might be due, in part, to various 
interventions currently underway, and illuminating disparities. 
The reports in this supplement also highlight several gaps in
the types of health surveillance information needed to guide 
efforts to increase use of important clinical preventive services. 
For example, as noted in the Rationale for this supplement, 
several preventive services of interest could not be addressed 
because of a lack of available information (1). Although all 
these reports present national data, most cannot provide data 
that are necessary to monitor progress at the state and local 
levels. This supplement challenges health and public health 
professionals to identify resources that can be used to provide 
information at the state and local levels.
Additional sources of health surveillance information might 
help address some of the gaps identified in these reports. 
Increasing use of electronic health information systems and 
electronic data exchange systems offers the possibility of 
collecting and reporting on use of clinical preventive services 
at the national, state, and local levels (1,28). State and local 
surveys, such as the Behavioral Risk Factor Surveillance System, 
might be able to capture more of the kind of information 
included in this supplement. Deidentified information from 
Medicare and Medicaid databases also might provide new 
opportunities for this type of surveillance (32). Additional 
sources of information for surveillance and an increased ability 
to link information from a various sources can help provide 
a more complete and integrated perspective on steps that 
stakeholders need to take to improve use of these services.
Future Reports on Clinical 
Preventive Services
Surveillance reports on the use of selected clinical preventive 
services by U.S. adults will be published periodically. Future 
reports might include additional indicators for clinical 
preventive services that are known to have important health 
benefits but were not included in this supplement for various 
reasons, primarily lack of adequate surveillance information 
(1). Such reports might include screening and counseling for 
alcohol consumption and for mental health, services that can 
benefit large segments of the adult population. Because this 
supplement does not address the important goal of improving 
use of clinical preventive services for adolescents and children, 
CDC is planning a surveillance report on use of those services 
and methods for improvement. As information becomes more 
available in public health surveillance systems, future reports 
might be useful for monitoring interventions implemented by 
public health and other stakeholders to improve service use.
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